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Bruk av elektrokonvulsiv terapi i psykiatrien 
Elektrokonvulsiv terapi (ECT) er en behandlingsmetode hvor man utløser et epileptisk anfall 
ved hjelp av elektrisitet påført mot pasientens hode under narkose og muskelrelakserende 
medikamenter. Risikoen for meget alvorlige bivirkninger eller mortalitet er lav og effekten 
er veldokumentert for alvorlige depresjoner, men også for andre psykiske lidelser som mani 
og noen former for schizofreni. Kjente bivirkninger er hodepine og forbigående 
hukommelsesproblemer. Forskjell i behandlingsmåte kan skyldes noen av bivirkningene.  
Dette arbeidet handler om kartlegging av bruk, demografiske data, diagnoser, praksis, samt 
holdninger til ECT,  i Norge og verden.  
I vårt material fant vi variasjon i bruk av ECT mellom land og regioner. I Norge var det 2.4 
per 10,000 innbygger per år som fikk ECT. Verden over varierte bruken av ECT fra 0.11 til 
5.1 per 10,000 innbygger per år. ECT uten narkose ble brukt i Asia, Afrika, Latin-Amerika, 
Russland, Tyrkia og Spania. Det var flest eldre kvinner med depresjon som fikk ECT i 
vestlige land, mens yngre menn med schizofreni dominerte i asiatiske land. Norske 
psykiatere uttrykte positive holdninger til ECT.  
Vi konkluderte med at det er stor forskjell i bruk av ECT både når det gjelder antall pasienter 
per 10,000 innbygger, og praksis i Norge, men også verden over, tross internasjonale 
aksepterte retningslinjer. Stor variasjon i den praktiske bruken av ECT viser behov for 
fortsatt å dele kunnskap om og refleksjoner rundt ECT. 
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Summary 
Introduction 
Electroconvulsive therapy (ECT) has been used to treat mental disorders since its 
introduction in 1938, and it is available in many countries on all continents. However, there 
are large variations in practice and in rates between countries and regions within those 
countries, despite internationally accepted guidelines. The ECT intervention is an application 
of electrical current to the scalp in order to provoke a generalized epileptic seizure, for the 
purpose of alleviating psychotic and depressive symptoms. Initially ECT was performed 
without anaesthesia and muscle relaxant (termed unmodified ECT), which among other 
things, incurred risks of bone fractures and tendon or muscular damage. ECT practices have 
developed since then; modification of the technique minimizes adverse effects without 
reducing efficacy. This includes the use of unilateral electrode placement, the adjustment of 
stimulus intensity to the seizure threshold of each patient, and use of anaesthesia and muscle 
relaxant (termed modified ECT). ECT still remains controversial, despite well-documented 
efficacy, especially for major depression, but also for mania and some forms of 
schizophrenia, and low serious adverse events. Common side effects are transient headaches 
and memory impairment, whilst long term memory impairment is uncertain and widely 
debated. Differences in ECT technique may account some for these variances.  
This thesis explores the topic of electroconvulsive therapy in terms of variations in rates of 
use, demographics, diagnoses/ indication, outcome, practice, adverse effects as well as 
attitudes, primarily in Norway but also worldwide. The aims of the present series of studies 
were to describe: the prescription rate of use of ECT, demographics and diagnoses of the 
patients at a county hospital in Norway over a period of 11 years (Paper I);  the use of ECT, 
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demographics and diagnoses, as well as attitudes among psychiatrists in Norway  (Paper II); 
the practical use of ECT in different psychiatric hospitals in Norway as well as side effects 
and outcomes (Paper III); the contemporary (1990 to November 2010) worldwide (by 
continent, country, region, large city hospitals and/or country hospitals) ECT utilization, 
parameters and practice, in psychiatric  establishments, both inpatient and outpatient (Paper 
IV). 
Material and methods 
The thesis consists of four papers. Paper I is based on data from patients admitted to the 
psychiatric unit of a county hospital between 1993 and 2003, and treated with ECT during 
their hospitalization. Data were collected retrospectively from specific ECT journals and 
medical records. The following data were collected: number of patients treated, number of 
treatments per course, gender, age and diagnoses. Papers II and III are based on answers to a 
40-item questionnaire (Appendix I) about the use of ECT in Norway in 2004. Data were 
collected from psychiatric hospitals, district psychiatric centres (DPC), and child and 
adolescent psychiatric units. Data included in paper II were number of patients treated, 
demographics (gender and age), diagnoses and psychiatrists’ attitudes. Data in paper III 
address the practical uses of ECT, side effects and outcomes. Paper IV is based on 
information from systematic search of studies published in 1990 through November 2010 in 
the databases Medline, Embase, PsycINFO, SveMed and EBSCO/Cinahl, in collaboration 
with the Norwegian Knowledge Centre. Studies reporting original data on ECT utilization 
and practice in continents, countries, regions, cities or local hospitals were included.  
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Results 
We found that there were variations in use of ECT between regions of Norway and between 
countries worldwide. The rate of ECT in Norway was 2.4 / 10,000 inhabitants per year and 
varied between health regions from 1.83 to 3.44 per 10,000 inhabitants per year (Paper II), 
whereas worldwide the rate varied from 0.11 to 5.1 per 10,000 inhabitants per year (Paper 
IV). In Norway, there were twice as many women as men who received ECT, and depressive 
disorders were the most common diagnostic indication (Papers I and II). Psychiatrists 
expressed generally positive attitudes towards ECT (Paper II). Unilateral electrode 
placement was preferred, while antidepressant, lithium and antipsychotic medication during 
ECT was often continued and continuation/maintenance ECT was used (Paper III). Most 
patients benefitted from ECT. Side effects such as memory impairment and headache were 
frequent, but not reported as serious adverse effects (Paper III). In the last study (Paper IV) 
we found that worldwide practices, indications and use of ECT varied considerably. 
Unmodified ECT was used in Asia, Africa, Latin America, Russia, Turkey and Spain. In 
Western countries, the majority of ECT treated patients were older women with depression, 
versus younger men with schizophrenia in Asian countries. Preferred electrode placement 
was generally bilateral, excepting some places (Europe and Australia/New Zealand). General 
trends were often inadequate training, and international guidelines not being followed. 
Mandatory reporting and overall country ECT register data were sparse. 
Discussion  
Methodological challenges and bias influencing the data results are discussed, on the 
background of  use of retrospective data (information depends on the quality of 
documentation), use of a questionnaire study design, and a systematic review providing a 
Worldwide picture relying on published data from 1990. We found that many countries have 
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no monitoring or reporting and poor/old data, or data from questionnaire studies. Reasons for 
differences in rates and practice in Norway and worldwide are discussed. One reason could 
be economic, another attitude, as well as patient and health personnel knowledge about ECT.   
Conclusion  
There are widespread differences in ECT utilization, administration and practice in Norway 
and worldwide. Most patients who receive ECT in western countries are women and elderly, 
and depression is the most common disorder. Most patients in Norway are reported to 
benefit from ECT and adverse effects are reported to be minor problems. Many patients are 
still treated with unmodified ECT today. Large global variation in ECT utilization, 
administration, and practice advocates a need for worldwide sharing of knowledge about 
ECT, reflection, and learning from each other's experiences. 
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Sammendrag 
Bakgrunn: 
Elektrokonvulsiv terapi (ECT) ble introdusert i 1938 og har siden den gang blitt tatt i bruk i 
mange land verden over. Litteratur tyder på at det er stor variasjon mellom land og innad 
regioner i et land selv om det finnes internasjonale aksepterte retningslinjer. Behandlingen 
består i at man utløser et epileptisk anfall ved hjelp av elektrisitet påført mot pasientens hode 
for å behandle psykiske symptomer. I begynnelsen ble ECT gitt uten narkose og 
muskelavslappende medikamenter, noe som kunne medføre risiko for beinbrudd eller 
muskelskader. Gjennomføring og teknikk av ECT har blitt endret siden den gang for å 
minimere bivirkninger uten å redusere effekten. Dette inkluderer bruk av unilateral 
elektrodeplassering, justeringer innen dosering av energi, samt bruk av anestesi og 
muskelrelakserende medikamenter (modifisert ECT). ECT er fortsatt sett på som en 
kontroversiell behandling, selv om risikoen for meget alvorlige bivirkninger eller mortalitet 
er lav og effekten er veldokumentert for alvorlige depresjoner, men også for andre psykiske 
lidelser som mani og noen former for schizofreni. Kjente bivirkninger er hodepine og 
forbigående hukommelsesproblemer, men hvorvidt det forekommer 
langtidshukommelseproblemer debatteres fortsatt. Forskjell i behandlingsmåte kan skyldes 
noen av disse bivirkningene.  
Denne avhandlingen dreier seg om ECT og inkluderer bl.a. kartlegging av dens bruk, 
demografiske data, diagnoser, effekt, bivirkninger, ECT praksis, samt holdninger til ECT, 
fortrinnsvis i Norge, men også verden over. Målet med arbeidet er å se på følgende 
problemstillinger: Undersøke bruk av ECT ved et sykehus i Norge over en tidsperiode på 11 
år (Paper I); undersøke bruk av ECT i Norge, demografi, diagnoser/indikasjoner og 
xvii 
psykiaterens holdninger til ECT (Paper II); se på den praktiske gjennomføringen ved norske 
sykehus, samt bivirkninger og effekt (Paper III); undersøke hvordan ECT verden over 
(kontinent, land, regioner, byer, sykehus) brukes (fra 1990 til novemeber 2010); utbredelse, 
parametere og praksis ved psykiatriske institusjoner (hospitaliserte og polikliniske pasienter) 
(Paper IV). 
Material og metode 
Dette arbeidet inneholder 4 artikler. Den første artikkelen (Paper I) er basert på opplysninger 
om pasienter som var innlagt psykiatrisk avdeling ved et sykehus i perioden 1993-2003 som 
fikk ECT. Data ble samlet inn retrospektivt fra både ECT journal og pasientens egen journal. 
Det ble samlet inn opplysninger om antall pasienter behandlet, antall behandlinger per 
pasient, kjønn, alder og diagnoser. Artiklene to og tre handler om bruk av ECT i Norge. 
Studien er basert på innsamling av data om bruk av ECT i Norge ved hjelp av et 
spørreskjema med 40 spørsmål. Dette spørreskjemaet ble sendt ut til sykehus, distrikts 
psykiatriske sentre, samt barne- og ungdomspsykiatriske avdelinger. Opplysninger som ble 
samlet inn var: antall pasienter behandlet, kjønn, alder, diagnoser, holdninger (Paper II) og 
ECT praksis, bivirkninger og effekt (Paper III). I den fjerde artikkelen ble det gjort et 
systematisk søk ved hjelp av databaser som omhandler bruk av ECT verden over. Det ble 
samlet inn opplysninger fra og med 1990 til november 2010 ved hjelp av Medline, Embase, 
PsycINFO, SveMed and EBSCO/Cinahl. Studier som primært rapporterte bruk av ECT og 
dens praksis i kontinent, land, regioner, byer og sykehus ble inkludert (Paper IV).  
Resultater 
I vårt material fant vi variasjon i bruk av ECT mellom land, regioner og innad i et sykehus. I 
Norge var det 2.4 per 10,000 innbygger som fikk ECT med en variasjon mellom 
helseregionene fra 1.83 til 3.44 per 10,000 innbygger (Paper II), mens verden over var 
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variasjonen fra 0.11 til 5.1 per 10,000 innbygger (Paper IV). Det var dobbelt så mange 
kvinner enn menn som fikk ECT og depresjon var den hyppigste indikasjonen (Paper I og 
II). Norske psykiatere uttrykte positive holdninger til ECT (Paper II). Unilateral 
elektrodeplassering var hyppigst brukt, antidepressiva, litium og antipsykotika ble ofte 
kontinuert,  og vedlikeholdsbehandling med ECT ble tilbudt (Paper III). Bivirkninger som 
ble rapportert var mild hodepine og forbigående hukommelsesproblemer. De fleste erfarte 
god effekt av ECT (Paper III). I den siste studien (Paper IV) fant vi at det var forskjell 
verden over i bruk av ECT. ECT uten narkose ble brukt i Asia, Afrika, Latin-Amerika, 
Russland, Tyrkia og Spania. Det var flest eldre kvinner med depresjon som fikk ECT i 
vestlige land, mens yngre menn med schizofreni i asiatiske land. Unilateral 
elektrodeplassering ble foretrukket  i noen land (Europa og Australia/New Zealand), mens 
bilateral elektrodeplassering ble mest gitt verden over. Generell trend var; ofte inadekvat 
opplæring, internasjonale retningslinjer ble ikke fulgt, samt lite innrapportering av tall til 
ECT registre eller myndigheter.   
Diskusjon 
Metodologiske svakheter og styrker diskuteres, som inkluderer bruk av: retrospektiv 
studiedesign (avhengig av kvalitet på dokumentasjon), spørreskjema (beskriver ikke 
nøyaktig praksis) og systematisk oversikt (artikler fra og med 1990, manglende 
innrapportering, eller at gamle data er rapportert). Det ble diskutert årsaker for variasjon i 
bruk og praksis av ECT i Norge og verden over. En årsak kan være økonomi, annen årsak 
kan være holdninger blant pasienter og helsepersonell vedrørende ECT.  
Konklusjon 
Det er stor forskjell i bruk av ECT både når det gjelder antall pasienter per 10,000 innbygger, 
administrasjon og praksis i Norge, men også verden over, tross internasjonale aksepterte 
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retningslinjer. De fleste pasienter som fikk ECT var eldre kvinner og depresjon var den 
hyppigste indikasjonen. Det ble rapportert at de fleste pasietene i Norge hadde god effekt av 
ECT og erfarte få bivirkninger. Det praktiseres fortsatt ECT uten narkose i flere land. Stor 
variasjon i den praktiske bruken av ECT viser behov for å fortsatt dele kunnskap om og 
refleksjoner rundt ECT.  
1 
1. Introduction 
This dissertation is about electroconvulsive therapy (ECT), its variations in rates of use, 
demographics, diagnoses, indication,  practice, outcomes, adverse effects as well as attitudes, 
primarily in Norway but also worldwide. 
1.1 History of convulsive therapy 
Knowledge about the impact of convulsions on illness has been understood as far back as 
ancient Greece, where the use of the electric torpedo fish, causing convulsions, was 
described in classical Greek writings as a treatment for the pain of arthritis and headache (1, 
2). Convulsive therapy, known to many as shock therapy, has been used to treat mental 
disorders since the 16th century, when Paracelsus used camphor by mouth to induce seizures 
to treat severe mental illness (3). In 1774 Auenbrugger used camphor to the point of 
convulsions to treat “mania vivorum” (4). In 1785 an account appeared in the London 
Medical Journal of camphor-induced seizures for the treatment of mania (5), and further 
reports have been found of this treatment in Europe and Russia from the middle of the 18th 
to the middle of the 19th century. Convulsive treatment seemed to have been forgotten for 
nearly a hundred years. In this period, until the early 1920s, little could be offered to those 
with severe mental illness except for different sleep-inducing therapies and calming 
medications, isolation, fresh air and light (sun) therapy, work therapy, and sudden “shock” 
such as cold therapy and cold and hot water baths. 
Between 1917 and 1938 four physical treatments were developed for the induction of 
marked physiological “shock” to treat mental disorders (6): 
2 
In 1917 Julius Wagner-Jauregg injected malaria infected blood to treat patients with tertiary 
syphilis, resulting in therapeutic fever cramps (7). He received the Nobel Prize in medicine 
in 1927 for this malaria-induced fever therapy (8). 
In 1933 Manfred Sakel injected insulin to induce hypoglycaemic coma as a treatment for 
patients with schizophrenia (9). Occasionally unintentional convulsions occurred. 
In 1934 Ladislas von Meduna successfully treated patients with catatonia and other forms of 
severe mental illness and denoted schizophrenia with chemical convulsion therapy by 
injecting camphor and later Cardiazol (pentylenetetrazol) (10). 
In 1938 the first patient treated with electroconvulsive therapy (ECT) was reported (11). 
1.2 History of electroconvulsive therapy 
ECT was first developed by Ugo Cerletti and Lucio Bini in Rome, Italy, in 1938 (12) . They 
experimented in the 1930s by administering electric current to dogs between one electrode in 
the mouth and one in the anus, but half of the dogs died. The idea of placing electrodes to the 
head was conceived after visiting slaughterhouse where pigs received electroshock to induce 
coma before they were slaughtered (13). The first human patient to receive ECT was a 39-
year-old man from Milan who was found wandering the streets of Rome in a psychotic state. 
He received 11 treatments with great success (12). ECT soon replaced chemical convulsion 
therapy and spread rapidly from Europe to other continents, including the United States, due 
to the displacement of psychiatrists during the Second World War (11). ECT was easier to 
control, was cheaper, had fewer side effects and was more convenient than the pharmaco-
convulsive treatments. ECT became a first-line treatment for schizophrenia and affective 
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disorders (14, 15). Cerletti and Bini were nominated for a Nobel Prize in 1950 
(www.nobelprize.org), but did not receive it.  
ECT first came to Norway in 1942 at Neevengården and Valen hospital and soon spread to 
other psychiatric clinics (16). ECT was at this time a standard treatment for depressive 
disorders (17), and in the years from 1944 to 1947 about half of inpatients received ECT 
(18). 
ECT was originally used in the treatment of schizophrenia. In 1940 Cerletti reported that 
ECT was even more effective for patients with mood disorder, of whom 90 % recovered 
(19). Initially, ECT was performed without anaesthesia and muscle relaxants (unmodified 
ECT), with the risks of adverse effects including bone fractures, tendon and muscle injuries. 
Unmodified ECT was given as late as the 1970s in Norway, but is now considered 
unacceptable (20). After introduction of psychoactive drugs in the 1960s for the treatment of 
depression, mania and schizophrenia, the use of and attitudes toward ECT radically changed 
(21, 22). Many came to believe that ECT was a barbarous and outdated treatment which 
should be discontinued, and the use of ECT declined in the 1970s (21). In the 70s there was a 
strong movement against institutionalized psychiatry, the antipsychiatry movement, which 
denounced ECT together with psychosurgery (23). However, psychotropic drugs were not as 
effective as expected, and for patients with medication resistant severe depression ECT was 
still found to be effective (24, 25). 
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1.3 Electroconvulsive therapy today 
The intervention of ECT, per se, that is, the application of electrical current to the scalp to 
induce a generalized cerebral seizure for the purpose of alleviating psychotic and depressive 
symptoms, is still much the same today as it was in the beginning. Modifications of Cerletti 
and Bini`s original bitemporal electrode placement and constant 120 Volt sine-wave 
electrical current (12) included the development of brief-pulse constant current devices and 
unilateral (UL) placement of electrodes. The use of sine wave constant voltage is declared 
unjustified due to the reported trade-off effect between effectiveness and memory 
impairment (26). In the attempt to reduce cognitive side effects, many countries 
(Scandinavia, Australia and New Zealand) adhere to unilateral electrode placement as first 
choice, but also practice switching to bitemporal placement when the clinical response is 
judged as too poor (27).    
ECT is often administered in a course or series of around 8 to 12 treatments, either 2 or 3 
times weekly. 
ECT is most effective in severe depression and catatonia, and is used when medication and 
other therapies have not been effective, cannot be tolerated, or will not help the patient 
quickly enough. The main indication has transformed during the years from first-line 
treatment of severe depression to last-resort treatment for pharmacotherapy-resistant 
depression, and for some patients who prefer ECT. However, ECT is still a first-line 
treatment for very severe life threatening clinical conditions (28, 29), and the American 
Psychiatric Association (APA) 2001 guidelines state that ECT should not be reserved for use 
only as a last resort (26).  
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1.4 Prevalence/rates of use 
Literature on the usage of ECT during the last decade is available from many countries (30-
36). There are large variations in practice and rates between countries and between regions 
within a country, despite internationally accepted guidelines (37, 38).  The reasons for such 
variations seem to be differences in economy, health policy, and knowledge and attitudes 
about ECT among patients and health personnel (38-40).  
Worldwide, it has been estimated that about one million patients receive ECT annually (29). 
ECT seems to have become a widely available treatment for mental disorders on all 
continents. In a recent textbook (41) ECT practice is described from USA/Canada and Latin 
America (42, 43), Western Europe (44, 45), Russia (46), Africa and Asia (47). Even so, 
empirical evidence about worldwide contemporary frequency rates, prevalence and practice 
has been scant. The 2009 study by Van Waarde et al. from the Netherlands includes data 
from nine other countries (48). A 2009 review by Gazdag et al. of ECT utilization in the past 
10 years includes thirteen studies (34). These studies give the impression of an overall 
paucity of ECT utilization surveys. 
Among the Scandinavian countries ECT has been used more seldom in Norway than in 
Denmark and Sweden (49). Data on ECT use in Norway have been limited, and the 
Norwegian Ministry of Health and Social Affairs has no statistics on its rate of use. There 
have been three earlier studies on ECT in Norway (20, 30, 50). The overall practice of ECT 
in Norway has not been investigated since the study by Volden and Götestam in 1978 (20).  
They reported an ECT rate of 0.98 patients per 10,000 populations per year, and that 2.8% of 
inpatients received ECT. Moksnes et al. studied the rate and characteristics of ECT practice 
in the Ullevål sector of Oslo during the years 1988-2002 (30). They found that the rate had 
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gradually increased in the Ullevål sector, more like that of Denmark and Sweden, because of 
a simultaneous decrease in these countries (30, 33). At the present time there are no formal 
training programs or supervision standards for ECT in Norway. There are no national 
guidelines for its use. However, the physicians who specialize in psychiatry are required to 
have knowledge about ECT, and existing internationally accepted guidelines are likely used. 
1.5 Mechanism of action of ECT 
The clinical practice of ECT is well established, although the complete mechanism of action 
is not known. ECT is used because it works. The therapeutic effect is coupled with the 
induction of a generalized cerebral seizure, i.e., repeated and synchronous firing of neurons 
in most of the brain for a period of at least 30 seconds. This is usually followed by a period 
of coma and disorientation, from which the patient only gradually recover (51), usually 
within 10 to 50 minutes (52). Possible mechanisms of the action of ECT have been 
extensively studied, and no reasonable signs of brain damage have been found (53-57). A lot 
of effects on neurotransmitters and receptors have been found, resembling those of 
antidepressants. Most interesting is that ECT increases dopaminergic function much more 
than any other antidepressant treatment (58, 59). 
The mechanism of action research focus today is mostly on ECT`s potential effects on brain 
neuroplasticity and chemical substances influencing this. ECT has been found to increase 
neurogenesis, angiogenesis, dendrite arborisation and synaptic proliferation in the 
hippocampus and frontal cortex, and thus counteracts effects that can be induced by 
depression in animal models (60). In humans these changes are related to increased 
hippocampus volume after ECT found on Magnetic resonance imaging (MRI) (61) and 
normalisation of a low choline signal on Magnetic resonance spectroscopic imaging (MRSI) 
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(55). These changes may be induced by increases in growth factors like Brain Derived Nerve 
Factor (BDNF), peptides like neuropeptide Y and other substances like nitrogen oxide (62). 
At the same time, down regulation of an often hyperactive hypothalamus-pituitary-adrenal 
axis may be important (63-65). 
1.6 Indications and efficacy 
ECT was first introduced for patients with schizophrenia. At that time psychotic affective 
disorders, especially those of bipolar type, were often diagnosed as schizophrenia. As early 
as 1941, ECT was also reported to be highly effective in the treatment of typical mood 
disorders (19).  
The main indications for clinical use of ECT today are severe major depressive disorders, 
especially delusional depression and catatonia, but ECT is also effective in patients with 
mania, mixed states, some forms of schizophrenia, other psychoses, neuroleptic malignant 
syndrome, and Parkinson’s disease (3, 26). In the early years, ECT was also attempted for 
use in the treatment of alcoholism, drug addiction, phobias, and even for homosexuality, 
which contributed to the stigma of ECT. ECT use today is more stringent on the basis of 
empirical evidence. A study from the USA in 1994-95 showed that 86.5 % of the indications 
were evidence based (66). Sienaert has recently published a review on ECT and its relevance 
for the practicing psychiatrist, describing indications as well as impediments and risks (67).  
1.6.1 Depression  
The most common indication for ECT is severe depressive disorder. Generally, ECT is 
regarded as a second line treatment. However, in severe depression it is also a first-line 
option, especially when psychotic features, high suicidal risk, catatonic stupor, inanition, and 
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severe vegetative dysregulation are present  (26, 68, 69). Moreover, ECT is often preferred 
when a rapid response is needed because it has shorter response latency than antidepressants 
(26, 70, 71). Relative indications for ECT as a first-line choice also include prior good 
response as well as the patient’s own request (26), as discussed in the editorial by Beale and 
Kellner with title ”ECT in treatment algorithms: no need to save the best for last” (72). 
Goodwin and Jamison (2007) also emphasize the importance of timing, and state: “It is 
unfortunate that ECT is often relegated to last-resort status in treatment guidelines and 
protocols. We believe the clinician should not hesitate to recommend ECT to severely ill 
patients as a first-line treatment. For the delusional and suicidal patient – indeed, for any 
depressed patient who is so ill that only the most reliable and rapidly effective treatments 
should be considered – ECT is the clearly superior alternative. ECT should also be offered to 
patients with treatment-resistant depression who have a history of adverse reaction 
(increased cycling, induced mania or agitation) whenever their symptoms threaten to become 
chronic or begin to have a significant negative impact on family or on occupational or 
academic functioning” (69). 
Response (partial reduction in symptoms after treatment) and remission (few or no 
symptoms after treatment) rates depend on the degree of treatment resistance to 
pharmacotherapy before ECT. Thus, the response rates are 80-90 % in patients who receive 
ECT as a first treatment and have not received antidepressants during the depression (26). 
Remission rates are also high in such patients, 60 to 90 % (71, 73-75). In resistant depression 
acute response rate to ECT is 60 to 90 %, but the remission rate is down towards 30 % (76-
80). 
Patients with psychotic depression have higher response and remission rates than 
nonpsychotic patients (81). In one study the response rate was 92 % in patients with 
delusional depression, compared with 55 % in patients without delusions (76). In another 
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study remission rates after bitemporal ECT in psychotic (n=77) and nonpsychotic (n=176) 
major depression were 95 % and 83 %, respectively (71). ECT is effective in bipolar as well 
as unipolar depression (74, 75, 82, 83). In one study remission rates were 65.3 %, 56.7 % 
and 70.5% in bipolar I, bipolar II and unipolar depression, respectively (84).  
ECT has been found to be significantly more efficacious than placebo and antidepressants in 
the treatment of unipolar depression (27, 85). However, only one study has compared ECT 
to a combination of drugs in acute depression. Dinan and Barry (1989) compared bilateral 
ECT twice weekly to lithium augmentation in 30 severely depressed tricyclic nonresponders. 
Ten patients were improved within two weeks in both groups, but lithium augmentation 
worked faster than ECT (86). 
1.6.2 Catatonia 
The first patients to be treated with chemical convulsive therapy by Meduna in 1934 had 
severe catatonia (87). Catatonia is also highly responsive to ECT, with either bilateral or 
high dose right unilateral electrode placement (88, 89). However, as time passed, 
schizophrenia was not regarded as a primary indication for ECT in Western countries. Since 
catatonia was partly linked to the diagnosis of schizophrenia, catatonia was often not 
recognized as an indication for ECT. In order to bring catatonia to the forefront, it has 
received its own chapter and code numbers in DSM-5 (90). 
1.6.3  Mania 
ECT is highly effective in patients with acute mania (91-93). One review found an 80 % 
improvement rate overall and 60 % in drug-resistant patients (91). Licht claimed in 1998 
(94) that “ECT is the most powerful antimanic treatment known today (95). ECT is generally 
used only when patients are intolerant or refractory to pharmacological treatment (26) . 
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However, in severe cases, ECT may be the first choice, as in delirious mania: “ECT is 
regarded as the definitive treatment for delirious mania, particularly in its malignant form” 
(96). In a Brazilian sample, psychotic features, violent behaviour and chronicity (previous 
admissions, duration of disease) predicted the choice of ECT in mania, and ECT reduced the 
risk of readmission (97). With optimal dosing, right unilateral (d’Elia) and bifrontal ECT are 
as effective as bitemporal ECT (98-102). 
1.6.4 Schizophrenia   
Literature suggests that ECT is effective in patients with schizophrenia with acute onset of 
psychoses, with short episode duration and with positive or affective symptoms (26, 103-
105). However, there is no sharp border between schizophrenia and psychotic affective 
disorders, and the choice of diagnosis may depend on the diagnostician’s preferences. To 
cite Abrams (3): “There is little doubt that many patients diagnosed as having acute or 
schizo-affective schizophrenia respond remarkably well to ECT … there is also little doubt 
that most of these patients are misdiagnosed manics”. In middle-aged and elderly patients 
with intractable catatonic schizophrenia the short-term efficacy of ECT was excellent, but 
the relapse rate was high (103).  
There is some evidence that ECT combined with antipsychotic drugs provides acute benefit 
to medication-resistant schizophrenic patients (106-108). The combination of ECT and 
neuroleptic therapy is found to be effective in preventing relapse (109). Adjunctive ECT can 
be efficacious in clozapine nonresponders suffering from schizophrenia (110). 
1.6.5 Other psychoses  
In 1899 Kraepelin tried to dichotomize psychoses into dementia praecox (later 
schizophrenia) and manic-depressive illness. Later, definitions of psychoses in between these 
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two groups have proliferated (111). In ICD-10 they are rubricated under “schizoaffective 
disorder” and “acute and transient psychotic disorders.” The latter includes polymorphic 
psychoses, which correspond to cycloid syndromes, according to Ottosson (112). He writes 
in his Swedish textbook that it is a rather unanimous clinical experience that ECT is superior 
to psychotropic drugs for cycloid syndromes with confusional or depressive elements. 
Dramatic response is often seen after 3-4 treatments, but additional treatments may be 
necessary for consolidation (112). Case reports support the now long-term clinical 
experience (113, 114). Postpartum psychoses typically present as polymorphic syndromes, 
and early ECT is strongly recommended (115-117). However, the confusing nomenclature 
has made controlled studies difficult to perform. In the DSM system, cycloid or polymorphic 
psychosis does not even exist, but mostly corresponds to schizophreniform psychosis and 
brief psychotic disorder. Moreover, these psychoses bear resemblance to psychotic bipolar 
mixed states and delirious mania, both strong indications for ECT (96, 118). 
1.6.6  Neurological disorders 
ECT improves psychiatric disorders in patients with Parkinson’s disease (PD) to the same 
extent as in other patients. In addition, ECT improves parkinsonian motor dysfunction in 50-
60 %, regardless of the presence or absence of psychiatric comorbidity (119-121). The 
improvement usually lasts only 2-3 weeks (122). However, maintenance ECT for up to four 
years has been reported with good response in a few patients (123). ”It is unfortunate that 
ECT has never gained favour with neurologists in the treatment of PD. In fact, the treatment 
is not even mentioned in any current treatment guidelines or exhaustive reviews on the 
subject,” write Popeo and Kellner (124). ECT has also been reported effective in drug-
induced Parkinsonism, tardive dyskinesia and dystonia (125).  
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Moreover, ECT is effective in neuroleptic malignant syndrome and toxic serotonin 
syndrome, viewed as malignant catatonia, and also when benzodiazepines have failed (88, 
105, 126). 
ECT has antiepileptic properties both in human beings and experimental animals by inducing 
endogenous production of an antiepileptic opioid (127). ECT has been used in refractory 
status epilepticus. In 80 % of reported cases cessation of status epilepticus was obtained, and 
in 27 % complete recovery was achieved (128).  
1.6.7 Predictors of efficacy 
Predictors for good outcomes with ECT have been reported to include factors such as 
severity and type of disorder, chronicity, medication resistance, medical and psychiatric 
comorbidity, use of medication, as well as electrode placement and stimulus dose (129). 
Patients with depression respond better to ECT than patients with other disorders. As 
detailed in 1.6.1, patients with psychotic depression respond better than those without 
psychosis (81), and medication resistance predicts reduced response rate (77, 130). However, 
the latter has not been found in all studies (79, 131, 132). Dombrovski et al. found lower 
rates of remission in patients with major depression to be associated with chronicity and 
medication resistance, but not with age or burden of physical illness (133). Longer episode 
duration, comorbid personality disorder, and schizoaffective disorder were associated with 
poorer outcome in a study by Prudic et al. (134). Comorbid psychiatric conditions as 
predictors of poorer outcomes have also been found in other studies (135). Debattista and 
Mueller (136) found that depressed patients with a personality disorder, particularly 
borderline personality disorder, may have a poorer outcome on some measures. However, 
13 
the available data suggests that depression in these patients can be effectively treated with 
ECT (136). 
The degree of response to the first few treatment sessions, especially the first one, predicts 
the final response as long as the electrical dose is sufficient (129, 137, 138).  
1.7  Special populations 
1.7.1 Older age and medical/neurological comorbidity 
Previous literature indicates a predominance of elderly women with affective disorder 
receive ECT in Western countries (30, 139-141). Several studies suggest that ECT is both 
effective and safe for the elderly (142-145), and elderly with depression are more likely to 
have had ECT than younger patients (146, 147). Older patients (147) and those who are 
more severely ill (129) are also more likely to benefit from ECT than from other treatments.  
In some patients with medical or neurological comorbidity, ECT may be a treatment of 
choice due to fewer side effects and speed of onset. A recent review recommends ECT for 
depression in Parkinson’s disease, dementia and cerebrovascular disease, as well as for 
refractory behavioural symptoms in dementia (148), although randomised evidence does not 
exist (143). 
1.7.2 Children and adolecents 
Data on the use of ECT for children and adolescents is scarce. Existing literature in this field 
suggests that ECT is also effective in this group for treating depression, mania and 
schizophrenia (149). ECT for children and adolescents should be considered when symptoms 
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are severe; including life-threatening symptoms, medication resistant conditions (150), and 
in patients intolerant to other treatments (26, 151, 152).   
1.7.3 Mental retardation and autism 
Several case reports and series have demonstrated that ECT is effective for affective 
disorders and particularly catatonia, including agitation and self-destructive behaviour, in 
patients with mental retardation and autism. This is important because ECT-responsive 
symptoms may often be thought of as merely behavioural disorders due to the organic brain 
disorder (153-155). 
1.7.4 Pregnancy and post-partum period 
ECT is also regarded as an effective treatment for severe mental illness during pregnancy 
and the postpartum period, notably psychotic depression, psychotic mania and mixed states 
and polymorphic psychosis (115, 156, 157). Consideration of risks and benefits of ECT 
compared to other treatment must be taken into account, including the risk involved for the 
foetus/unborn child (158). In the postpartum period ECT can induce rapid remission and 
facilitate continuing breast feeding.  
1.8 ECT and medication 
Antidepressants (AD) and antipsychotics are usually continued during ECT (26, 159). 
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1.8.1 Antidepressants 
Current guidelines regarding concomitant use of AD during ECT vary in recommendations 
(26, 160, 161). According to the APA ECT guidelines, concurrent use of AD medication and 
ECT should be considered particularly for patients with medication resistance (26). 
Lauritzen et al. suggested that concomitant antidepressant medication, in this case adding 
imipramine to ECT, resulted in superior efficacy compared to adding paroxetine; however, 
during continuation-ECT (C-ECT) relapse rates were reduced in patients receiving 
paroxetine relative to imipramine or placebo (162). Baghai et al. also found a significant 
enhancement of therapeutic effectiveness in concomitant medication during ECT; in their 
retrospective study patients received several classes of AD (163). In a prospective, 
randomized, placebo-controlled study, patients with major depressive disorder referred to 
ECT (n=319) were randomized to concomitant nortriptyline, venlafaxine or placebo (164). 
The remission rates exceeded placebo by 14.5 % and 12.5 % with mean doses of 67 mg 
nortriptyline and 187 mg venlafaxine, respectively. This was statistically significant for 
nortriptyline. Relative to placebo, nortriptyline reduced the cognitive side effects of ECT, 
whereas venlafaxine tended to worsen them. The noradrenergic effect of the optimal dose of 
nortriptyline may have accounted for this, while the dose of venlafaxine was suboptimal. At 
the end of the ECT series, the placebo group was randomized to nortriptyline or venlafaxine, 
and lithium was added in all groups. Starting the antidepressant medication at the beginning 
versus the end of the ECT-series had no impact on post-ECT relapse, which was comparable 
for nortriptyline plus lithium and venlafaxine plus lithium. However, another study did not 
find advantage for concurrent antidepressant treatment (165). 
16 
1.8.2 Antipsychotics 
There are many studies supporting the use of concurrent antipsychotics and ECT. A recent 
Cochrane review found ECT, including continuation/maintenance-ECT, added to 
antipsychotics to be superior to antipsychotics alone in schizophrenia (106). The 
combination was particularly useful when rapid improvement was desired. The review also 
concluded that ”even though this initial beneficial effect may not last beyond the short term, 
there is no clear evidence to refute its use for people with schizophrenia.” An open review of 
eleven Indian studies (n=651) and a meta-analysis of four Indian controlled trials (n=113) 
indicated a main benefit of the combination in the first few weeks of treatment of 
schizophrenia due to an acceleration of treatment response (107) . In a retrospective study of 
patients with either depression (75.4 %) or schizophrenia/schizoaffective disorder (19.9%) 
the combination of ECT and atypical antipsychotics was significantly more effective than 
ECT and typical antipsychotics and ECT without antipsychotics (166). Some authors have 
given preference to clozapine in combination with ECT to patients who have not responded 
to clozapine alone (110, 167). 
1.8.3 Lithium 
Guidelines recommend lithium for prevention of relapse after successful ECT, but during 
ECT it should be considered only after a risk/benefit analysis, due to possible neurotoxic 
effects in combination with ECT (26, 168, 169). However, studies have also found this 
combination to be safe (170, 171). If lithium is continued during ECT, Sackeim has 
recommended not giving lithium the day before each ECT session (172). 
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1.8.4 Anticonvulsants 
Anticonvulsant prescribed for mood disorders should be discontinued before ECT, because 
they may increase seizure threshold and shorten seizure length (26). However, a review of 
Sienaert et al. found that ECT most often can be safely and effectively administered to 
patients treated with various anticonvulsants, but there was no evidence to combine the two 
treatment modalities to augment therapeutic efficacy (173, 174). 
1.8.5 Benzodiazepines 
The use of benzodiazepines during ECT may shorten seizure duration and compromise the 
response (175-178). However, in one study 22.5 mg oxazepam at night did not shorten 
seizure duration (179). 
1.9 Relapse rates and relapse prevention 
Relapse rates following ECT are high (180, 181). Relapse is “the exacerbation of an ongoing 
episode after an initial suppression of symptoms” (182). Without prophylactic treatment 80-
90 % of patients relapse within six months after ECT (183). Continuation therapy might be 
necessary (184, 185). Continuation therapy is the treatment that occurs during the months 
immediately after resolution of an acute episode of illness with the primary purpose of 
preventing relapse (182). Patients that were medication-resistant before ECT, female 
patients, and those with more severe residual depressive symptoms following ECT had more 
rapid relapse (183).  
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1.9.1 Continuation pharmacotherapy (C-Pharm) 
The most common practice after successful treatment with ECT is to continue with 
medication to prevent relapse (26). Earlier studies on the use of concomitant AD in 
combination with ECT found that combining ECT with AD resulted in more likely 
remission, and that treatment with Tricyclic antidepressants (TCA) or Monoamine Oxidase 
Inhibitor (MAOI) reduced post- ECT relapse within six months (relapse rate with TCA - 
20%, relapse rate with controls - 50%) (186, 187). However, later studies document higher 
relapse rate with C-Pharm. In a community setting, relapse rate during 24-week follow-up 
was 64.3%, and the median time to relapse was 8.6 weeks  (134). Comorbid substance 
dependence and treatment with benzodiazepines or antipsychotics during the follow-up 
period were associated with increased risk of relapse/recurrence (188). Sackeim et al. 
randomized 84 patients with major depressive disorder in remission after ECT to placebo, 
continuation nortriptyline or continuation nortriptyline plus lithium for 24 weeks; relapse 
rates were 84 %, 60 % and 39 %, respectively (183). Kellner et al. randomly assigned 
patients in remission after ECT to continuation ECT (N=75) or continuation nortriptyline 
plus lithium (N=74) for 24 weeks (184). Relapse rates were 37 % in both groups. Thus, the 
relapse rates with the combination of nortriptyline and lithium in the two studies were 
comparable, 39 % and 37 % in 24 weeks, respectively (183, 184).  In another study where 
patients received treatment “care as usual” after responding to ECT administered in a 
controlled trial, 51% relapsed within six months after ECT. All but one “usual care” patient 
received some form of C-Pharm post-ECT, one received Continuation- ECT (C-ECT) alone 
(189).  
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1.9.2 Continuation ECT (C-ECT) 
C-ECT is ECT given immediately after an ECT series to prevent relapse of the episode and it 
lasts up to six months, whereas maintenance ECT (M-ECT) is a course that begins after the 
end of C-ECT and is intended to prevent recurrence of a new episode. C-ECT and M-ECT 
should be considered in patients who have responded to ECT if pharmacotherapy alone has 
not been effective in the prevention of relapse, if pharmacotherapy cannot be safely 
administered, or if the patient prefers treatment with ECT (190). Goodwin and Jamison write 
that “maintenance ECT is considered an appropriate choice for patients who consistently 
relapse when attempts are made to stop ECT and do not maintain remission with 
medications. This has been incorporated into some of the international guidelines …” (69). 
Combining C-ECT and C-pharm may be more effective in relapse prevention after a 
successful treatment with ECT than pharmacotherapy alone. A two-year randomized study 
about continuation/maintenance treatment with nortriptyline (CM-NT) versus combined 
nortriptyline and ECT in late-life psychotic depression found a relapse rate of 11.8 % with 
CM-NT and a relapse rate of 5.9 % with C-ECT and NT (191). Another study found the 
cumulative probability of surviving (by using the Kaplan-Meyer surviving curves) without 
relapse or recurrence at two years to be 93 % for C-ECT and medication, and 52 % for 
medication alone (192). 
Prospective studies have failed to show higher efficacy for a fixed-schedule C-ECT as 
monotherapy than pharmacotherapy for relapse prevention after a successful treatment with 
ECT. Individualized intervals between ECT sessions instead of a fixed schedule and 
concomitant medication may reduce relapse rate and morbidity compared with standard 
procedures with abruptly terminated ECT after remission of symptoms (193). 
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C-ECT has been used for patients with bipolar disorder or schizophrenia as well (109, 194). 
There are no guidelines about the duration of C-ECT, but one study suggests that it should 
be open-ended (93).  
1.10 Adverse effects 
As with other medical interventions, there is a risk of adverse effects. The most common 
adverse effects of ECT are somatic complaints such as headache, transient cardiovascular 
complications such as transient heart rhythm abnormalities, transient elevation in heart rate 
or blood pressure and neuropsychiatric adverse effects such as cognitive changes. Adverse 
effects are associated with general anaesthesia, convulsions/seizure and concomitant use of 
medication during ECT and other aspects. Adverse effects can be reduced by pre-ECT 
evaluation and use of modified ECT technique. The most common adverse effects of ECT 
are usually temporary and well tolerated. 
1.10.1  Mortality 
Among more than 8,000 patients who received 49,048 ECT treatments in Texas between 
1993 and 1998, only one death could be linked to the associated anaesthesia. An additional 
four deaths might possibly have been associated with the anaesthesia, for which the 
calculated mortality rate is 2-10 per 100,000 treatments. No deaths were linked to the ECT 
stimulus or seizure (195). Among 2,279 patients given 17,394 ECT treatments in Minnesota 
during the period 1988-2001 there were no deaths during or immediately after ECT (196).  
The mortality rate in elderly patients during an ECT series is estimated to be far below that 
of elderly community residents in the general population during a six week period (3). 
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1.10.2  Somatic adverse effects 
Cardiovascular complications are the main potentially serious medical complication of ECT. 
Transient cardiac arrhythmias are common, especially in patients above 50 years of age. 
However, even in older age and in patients with cardiac disease, serious events “virtually 
never occur during the procedure” (3) as long as cardiac function is stable before ECT. 
Common side effects are headache, nausea and muscle pain, which usually lasts several 
hours, sometimes longer (67). Post-ECT headache occurs in up to 48 % of patients, but can 
be treated with analgesics prophylactically (197, 198), whereas antiemetic medication can 
reduce nausea. Tooth injuries can occur despite use of bite block. 
1.10.3  Neuropsychiatric side effects 
An effective ECT seizure is succeeded by a comatose stage from which consciousness and 
orientation are gradually regained (51), usually within 10 to 50 minutes (52). Disorientation 
is shortest for person, longer for place, and longest for time (199), which is displaced 
backward in years from the correct response (200). After a single seizure this may resolve 
fairly rapidly. However, during an ECT course, recovery from one seizure may be 
incomplete before the next, so that the effects accumulate (26, 201). Retention of memories 
is impaired for the treatment period and close to it. A temporal gradient appears, i.e., 
memory increasingly improves distant to the treatment period (Ribot’s law) up to some 
weeks or possibly a few months. However, the view that events occurring closest to ECT are 
most disrupted is controversial, because such memory problems may represent a partial 
consequence of depression before treatment (202). Anyway, significant improvements take 
place over the weeks and months after ECT. There is no lasting impairment of executive 
function and learning capacity, which is often improved (3, 26, 202-204).  
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The degree of cognitive deficits depends on both treatment and patient factors (201, 203, 
205-207). In general, it increases with seizure duration, number and frequency of treatments 
in a series, and dosage of anaesthetic agents. Pulse current requires less energy than sine 
wave current to elicit a seizure and therefore gives less cognitive disturbance. For the same 
reason, ultrabrief (≤0.3 ms) pulse stimulation may possibly give less disturbance than brief 
(0.5-1,5 ms) pulse stimulation (208). Cognitive disturbance is less pronounced with 
unilateral and probably bifrontal than with bitemporal electrode placement. Women show 
more deficits than men, probably due to lower seizure threshold. High age, low premorbid 
intellectual function and brain disease are associated with greater cognitive deficits. 
However, in such patients ECT often results in improved global cognitive status as a 
function of symptomatic response when the transient deficit wanes (26). In the elderly, 
postictal confusion can take several days or even weeks to resolve. Nevertheless, the global 
results of ECT are at least as good as in younger patients (26, 209). In general, poor 
symptomatic outcome of ECT is also associated with greater cognitive deficits, due to the 
combination of cognitive impairment of persistent depression and ECT (210). 
1.10.3.1.Objective cognitive change 
The extent and duration of objective cognitive change associated with ECT in depressed 
patients were recently meta-analysed by Semkovska & McLoughlin (211). Twenty-four 
cognitive variables from 84 studies with 2,981 patients were included. However, no 
standardized retrograde amnesia tests were identified. Abnormalities in other functions were 
mainly limited to the first three days after the treatment series, when significant decreases 
with effect sizes from – 1.10 to – 0.21 were observed in 72% of variables. Delayed recall 
was more affected than immediate recall, episodic verbal more than episodic visual memory, 
unstructured more than organized and contextualized information. Four to 15 days after 
ECT, all but one variable were normalized or improved, the one exception only present in 
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patients having received sine-wave ECT. After 15 days no negative effect sizes were 
observed, and 57% of variables showed small to medium size improvement beyond baseline, 
including processing speed, working memory, anterograde memory, and some aspects of 
executive function. As regards retrograde amnesia, the general view is that personal 
autobiographical memory is more affected than impersonal memory (202). On the other 
hand, Lisanby et al. found that impersonal public events are more affected than personal 
events (212).  However, Abrams (3) pointed out that this was based on non significant 
trends, and that the data only showed that, two months after ECT, neither personal nor public 
memory performance differed significantly from pre-ECT baseline, regardless of stimulus 
dose or electrode placement.  
In a second meta-analysis of 39 studies with 1,415 patients, Semkovska et al. (203) found 
that, up to three days after final treatment, unilateral ECT was associated with significantly 
smaller decreases in global cognition, delayed verbal memory retrieval, and autobiographical 
memory, compared to bitemporal ECT. In unilateral ECT, higher electrical dosage predicted 
larger decreases. However, more than three days after the ECT series, no significant 
differences remained between the two electrode placements, and electrical dosage no longer 
predicted cognitive performance in unilateral ECT. Cognitive functioning improved with 
increasing time after final treatment, this interval being a more useful predictor of cognitive 
function than electrode placement and electrical dosage. 
All but two studies included by Semkovska et al. (203) that measured retrograde amnesia for 
information learned shortly before ECT or for autobiographic memory presented results in 
percentage recalled from a baseline of 100% for everybody. This excluded true effect sizes 
to be generated (203). The reported range of percentage loss in consistency of recalled 
memory a few weeks or months after ECT was found to be 25-40%, nearly the same as the 
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28-40% reported in the healthy population after a similar interval (203, 213, 214). The two 
studies that quantified retrograde autobiographical amnesia so that effect sizes could be 
calculated, demonstrated improvement in autobiographical memory at follow-up after 
unilateral ECT (215, 216). 
Only one randomized study comparing long-term consistency loss of retrograde 
autobiographical memory after right unilateral and bitemporal ECT has used depressed 
patients not receiving ECT as a control group (217). At six-month follow-up patients treated 
with either brief pulse (n=8) or sine wave (n=9) unilateral ECT were comparable to controls, 
with about 20% consistency loss. Patients treated with bilateral ECT had significantly higher 
loss, 30% with brief pulse stimulus (n=9) and 38% with sine wave stimulus (n=11). 
However, Abrams (3) pointed out that these results cannot be considered definitive because 
of insufficient publication of details and lack of peer-review process, and that subsequent 
investigators had not been able to confirm the results. No study up to the year 2000 had 
detected persistence of memory deficits with brief pulse ECT even as early as 1-2 months 
post-treatment (3). 
However, in 2007 Sackeim et al. (210) published the largest (n=347) prospective 
observational study on cognitive effects of ECT, this being consistent with the results of 
Weiner et al. (217). At six-month follow-up, there was improvement relative to baseline on 
all tasks, including autobiographic memory, after pulse right unilateral ECT. After 
bitemporal ECT most tasks were improved or unchanged, except autobiographic memory 
was reduced. With sine-wave bitemporal ECT, one measure of reaction time was also 
reduced. Retrograde amnesia increased linearly with the number of bitemporal treatments, 
but was unrelated to the number of unilateral and bifrontal ECT. However, patients were not 
randomized. Therefore, patients with more severe depression may preferentially have been 
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prescribed bitemporal ECT and required a larger number of treatments (202). Moreover, at 
six-month follow-up 53% of the main cognitive outcome data were missing (203, 210).  
1.10.3.2. Subjective cognitive change 
Reports of subjective cognitive complaints after ECT appeared from the early 1940s (218). 
In 1975 Squire and Chace compared 38 patients who had received bilateral ECT, right 
unilateral ECT, or hospitalization without ECT six to nine months previously (219). Six 
objective memory tests revealed no memory impairment after ECT. Nevertheless, the group 
that received bilateral ECT reported subjective memory impairment significantly more often 
than the two other groups. Squire and Chace hypothesized that the marked memory 
impairment initially associated with bilateral ECT may cause some individuals to become 
more alert to subsequent memory failures and then to underestimate their memory abilities. 
Alternatively, occasional failures of recall that are not detected by objective tests may persist 
after ECT. 
Patient self-assessment of memory after ECT was reviewed in 2000 by Prudic, Peyser and 
Sackeim (218). They found that older studies reported bilateral ECT resulted in increased 
subjective memory complaints. However, studies after about 1980, when brief pulse ECT 
became more prevalent, showed little effect of electrode placement and general improvement 
in subjective memory evaluations within a few days after ECT. Subjective memory 
assessment was poorly related to objective findings, but strongly influenced by mood state, 
as recently confirmed in a cohort study of aircraft maintenance personnel (220). 
In a 2003 review of patient perspectives, Rose et al. (28) came to the opposite conclusion of 
Prudic, Peyser and Sackeim (218). Based on seven studies, they found that at least one third 
of patients reported persistent memory loss after ECT, mostly concerning bilateral ECT, 
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However, the study of Rose et al. was re-evaluated by Bergsholm (221), who found it 
severely flawed, making their results inconclusive and misleading. For example, one study 
evaluating memory problems within 48 hours of an ECT series was included as representing 
persistent memory loss; one study had only 37% valid responses, and two studies, probably 
overlapping, selected patients from advocacy network groups and was likely biased against 
ECT. 
The latest review reported patient knowledge, experience and attitudes toward ECT from 75 
studies (222). A vast majority perceived ECT to be helpful and had positive views regarding 
the treatment, whereas a sizeable minority was quite critical. Thirty of the studies reported 
rates of subjective memory impairment from three to 100%, while autobiographical memory 
impairment evaluated by objective measures is relatively short term (<six months post 
treatment), whereas impairment evaluated by subjective accounts is more persistent (>six 
months post-ECT) (202). Some individuals who have received ECT report that their ability 
to remember old or even new material never returns to “normal” following ECT (223, 224). 
A small number of patients complain of severe cognitive impairment and sometimes even 
personality change after ECT. Such cases have not been reported in any carefully controlled 
follow-up studies (225). Often cited is Ann B. Donahue, who reported profound patchy 
memory loss that extended back at least five years after 33 ECT sessions, initially unilateral 
and then bilateral (226). Nevertheless, she stated that ECT saved her mental health and 
possibly her life, and that, if necessary, she would elect to undergo ECT again. However, 
people forget even important events ranging from salient changes in personal status to 
dietary behaviour (227). Thus, healthy air traffic controllers, 25 to 48 years of age, forgot a 
mean of 40 % of reported life change events after nine months. The variation was great 
across persons, and one fourth forgot 80% (228). Fink has suggested that the rare complaints 
of personal memory loss after successful ECT are best characterized as somatoform 
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disorders (229). This compares to attributing psychosomatic symptoms to dental amalgam 
fillings (230) or any somatic therapy in psychiatry (231).  
The discrepancy between the objectively measured cognitive function and subjectively 
experienced impairment creates a need to take both perspectives into consideration (224). 
The complexity of cognitive function and cognitive side effects needs to be discussed with 
the patient on a number of occasions, and the clinician must be interested in the patient’s 
experience (224). In the end, it is the value placed on memories versus the subjective 
experience of wellness that seems to determine the patient’s view of the cognitive side 
effects (206).  
1.10.3.3. Prolonged seizures, tardive seizures and status epilepticus 
Prolonged seizures, i.e., seizures lasting more than 90-180 seconds in EEG, occur in 1-2% of 
treatments, mostly during the first treatment in young people (3, 26, 225). They should be 
stopped with, for example, midazolam or propofol. Tardive seizures (late return of seizure 
activity) during the recovery phase after a treatment, or non-convulsive status epilepticus, 
may be triggered by drugs (theophylline, lithium) (169, 232, 233) and pre-existing medical 
conditions that lower seizure threshold, such as electrolyte imbalance and previous brain 
damage (234). EEG is mandatory for diagnosis, and these very rare conditions must be 
treated as soon as possible. 
1.10.3.4. Mania 
The frequency of mania in bipolar disorder after treatment with ECT and antidepressants is 
in the same range as the natural risk of a switch from depression to mania during the 
recovery phase, 4-8% (225). The long-term risk of developing elevated mood in unipolar 
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depression is about 20%. Thus, there is also a small natural risk of mania after ECT in 
patients diagnosed with unipolar depression. 
In the experience of Abrams (3), a maniform syndrome during ECT is favourable and an 
indication for observing the patient without further treatments. The majority will go on to 
enjoy full remission. The few who slip back into depression or remain manic can be treated 
with additional ECT or pharmacotherapy or both. 
1.11 Contraindications 
There are no absolute contraindications for ECT, but there are situations of increased risk 
that need special attention, such as patients with disorders of the central nervous system 
(CNS), cardiovascular and respiratory system (26), as well as pregnancy (158). 
Recent myocardial infarction, unstable angina pectoris, decompensates congestive heart 
failure and other severe vascular diseases increase the risk of ECT treatment. Other 
conditions that elevate risk to ECT are increased intracranial pressure, recent cerebral 
infarction, severe pulmonary conditions or high anaesthesia risk in general (26). The ECT 
seizure itself does not seem to increase intracranial pressure, but the anaesthetic procedure 
may (235). Intracranial aneurysms are supposed to be a risk factor, but no complications 
have ever been reported (236), in spite of asymptomatic aneurysms occurring in 3-6 % of the 
population (237).   
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1.12 Clinical procedure of ECT 
The modern practice of ECT requires up-to date equipment, high-level facilities, and highly 
trained medical staff including psychiatrist, anaesthetist and treatment nurse. The treatment 
is standardized through internationally accepted guidelines, and if modern methods are being 
used ECT is safe, with few side effects and good clinical outcome (3, 26, 225). 
A general medical history and a physical examination including blood pressure are done for 
all patients before treatment (26). Symptoms should be evaluated regularly during treatment, 
for example by Montgomery and Åsberg Depression Rating Scale (MADRS) or three target 
symptoms and the Clinical Global Impression scale (CGI). Porter et al. have proposed 
cognitive tests for routine use during ECT, including reorientation time, which should 
always be measured (238). Otherwise, Weiner et al. (239) consider formal testing of memory 
as counterproductive because it does not catch the most bothersome memory problems. 
Instead, they recommend “bedside” testing of delayed recall of three items, different for each 
treatment, and of ability to recall life-relevant material, global self-rating, and rating by a 
significant other. Payne and Prudic highly recommend patients use a daily log or diary of  
visits and calls from family and results of meetings, and that they write down important 
passwords (206). As a result of cognitive side effects (memory-impairment) association with 
sine-wave current, it is now advised that brief-pulse wave be the standard treatment. The 
parameters of the stimulus can vary widely (pulse width from 0.3 to 1 ms, frequency from 20 
to 120 Hz, duration of the stimulus 0.5-8 sec) and are adjusted for each patient, according to 
seizure threshold, clinical efficacy and side effects. Modern equipment delivers brief or 
ultrabrief pulse stimulation, a current of 0.8 to 0.9 Ampere (A), and has EEG, ECG and 
EMG. In addition, physiological monitoring during ECT, such as blood pressure and pulse 
oximetry, are included. 
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1.12.1  Consent 
International guidelines recommend that patients consenting to ECT receive information 
about the treatment and that they may withdraw consent at any time.  In some countries 
patients must give written consent before receiving ECT, whereas verbal consent is 
sufficient in other countries (240). The practice of consent differs between countries (240, 
241). 
1.12.2  Anesthesia 
Anaesthetics are used together with succinylcholine as a muscle relaxant for ECT (modified 
ECT) (26). Some countries still practice unmodified ECT due to lack of equipment, lack of 
personnel, lack of anaesthesiologists, contraindication for anaesthesia, convenience, 
emergency, or for economic reasons (242, 243). Methohexital or propofol are most 
commonly used as anaesthetics (26).   
1.12.3  Electrode placement 
There are three main electrode placements; right unilateral (d’Èlia) (244), bilateral and 
bifrontal electrode placement.  
The UK ECT review group found that bilateral ECT had stronger antidepressive effect than 
unilateral ECT, and a high stimulus dose is more efficacious than a low dose, but bilateral 
ECT is associated with greater temporary memory impairment than unilateral ECT (27). 
However, studies with low dose unilateral ECT, known to be ineffective, were included in 
this meta-analysis. 
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Right unilateral electrode placement (RUL) administered just above the seizure threshold is 
not as efficacious as bitemporal electrode placement (BL) ECT (77). When high-dose RUL 
is used, studies have found the treatment may be at least as effective as bitemporal electrode 
placement, but with less memory impairment (244-248).  RUL is now the recommended 
electrode placement (26). Bilateral may sometimes be necessary when a maximum 
antidepressant effect is needed. 
Bifrontal electrode placement has been less frequently used than the others, but is suggested 
to have fewer cognitive adverse effects than bitemporal (249, 250). Sienaert et al. found no 
significant differences between the patients given bifrontal ECT and those given unilateral 
ECT, although patients receiving unilateral ECT achieved response/remission-criteria after a 
smaller number of treatments (251). A recent review found that bifrontal ECT is not more 
effective than bitemporal or right unilateral ECT, but may have modest short-term benefits 
for specific memory domains. Bifrontal ECT has potential advantages, but given longer 
experience with bitemporal and right unilateral, bifrontal ECT requires better 
characterization (252). 
1.12.4  Dose of electricity 
The total dose of electricity is determined by amperage, pulse width, frequency of pulses and 
total stimulation time. There are different methods for determining the electrical charge 
required to induce an effective seizure. With the “stimulus titration method,” one first 
determines seizure threshold by starting at a low level and increasing the electrical energy 
until the threshold is reached. Treatment is then provided with a charge well above the 
seizure threshold (77), generally 1.5-2.5 times the threshold in bilateral ECT, 4-8 times the 
threshold in right unilateral ECT (253, 254). McCall et al. (255) found in right unilateral 
ECT that doses 3-5 times the seizure threshold were more effective than 2.25 times, and 8-12 
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times more effective than 3-5 times. However, an increase in stimulus dose may also 
increase adverse effects. 
Factors which can influence the seizure threshold are age, gender, medication and 
anaesthesia. Accordingly, another method of dose finding is based on the patient’s age, to 
which the dose is adjusted (aged-based dosing). A third method is to use a fixed high dose, 
usually about 400 mC (256). The stimulus dose should be adjusted for gender, in that men 
may have up to double the seizure threshold of women (253). Moreover, the dose must 
sometimes be adjusted during the treatment series due to increasing threshold. 
1.12.5  Seizure monitoring 
A generalized cerebral seizure is necessary, but is not always sufficient to achieve 
antidepressant effect. Seizure duration of at least 25-30 seconds and a good EEG quality are 
usually necessary for effect, as is heart rate acceleration and a period of postictal 
disorientation. Therefore, seizure monitoring includes observation of motor activity, EEG, 
cardiovascular response and postictal disorientation time (3).  
1.12.6  Number of treatments 
The treatment is administered two to three times per week. A treatment series is usually 
between six and 12 treatment sessions. The CORE group (Consortium for Research in 
Electroconvulsive Therapy) found that an average of 7.3 sessions with ECT were necessary 
to obtain effect, which is consistent with the results from other studies (184, 244, 257). 
However, in some cases as many as 20 treatments may be necessary (26). 
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1.13 Attitudes 
Despite documented efficacy, ECT still remains controversial, fiercely debated and stigma-
bound. Reasons for negative attitudes among the general public, medical students, 
psychology students, other health workers, and even psychiatrists may be lack of knowledge, 
education and experience, as well as ideology (258-264). The negative impression of non-
modified ECT, cognitive side effects and unfavourable descriptions in books and films (One 
Flew Over the Cuckoo’s Nest) may have contributed to the negative attitudes as well. 
Reported experience of side effects such as memory impairment has been extensive (28). 
The attacks against ECT have led to stigmatization, and many psychiatric treatment facilities 
do not offer ECT. 
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2. The thesis 
2.1 Aims of thesis 
The aim of this dissertation is to study the practice of ECT and rates of use in Norway and 
worldwide.  
This doctoral dissertation protocol on use of electric stimulation of the central nervous 
system in psychiatry covers these aspects: 
 
1. ECT prescription rate, demographic distribution and diagnoses of the patients at a 
county hospital in Norway over a period of 11 years (Paper I). 
2. The use of ECT, demographics and diagnoses in different psychiatric hospitals, as 
well as attitudes among psychiatrists in Norway (Paper II). 
3. The practical use of ECT (Administration of ECT and ECT parameters), as well as 
side effects and outcomes in different psychiatric hospitals in Norway (Paper III). 
4. The contemporary (1990 until 2011) worldwide (by continents, countries, regions, 
large city hospitals and/or country hospitals) use of ECT, ECT parameters (ex. 
electrode placement, dosage strategies) and practice, in psychiatric (both inpatient 
and outpatient) establishments (Paper IV). 
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3. Material and methods 
3.1 Material 
We studied patients who received ECT at a county hospital between 1993 and 2003, as well 
as patients in Norway receiving ECT in 2004 (Papers I-III). In paper IV a retrospective study 
of the scientific literature on the use of ECT worldwide was performed using databases or 
papers published between 1990 and November 2010. 
Table1. Characteristics of papers I-IV 
Paper I II-III IV 
Design Retrospective Cross-section Systematic review 
Year 1993-2003 2004 1990 to November 
2010 
Geographical area Ålesund, Norway Norway Worldwide 
Selection  Data about ECT 
treatment extracted 
from patient journals 
and ECT journals 
Questionnaire to 
psychiatric units, 
DPS and child and 
adolescent units 
about ECT practice 
and treatment 
A systematic 
database search and 
data extracted from  
observational studies 
on ECT use, rates 
and practice 
N N= 210 patients 
Women 65 % 
N= 672 patients 
Women 66 % 
Response rate: 54 % 
N= 70 included 
studies 
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The study in Paper I was carried out at a psychiatric unit at a county hospital, Ålesund, 
located on the western coast of Norway, which provides health services for patients 18 years 
and above, with a catchment area of 122,000 inhabitants in 1993, increasing to 127,000 in 
2003. Between 1993 and 2003 the mean number of annual admissions to the psychiatric unit 
was 491 (range, 299-822). Beginning in 1998, all acute patients from the region were 
admitted to the county hospital as the hospital built a new psychiatric unit (for involuntary 
patients). We wanted to study patients admitted to the psychiatric unit from 1993 to 2003 
who received ECT as part of their hospitalization. We found 210 patients who had received 
ECT during this period. Of these 137 (65%) were women, and the patients had a mean age of 
54 (range 20-94). 
Papers II and III were based on responses from psychiatric departments that had received a 
questionnaire about electroconvulsive therapy. Data were collected between March and 
December 2005. A total of 67 (54 %) units finally responded, including 26 (67 %) of the 39 
psychiatric hospitals, 32 (46 %) of the 69 district psychiatric centres (DPCs), and nine (53%) 
of the 17 child and adolescents units. Responses came from all health regions. ECT 
equipment was present and used in 19 (28 %) of the responding units. There were 672 
patients who received ECT in 2004 in those 19 psychiatric units.   
In Paper IV a systematic literature search was undertaken in the following databases: 
Medline, Embase, PsycINFO, SveMed and EBSCO/Cinahl, limited from 1990 to November 
2010 (Appendix I, Table 1, Paper IV). 
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3.2 Methods 
3.2.1 Design of studies  
3.2.1.1. Paper I 
Paper I is based on data collected retrospectively from dedicated ECT journals and patient 
medical records. These two sources of information were not independent, as the same 
physician recorded both, but they included different details. Medical records of six patients 
could not be retrieved, and for these patients information was obtained only from the ECT-
journals. Information about total patients admitted to the psychiatric unit was obtained from 
the administration of the hospital. We chose a retrospective study design to be able to 
evaluate the stability of rate of use of ECT, age, gender and diagnoses of patients over a 
period of 11 years (Paper I). 
3.2.1.2. Papers II &III 
Papers II and III are based on data from a questionnaire (see appendix I). The questionnaire 
contained standardized, open and partly open questions regarding the use of ECT. These 
questions were evaluated by three psychiatrists (OML, PB, and BW). Reasons for the choice 
of a cross-sectional design were to examine prevalence rates, demographics, diagnoses and 
indications of ECT in Norway today. In addition, some supplementary questions regarding 
psychiatrists’ attitudes regarding ECT made it possible to explore reasons for not prescribing 
ECT. 
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3.2.1.3. Paper IV 
In paper IV the method for screening the literature and data extraction followed the 
guidelines of the “Cochrane Handbook for Systematic Reviews of Interventions”, Chapter 
13, concerning inclusion of non-randomized trials. Search terms intended for Medline were 
adapted as required for other databases. Terms used were ‘electroconvulsive therapy,’ 
‘electroshock,’ ‘electroconvulsive,’ and ‘ECT,’ combined with any of the following: ‘use,’ 
‘utilization,’ ‘practice,’ ‘survey,’ ‘statistical data,’ ‘frequency,’ and the search was limited to 
human use from 1990 until November 2010. Relevant references, known to authors of this 
review, published on governmental internet sites, or from published text books (Swartz 
2009) or reference lists in retrieved included papers, were added by hand. 
3.2.2 Method description  
3.2.2.1. Inclusion and exclusion criteria: 
Paper I:  
Inclusion criteria:   
All patients admitted to the psychiatric unit from 1993 to 2003 who received ECT as part of 
their hospitalisation were included in the analyses. All patients were 18 years or above. 
Some of the patients had more than one ECT series, but only the first ECT series in the 
period was included in the data analyses. All patients provided informed consent to ECT 
treatment. Six patients withdrew consent and treatment was terminated. 
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Papers II and III: 
Inclusion criteria: 
The questionnaire was sent to all Norwegian psychiatric hospitals, DPCs and child and 
adolescent psychiatric units (125 units in total), and concerned the use of ECT in 2004. A 
DPC provides specialized outpatient health service and inpatient treatment for the nearby 
population up to about 150,000 inhabitants, while psychiatric hospitals provide tertiary 
health services. The questionnaires were sent to the head of the psychiatric department of 
each unit. A new set of questionnaires was sent to those who had not answered within three 
months. Data about ECT equipment and their dispersion were based on answers to the 
questionnaire and from information from technical consultants with knowledge of the 
departments’ equipment. 
Exclusion criteria: 
Departments treating patients with substance dependence, habilitation units, psychosomatic 
and pure psychiatric outpatient departments were not included. 
Paper IV: 
Screening of literature was done by two researches (KAL, BH) who independently checked 
the titles and, where available, the abstracts of the studies identified by the electronic 
database searches. All references appearing to meet inclusion criteria, including those with 
insufficient details, were requested in full text. All researchers (KAL, LJVS, BH) consisting 
of two pairs independently extracted data from the retrieved full text articles according to a 
pre-made data extraction scheme. All discrepancies were resolved by consensus 
meeting/discussion, and the final decision taken by the first author (KAL). 
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Inclusion criteria:  
Data-based observational studies or surveys with reported ECT utilization, frequency, or 
prevalence rates, by data collected from 1990 and until November 2010, for patients in 
psychiatric establishments (inpatients or outpatients) in well-defined continents, countries, 
regions, cities, or local hospitals were included. Also included were relevant studies 
published near the date limits for this study (from 1990) for geographical areas that had few 
pertinent publications. English, Scandinavian (Norwegian, Swedish, Danish) and European 
(German, French, Spanish, Portuguese, Turkish) languages were included. In addition to the 
authors’ European language fluency, the online Google translation tool 
(http://translate.google.com/) was used when needed (such as for Portuguese and Turkish). 
Exclusion criteria: 
Excluded were studies or surveys that were not data-based, had no or unclear report of ECT 
utilization, frequency, prevalence rate, practice, or had ill-defined populations. All reports of 
utilization frequency, prevalence rates of ECT in selected samples or subgroups (e.g., 
young/adolescent, elderly) or special populations (such as pregnancy, disability, mental 
retardation) and qualitative studies about clinicians’ or physicians’ subjective experience 
(views or opinions) on ECT were also excluded. 
3.2.3 Instruments and variables 
3.2.3.1.Instruments 
In Papers II and III a questionnaire consisted of 40 items in three parts. Parts one and two of 
the questionnaire were to be filled out by all addressees and included questions about the 
institution, whether ECT was used or not and psychiatrists’ attitudes towards ECT. The 
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questions about attitudes (seven items) were similar to the attitude questions from a 
questionnaire study about ECT in Germany (265). Part three of the questionnaire was to be 
filled in only by departments using ECT, and dealt with the implementation of ECT, such as 
practical routines, consent routines, demographics, diagnoses, side-effects and outcomes of 
ECT. 
3.2.3.2. Description of variables 
Paper I 
The following data was collected from the ECT journals and medical records: gender, age, 
diagnosis and number of treatments in the course. Age was later divided into groups: <25, 
25-34, 35-44, 45-54, 55-65, >65 years. When analysing use of ECT per 100,000 population 
per year, age was divided into three age groups due to small number of patients in some 
groups: 20-49 years, 50-69 years and over 70 years. Diagnoses were based on ICD-10 and 
grouped into schizophrenia and paranoid psychosis (F20- F22), bipolar disorder (depressed, 
mania or mixed) (F31), major depressive disorder (F32-F34), anxiety disorder (F40-F43), 
puerperal mental disorder (F53) and personality disorder (F60-F61). Until 1998 patients 
were diagnosed using ICD 9, later with ICD 10. ICD 9 diagnoses were transformed into 
corresponding ICD 10 diagnoses by two psychiatrists. 
Papers II-III 
In Paper II information collected included questions about the institution, whether ECT was 
used or not, reasons for not prescribing ECT, referral to other facility, population base and 
number of inpatients. We also collected information about waiting lists, travelling distance, 
number of treated patients, gender, age distributions, diagnoses, indications, and attitudes. 
Age was divided into groups: < 18, 18-24, 25-44, 45-64, >64 years. Diagnosis information 
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consisted of ICD-10 categories and was grouped into schizophrenia (F20), polymorph 
psychosis (F23), schizoaffective disorder (F25), bipolar disorder (depression, mania, mixed 
episode) (F31), unipolar depression (F32-33), Parkinson’s disease (G20), and other 
diagnosis. It was possible both to give the total number of patients in each diagnostic 
category and to isolate those diagnoses for which ECT was usually used. Of the 672 patients, 
we received diagnostic information from 319 patients in 16 of the 19 units. Indications were 
divided into lack of psychopharmacologic effect, patients` decision, psychotic features, 
refusing to eat and drink, suicide risk, catatonia, postpartum, side effects of drug treatment 
and other indications. It was possible both to give the total number of patients in each 
indication category and only indications usually used for ECT. We received information 
about indication in 163 patients in 10 units. Opinion and attitude questions to psychiatrists 
about ECT contained seven questions and could be answered with yes or no; ECT is 
redundant because of psychopharmacology, hospitals ought to offer ECT as a treatment 
option, there are clear indications for ECT, ECT is a last resort, ECT does not cause 
reversible memory impairment, ECT is underused, and ECT can cause brain damage.  
In Paper III information collected included questions about the administration of ECT; staff 
(who decided whether ECT should be prescribed, who performed ECT, with or without 
supervision, who gave anaesthesia, and personnel present during treatment); ECT training 
program; and, treatment capacity per day. Information about consent routines was collected 
and divided into three non-exclusive categories; oral information, written information and 
written informed consent. Information about treatment characteristics included pre-treatment 
examination; anaesthetic agents used, use of hyperventilation, intubation, oropharyngial tube 
and tooth protection; electrode placements (right unilateral, bilateral or bifrontal), methods 
of deciding stimulus dose, monitoring (EEG, cuff method, observation of convulsive motor 
activity), number of treatments, and equipment and facilities. Information about 
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psychotropic drugs used during treatment was collected. This question was open and later 
divided into antidepressants, antipsychotics, lithium, anticonvulsants and benzodiazepines. 
The psychotropic drugs were divided into continued, reduced or discontinued. In addition, 
we collected information about the use of continuation/maintenance ECT and ambulatory 
ECT. Information about outcomes was divided into very much improved, much improved, 
minimally improved, no change and worse. We received information about outcomes in 246 
patients from 10 units. Information about adverse effects was divided into memory 
impairment and headache. Memory impairment was divided into minimal, much, very much 
and long-lasting, whereas headache was divided into minimal, much and very much. We 
received information about adverse effects in 263 patients from 10 units about memory, and 
about 274 patients from 11 units regarding headache. It was possible to report deaths related 
to ECT. It was not possible to indicate no side effects. See appendix I for questionnaire 
details. 
Paper IV 
In Paper IV information collected included: number of persons treated with ECT, number of 
ECT administrations, the percentage of ECT-treated patients among the inpatients 
(psychiatric hospital admitted), and average number of ECTs administered per patient (in 
one course). Information about ECT parameters, such as use of modified or unmodified 
ECT, electrode placement, type of ECT device, as well as diagnoses and main indications 
were also collected. Gender and age were noted, as well as ethnicity, education, side effects, 
mortality, adverse events, use of written consent and involuntary conditions.  
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3.3 Ethical consideration 
Ethics approval was not required by the Regional committees for medical and health 
research ethics, for data collection in Papers I-III. Paper I was considered to be a quality 
control of retrospective data and, as such, the committee stated that no further approval was 
needed. For Papers II and III it was not possible to identify patients on the data collection 
procedure. The psychiatrists responding in Papers II-III were anonymous and decided 
whether they wanted to answer or not. 
3.4 Statistical analysis 
In Paper I the frequencies per year were calculated as percentage of inpatients receiving 
ECT, number of ECT patients and treatment sessions per 100,000 population, and mean 
number of sessions per ECT series.  These were analysed by Poisson regression, with year as 
independent variable, adjusting for number of inpatients and population. The yearly variation 
in use of ECT was analysed in mixed model Poisson regression, with year as random effect. 
The proportion of psychiatric patients given ECT per year was analysed in logistic 
regression, with gender, age group and year as covariates. Population development 
information for the years 1993-2003 was obtained from Statistics Norway (195). 
In Paper II rate of ECT use per 10,000 population per year and number of inpatients 
receiving ECT in various health regions and for the whole country were calculated based on 
the answer to the question regarding the number of patients treated in 2004, and applying 
data from Statistics Norway (266). Descriptive analyses were made of demographics, 
diagnoses, indications, and attitudes. Rates of ECT use were compared between health 
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regions with Pearson’s chi squared test. Some units failed to answer certain items, resulting 
in variations in N between the questions.  
In Paper III descriptive data are presented with percentages. The following items were 
described: administration of ECT, consent routines, pre-treatment examinations, treatment 
courses, psychotropic drug use during treatment, continuation/maintenance ECT (CM-ECT), 
ambulatory (outpatient) ECT (A-ECT), training, side effects, and outcome. Some units did 
not answer all items, resulting in some variations in N in the results.  
In Paper IV, where possible, utilization data have been presented either (1) as number of 
persons ECT treated per 10,000 resident population per year; that is, treated person rate 
(TPR), (2) number of ECT administrations per 10,000 resident population per year; that is, 
ECT administration rate (EAR), (3) the proportion in percent (%) of ECT-treated patients 
among the inpatient (psychiatric hospital admitted) population; that is, inpatient prevalence 
(iP%), and (4) average number of ECTs administered per patient (in a course); that is, 
average ECT number (AvE). Information about ECT parameters, diagnoses and main 
indications, gender and age are also presented. Other information such as ethnicity, 
education, side effects, mortality, adverse events, use of written consent, and involuntary 
conditions has also been noted. 
The statistical analyses were carried out using SPSS version 19 (Paper I) and 15 (Paper II 
and III), and Stata Version 12 (Paper I). 
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4. Summary of papers  
4.1 Paper I 
Jarosch-von Schweder L., Lydersen S., Bergsholm P., Ottesen Kennair LE., Linaker OM.  
Electroconvulsive therapy at a county hospital: Rates of use, demographics and 
diagnoses. Submitted. 
Objective: This retrospective study of the clinical use of ECT in a county hospital, Norway, 
between 1993 and 2003, aimed to determine the rates of use, patient demographics and 
diagnoses, and to compare standards for ECT practice at this specific hospital, with similar 
studies conducted elsewhere.  
Method: The study is based on data collected from specific ECT records and patient medical 
records. Frequency rates were calculated as number of ECT treatments per 100,000 per year, 
number of patients receiving ECT per 100,000 per year, and percentage of inpatient 
admissions who received ECT.  
Results: Over the course of 11 years, 210 patients had received ECT, representing 4.2 % of 
all patients. Only the first ECT series was analysed. There was no trend in the proportion 
receiving ECT during that period. It varied between 1.8% in 2000 to 5.7% in 1997. There 
was a mean of 15.2 patients per 100,000 per year treated with ECT during that period.  In 
total, 1,657 ECT treatments were administered to the 210 patients, giving a rate of 109 ECT 
treatments per 100,000 person per year. Of the patients, 137 (65%) were women, and 76 
(36%) were 65 years old or older. ECT was used more in the older age groups, 50-69 years 
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and 70 years and above. Depressive disorders were the most common diagnostic indication 
(N=157), followed by bipolar disorder, (N=22) and other diagnoses (N=22). 
Conclusion: We found the rate of use to be stable during the study period. Most patients 
who received ECT were women and elderly, and depression was the most common disorder. 
4.2 Paper II 
Schweder L.J., Lydersen S, Wahlund B., Bergsholm P. and Linaker O.M.  
Electroconvulsive therapy in Norway: rates of use, clinical characteristics, diagnoses 
and attitude. J. ECT. 27,292-295. 2011a. 
Objectives: The aim of the study was to describe the rate of use and geographic and 
demographic distribution of electroconvulsive therapy (ECT) in Norway in 2004, as well as 
attitudes among Norwegian psychiatrists about ECT. 
Methods: A 40- item questionnaire on the practice of electroconvulsive therapy was sent to 
125 Norwegian psychiatric hospitals, district psychiatric centres (DPC), and child and 
adolescent psychiatric units in 2004.  
Results: A total of 67 (54 %) psychiatric units finally responded, including 26 (67 %) of the 
39 psychiatric hospitals, 32 (46 %) of the 69 DPCs, and nine (53%) of the 17 child and 
adolescent units. ECT equipment was present and used in 19 (28 %) units. Lack of facilities 
(equipment and anaesthesia) was the main reason for not employing ECT. There were 672 
patients who received ECT during 2004, which gives a yearly incidence of 2.4 / 10,000 
inhabitants. In total, 5.3 % of all inpatients received ECT. The rate of ECT use varied 
significantly from 1.83 to 3.44 per 10,000 inhabitants per year between the different Health 
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Regions. Of the 672 patients, we got gender information on about 394 (59%), of which 135 
were men and 259 were women. We got age information from 367 patients. Patients in the 
age group >64 (55 %) most commonly received ECT. The most common diagnoses were 
depressive episode or recurrent depressive disorder (70 %), followed by bipolar depression 
(19 %), and schizoaffective disorder (4 %). Lacking effect of psychopharmacologic 
treatment was the most common reason for ECT. The responders expressed generally 
positive attitudes towards ECT. Almost all considered ECT important, thought that hospitals 
should offer ECT, and that there are solid indications for such treatment. Most expressed 
concern about underuse of ECT.  
Conclusions: ECT is widely available in Norway, but use is unevenly distributed between 
health regions. The attitudes toward ECT are generally positive among psychiatrists. 
4.3 Paper III 
Schweder L.J., Wahlund B., Bergsholm P. and Linaker O.M.  
Questionnaire study about the practice of electroconvulsive therapy in Norway. J. ECT 
27;296-299. 2011b. 
Objectives: The aim of the study was to describe the contemporary practice of 
electroconvulsive therapy (ECT) in Norway.  
Methods: A 40-item questionnaire on the practice of electroconvulsive therapy was sent to 
125 Norwegian psychiatric hospitals, district psychiatric centres (DPC), and child and 
adolescent psychiatric units in 2004.  
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Results: A total of 67 (54 %) psychiatric units responded, including 26 (67 %) of 39 
psychiatric hospitals, 32 (46 %) of 69 DPCs, and nine (53 %) of 17 child and adolescents 
units. Trainee psychiatrists most often administered ECT, with or without supervision, but 
underwent a training program before ECT. In one hospital the nurses administered ECT. 
Written informed consent was used in 50 % of institutions providing ECT. Oral information 
about ECT was always given. Psychiatrists were mostly satisfied with the facilities, and up-
to-date equipment was used. Only modified ECT was administered and mostly anaesthetists 
gave anaesthesia. Right unilateral electrode placement was preferred, but with variations in 
dosage strategies. The practice in most of the departments was to discontinue some classes 
of psychotropics prior to ECT, mostly benzodiazepines and anticonvulsants. 
Antidepressants, lithium and antipsychotics were most often continued. 
Continuation/maintenance and ambulatory ECT were used in 88 % and 63 % of departments 
respectively. Most patients benefitted from ECT (78 %). Headache and memory impairment 
were frequent, but not reported as serious adverse effects. 
Conclusions: The administration of ECT in Norway in 2004 was mostly in accordance with 
international guidelines. Compared with the last Norwegian survey in 1978, all institutions 
used modified ECT and brief pulse machines, and unilateral ECT was the preferred electrode 
placement.  National guidelines should be developed, as there were considerable variations 
in practice among the hospitals. 
4.4 Paper IV 
Leiknes, K.A., Jarosch-von Schweder, L., Høie, B.  
Contemporary use and practice of electroconvulsive therapy worldwide. Brain Behav. 
2012 May;2(3):283-344. 
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Objective: To explore contemporary (1990 and after) utilization and practice of 
electroconvulsive therapy (ECT) worldwide.   
Methods: Systematic search (limited to studies published 1990 to November 2010) was 
undertaken in the databases Medline, Embase, PsycINFO, SveMed, and EBSCO/Cinahl. 
Primary data-based studies which reported ECT utilization and practice in psychiatric 
institutions internationally, nationally, or regionally were included. Relevant references 
known to authors of this review, published on governmental internet sites, or from newly 
published text books or the reference lists in retrieved included papers were also found. Two 
researchers independently checked study titles and abstracts according to inclusion criteria. 
All researchers, consisting of two pairs, independently extracted data from the retrieved full-
text articles according to a predetermined data extraction scheme.  
Results: Seventy studies were included, seven from Australia and New Zealand, three from 
Africa, 12 from North and Latin America, 33 from Europe, and 15 from Asia. Worldwide 
ECT differences and trends were evident. Average number of ECT administered per patient 
was eight. Unmodified ECT (ECT without anaesthesia) was used in Asia, Africa, Latin 
America, Russia, Turkey and Spain. Worldwide preferred electrode placement was bilateral, 
although some places (Europe and Australia/New Zealand) preferred unilateral. Although 
brief-pulse wave was mainstream, sine-wave devices were still used. The majority of ECT 
treated patients were older women with depression in Western countries, versus younger 
men with schizophrenia in Asian countries. ECT under involuntary conditions (admissions), 
use of ambulatory-ECT, acute first line of treatment, as well as ECT administered by other 
professionals (geriatricians, nurses) were noted in some places. The general trends were that 
only some institutions within the same country provided ECT, training was inadequate, and 
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guidelines were not followed. Mandatory reporting and overall country ECT register data 
were sparse.  
Conclusion: Many patients are still treated with outdated unmodified ECT today. There are 
widespread differences in ECT utilization, administration and practice worldwide. There is a 
need for sharing of knowledge about ECT, reflection and learning from each other’s 
experiences.  
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5. Discussion 
5.1 Main findings 
We found that there were variations in use of ECT between regions in Norway and between 
countries worldwide. Among patients receiving ECT there was a preponderance of older 
women with depression in western countries including Norway, versus younger men with 
schizophrenia in Asian countries. Most Norwegian patients were reported to benefit from 
ECT, and side effects, such as memory impairment and headache, were reported to be minor 
problems. In Norway, antidepressants and antipsychotics are commonly used during ECT.  
There are still countries using unmodified ECT. Preferred electrode placement was bilateral, 
except in Europe and Australia/New Zealand, where unilateral electrode placement was 
preferred. Psychiatrists in Norway expressed generally positive attitudes towards ECT. 
5.2 Empirical issues 
5.2.1 Precription rates of ECT  
Our results presented in this thesis confirm that there are large variations in clinical practice 
between countries and regions (34, 37, 242, 267, 268), despite international guidelines (26, 
160, 161). Our studies present ECT utilization and practice from all continents, indicating a 
widespread use of ECT in the world today. Two continents, Africa and Latin America, have 
sparse ECT country data. This may indicate a trend away from ECT (269), which does not at 
all seem to be the case in the rest of the world. Although reports of ECT seem abundant in 
Europe, Asia, North America and Australia, the data does not cover all countries known to 
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have ECT practice. There are, for example, no “up to date” (1990 and after) ECT studies 
identified from either Iceland or Canada. 
ECT in Norway during 2004 was given to 2.4 patients per 10,000 inhabitants, which was 
higher than the 0.98 patients per 10,000 inhabitants reported in the previous study in 1978 
(20). The frequency was lower than in Belgium, 6.8 in 2003 (36); the Netherlands, 8.5 in 
2007 (48); Denmark 3.0 in 1999 (33); and Sweden, 4.9 in 2008 (270). Most responding 
psychiatrists (Study II) from Norwegian hospitals expressed concern about underuse of ECT. 
This could have implications for patients not receiving necessary ECT. However, the rate of 
use in Norway was higher than in Germany, 0.08 in 1986 (265); Poland, 0.11 in 2005 (34); 
Spain, 0.61 in 2001 (242); Russia, 0.54 in 2003/2004 (35), and, Lithuania, 0.375 in 2010 
(268). In Poland (34) anaesthetists are not available in many hospitals, and there is also a 
lack of training courses, both of which contribute to the low rate. In Russia (35) ECT 
depends more on individual enthusiasm than on regulatory standards. In Germany negative 
attitudes among patients and health personnel contribute to the low rate of use, despite 
positive attitudes among psychiatrists (265).    
In our study of ECT at a county hospital, the use of ECT remained stable between 1993 and 
2003, similar findings to a study in Hong Kong (271).  
Our study of ECT in Norway shows that ECT is used in many hospitals and one or a few 
district psychiatric centres. Our data confirm that there are large variations in rates between 
the various health regions, although the number of hospitals providing ECT is spread among 
the health regions. The rate was lowest in the northern health region, and highest in the 
western health region. Such regional differences have been reported in other studies (36, 
265). We have not found any data, such as availability of ECT or attitudes, which explain 
these geographical differences, except for a high, non-significant negative correlation 
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between use and distance to the ECT facilities. It is conceivable that long distances may 
contribute to lower ECT rate. Most hospitals that offer ECT use it frequently, 47 % treated 
more than 30 patients with ECT per year. However, the capacity of providing ECT was 
reported to be too low. Patients had to wait more than one month for treatment, which may 
result in longer episodes of illness. The main reasons for not using ECT were lack of 
equipment or unavailable anaesthesia, in line with an earlier Norwegian study, as well as 
other reports (20, 242, 272). Other potential reasons are lack of financial support, negative 
public attitudes towards ECT, and long distances to hospital, especially in the northern 
region of Norway. In our review of ECT worldwide (data from 1990), rates are computed in 
the data extraction to TPR (treated person rate) per 10,000 population to make it comparable, 
due to no internationally accepted uniform standards of ECT utilization reporting. The TPR 
per 10,000 (general population) varied from 0.11 (34) to 5.1 (273); likewise, the proportion 
of inpatient receiving ECT varied greatly with 21-28 % in Africa (274, 275) to 0.4-1.3 % in 
the USA (276, 277). Although the large worldwide differences in ECT utilization have been 
pointed out previously (34, 37, 242, 267), and the differences between countries on the basis 
of practice reports are not so easy to compare (due to large area and different languages) 
(278), overall variations in contemporary practice between the continents (Asia and Africa 
vs. USA, Australia and New Zealand, Europe) revealed by this review are large. 
Explanations of these variations are complex, encompassing not only the diversity in 
organization of psychiatric services, but probably also grounded in professional beliefs 
concerning the efficacy and safety of ECT (27). 
5.2.2 Demographics and Diagnosis  
ECT has long been held as a last-resort treatment for medication-resistant and very severe 
life-threatening clinical conditions (21, 279) as reported from the USA (29). However, a 
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change in ECT indication towards first line acute treatment (life-saving, catatonia, previous 
good response and patient preference) is apparent not only in Europe (152, 265, 280), but 
also Saudi Arabia (281) and Australia (282).  
The most common indication for ECT use in Norway is depressive illness (89%), as in the 
Norwegian 1978-study (20), but it is sporadically used in psychotic disorders other than 
psychotic depression (4.7 %). The reason might be the availiability of antipsychotics and that 
ECT is generally not an accepted treatment for psychosis in Norway.  
It is also rarely used in mania (0.9 %), although the response rate in mania is as high as in 
depression (91). In Europe, some sites (Brussels and Wallonia in Belgium) seem to regard 
ECT as a pure ‘antidepressant,’ using it exclusively for the treatment of depressive disorder 
(36). Interestingly, in Asia (ex. India, Thailand, Pacific Region, Japan) ECT seems to be 
regarded as an “antipsychotic” agent (31, 243, 278, 283-285). Discrepancies in indications 
could be due to differences in diagnostic practice, a lower recognition and under-treatment of 
depressive disorder, limited access to updated literature, and lower mental health care 
budgets (31). Another explanation might be the historical use of ECT in Europe and early 
spreading from Europe to the United States.  
In our study of ECT at a county hospital we found that seven women (3%) with puerperal 
depression were treated with ECT. This treatment, with proper medical care, is effective in 
all trimesters of pregnancy, as well as in the postpartum period (156). However, 
consideration of risk and benefits of ECT must be taken into account, including the risk 
involved for the foetus/unborn child (158).   
In Norway more women than men received ECT, and the majority of those patients were in 
the ≥65 (55 %) age group. Reasons for the increased usage in older adults might be higher 
56 
prevalence of severe depression among the elderly, higher rates of psychomotor changes and 
psychotic features in depressed elderly, somatic comorbidity making psycho 
pharmacological treatment contraindicated, as well as complications associated with 
polypharmacy. These results correspond to previous literature from Western countries (139, 
141), also in Hong Kong (286), which indicates a predominance of patients receiving ECT 
to be elderly females with affective disorder (unipolar/bipolar depression) (139-141, 180). 
Except for younger patients, female gender and depression predominance was also found in 
Saudi Arabia (281) and Pakistan (287). Interestingly, study IV found that in the USA the 
typical ECT patient is said to be an elderly white female paying for treatment with insurance 
or private funds (277). Higher ECT treatment rates are found among Caucasians in 
Pennsylvania (277), England (288) and Western Australia (289), which might imply 
discriminatory factors in selection for treatment. There were no patients under 18 years of 
age who received ECT in Norway in our studies. Though, severe depression, mania and 
schizophrenia are also present in patients under 18 years, and for these patients ECT might 
be a treatment choice for achieving remission of symptoms (290). Current studies report 
equal clinical efficacy to adults (150, 291). 
5.2.3 Effects and Adverse effects 
The response rate to ECT in severe depressive disorders is high (26), and our results from 
Norway indicate that 78% of the patients were very much or much improved after ECT.  
Medication treatment failure has been suggested to predict the efficacy of ECT, whereas 
others report that antidepressant medication resistance does not influence short-term 
response to ECT (292). Our results indicate that patients benefit from ECT despite failing 
antidepressant medication trials.  
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There is an ongoing debate about the contribution of ECT to memory impairment after 
treatment. In our study, much or very much memory impairment was reported by 15 % of 
the patients after ECT. This was long-lasting, up to four months, in four patients (2%). 
However, we do not know whether these adverse effects were related to ECT or to other 
factors, such as continued low grade depression, anaesthesia, seizure length, old age, drugs 
and somatic illness. Cognitive adverse effects can be reduced without loss of efficacy by 
using high dose right unilateral ECT, which was generally employed in Norway, instead of 
bitemporal ECT (77, 293). Ultra brief electrical pulses and other electrode placements 
(bifrontal; left anterior right temporal) may possibly also reduce cognitive side effects (294, 
295), but these methods are seldom used in Norway.  
As in our study, mild transient headache after ECT is common (197). Prophylactic analgesic 
treatment may be warranted in those who experience marked post-ECT headache.  
Worldwide, reports about side effects, adverse events, and mortality rates are sparse. 
Mortality rates were reported from Thailand (0.08%) (31) and Texas (14 deaths per 100,000 
treatments within two weeks after ECT) (296). However, it is not clear if these deaths were 
caused by ECT or comorbid somatic illnesses, e.g., cardiac arrhythmia, anaesthetic 
complications or suicides. Side effects from unmodified ECT are typically fractures, 
dislocations and teeth injuries (243). 
5.2.4 ECT and medication 
Although the American Psychiatric Association Task Force on ECT discouraged 
combination treatment, due to minimal evidence for enhanced efficacy and concern about 
increased adverse effects (26), combination treatment with antidepressants and 
antipsychotics commonly are continued during ECT in Norway. There are few studies that 
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support the concomitant use of antidepressant during ECT. In one study, Sackeim et al. 
found that concomitant treatment with nortriptyline or venlafaxine during a course of ECT 
enhanced the efficacy in major depression relative to placebo (164), and nortriptyline 
reduced the cognitive side effects of ECT, whereas venlafaxine tended to worsen them. High 
dose venlafaxine together with ECT should therefore be avoided because of the adverse 
effects, including cardiac effects as asystoly (163, 297). A recent Cochrane review found that 
ECT, including CM-ECT, added to antipsychotics was superior to antipsychotics alone in 
schizophrenia (106), and adverse effects did not appear different from that seen with ECT 
alone (298, 299). In more than half of the responding institutions in Norway, lithium was 
continued during ECT. There are case reports and reviews that have found this combination 
to be safe (170, 171), but there is no consensus on the safety on this practice (159). 
Guidelines recommend lithium during ECT only after a risk/benefit analysis, and 
discontinuing lithium seems to be the appropriate practice (26, 159, 168). If lithium is 
continued during ECT, Sackeim has recommended not giving lithium the day before each 
ECT session (172). Benzodiazepines and anticonvulsants were mostly discontinued, 
probably because these might raise the seizure threshold and decrease efficacy. However, 
Sienaert et al. found that not all anticonvulsants have equivalent effects in this regard, with 
lamotrigine being less problematic than others (173). In patients who do not respond to ECT 
alone, the concomitant use of psychotropic medication during ECT might be useful. Since 
there is a  high relapse rate after ECT and a delay in the onset of effect after starting with 
AD, use of concomitant medication should be re-evaluated (159). 
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5.2.5 Clinical Practice/ECT parameters 
5.2.5.1. Administration 
ECT worldwide is mainly administered by psychiatrists and trainee psychiatrists. However, 
our studies found that other professionals also administered ECT in Europe, such as 
geriatricians, and in Norway, nurses (48). This is not in accordance with international 
guidelines, which recommend a psychiatrist at least being present (26). In contrast to some 
other countries (35, 300, 301), almost all units in Norway, even four not providing ECT, 
had a training program for ECT, despite no national formal standard being available. 
5.2.5.2. Consent 
Written informed consent should include information about benefits and risks of ECT, 
alternatives to ECT and information about the patient’s decision capacity (302). Despite oral 
consent to ECT being legally sufficient in Norway, written informed consent was used by 
50% of institutions in our study. The departments not using written informed consent might 
have used oral consent together with oral and/or written information about ECT.  
Written information is important for patients and close relatives, whereas written consent 
may not be appropriate. Thus, Ottosson and Fink (303) write: “It may be too much to insist 
on a signed, written consent. A nod of understanding and cooperation for the treatment as 
personnel meet no objection when preparing the patient should be acceptable. The insistence 
on a signed written consent encourages distrust and disturbs the delicate relationship 
between the patient and the psychiatrist. Yet, as the signed consent has become a standard of 
care in the United States and some other cultures, we accept this intervention as promoting 
better care.” 
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Worldwide ECT is administered to a substantial number of patients under involuntary and 
guardian consent conditions, ranging from 1-3 % (139, 242, 296) to 20-29 % (265, 304, 305) 
in the USA and Europe. In Asia written informed consent is mainly obtained directly or 
counter signed by family members (31, 281, 284, 287). Consent given by legal bodies varies 
from 18 % in Scotland (under the Scottish Mental Health Act) (305) to 60 % in Sydney, 
Australia (by the Mental Health Review Tribunal) (282). Mandatory reporting of data for 
ECT usage is done only in a few places, i.e., Texas, USA, and Australia (139, 296, 306). 
Likewise, legislature regulation of practice is sparse, although found at some sites. Such 
regulations include obligatory anaesthesia (34, 263), obligatory written informed patient 
consent (34), ECT licensed facilities (306), exclusion of ECT for patients less than 16 years 
of age (139), and court or legal body allowance for involuntary ECT (282). 
5.2.5.3. Modified/unmodified ECT 
Modified ECT is practiced in all institutions in Norway, which was not the case in the survey 
for 1968 to 1978 (20). In Norway ECT narcosis is given by an anaesthesiologist, mostly 
assisted by a nurse anaesthetist, which is recommended in guidelines (161). As in other 
countries, it is difficult to recruit trained anaesthesiologists to participate in ECT, and 
ambulatory anaesthesia teams are not common for ECT (36, 272). This has important 
implications for patients since this contributes to a low ECT capacity and long waiting 
periods for even severely ill patients in some institutions.  
An important finding in this thesis is that some countries still practice unmodified ECT.  On 
a worldwide scale, the number of patients receiving unmodified ECT is large. In Russia >80 
% of patients receive unmodified ECT, whereas in Asia >55 % receive unmodified ECT (14 
countries reported 129,906 unmodified ECT to 22,194 patients) and overall in Thailand 
estimated at 11.2 patients treated with unmodified ECT per 100,000 (307). The reasons for 
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this are diverse; Lack of equipment, lack of personnel, lack of anaesthesiologists, 
contraindication for anaesthesia, convenience, emergency and economic reasons (243). 
Whether these arguments are acceptable in light of knowledge about benefits and harms of 
modified ECT is another question. Despite attempts to ban it (308), argumentation defending 
unmodified ECT practice (309) is ongoing today (310). Our findings suggest that 
internationally acknowledged guidelines appear to have failed (311) in influencing important 
aspects of today’s ECT practice worldwide. In Europe, the USA and Australia/New Zealand, 
modified ECT was almost exclusively used. In several countries, Chuvash Republic in 
Russia, Russia, Spain and Japan, the practice of reported modified ECT was sometimes 
without muscle relaxants, and with assistants used to restrain extreme motion from the 
convulsions in Japan (312). The alarming practice of muscle relaxants without anaesthesia is 
also undertaken in a few Asian institutions (283). How the latter practice has come about is 
not easy to decipher, but availability and recruitment of anaesthesiologists are pointed out 
both in Asia and Europe (313, 314).  
5.2.5.4. Electrode placement 
Preferred placement of electrodes worldwide (approx. 80%) is bilateral, as it was originally  
(12). Australia, New Zealand (315), Vienna (316),  Munich (141) and Netherlands (48), 
though, adhere to unilateral as first choice, but use both types, which may indicate variation 
in practice of ECT. Right unilateral was the predominant electrode placement in Norway, in 
accordance with the recommendations of APA (26) and Scandinavian authorities such as 
d’Elia and Ottosson (51, 293), but bitemporal placement was also often used. Change from 
right unilateral to bitemporal placement is common practice if the response is insufficient, 
although two small studies suggest that continuous high-dose right unilateral stimulation 
may be at least equally effective with fewer side effects (245, 246). Fewer variations in ECT 
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practice between hospitals and countries and closer compliance to guidelines could be 
desirable even in Norway. 
5.2.5.5. Continuation electroconvulsive therapy (C-ECT) 
ECT is typically discontinued following response. Without continuation therapy, either with 
medication (antidepressants, lithium, anticonvulsants, and antipsychotics) and/or ECT, the 
risk of relapse is high within six months (183). The effect of C-ECT is well documented for 
depression (184). In Norway C- ECT for depression was available and used in 14 of 21 
institutions.  
5.2.6 Attitudes  
Attitudes of psychiatrists toward ECT were generally favourable in Europe as found in study 
II (Norway) and IV (for example Spain, Germany and Russia) of this thesis.  
In study II we found that the responding psychiatric hospitals in Norway generally had 
positive attitudes towards ECT. It is seen as an important treatment option, but probably still 
mostly considered for patients resistant to medication. In spite of lack of treatment guidelines 
for ECT in Norway, most clinics use the generally accepted indications and 
recommendations described by the American Psychiatric Association (26). Most express 
that ECT is underused and that it should be a treatment option in every hospital. Our attitude 
survey does not explain the relatively low use of ECT in Norway, or the unequal distribution 
of ECT use between health regions. The limited availability of ECT may be one cause for 
lower rates of use in some areas.  
Reasons for not prescribing ECT in Europe were attributed to lack of equipment, economy 
and difficulties in recruiting anaesthetists, but no doubt also patient and health personnel 
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knowledge of and attitudes towards ECT, as well as economy, infrastructure, and policy 
were influential (38-40).  
Negative attitudes may arise from ignorance, whereas positive attitudes come from 
experience and knowledge/information, as well as education and training resources in the 
psychiatric hospitals and medical schools. 
5.3 Methodological issues 
Methodological issues of this thesis will be considered from the two main forms of error; 
systematic error, referred to as bias, and random error (295). 
5.3.1 Systematic error (bias) 
5.3.1.1. Selection bias 
Selection bias is the error arising from procedures used for finding and including patients in 
Paper I, respondents in Papers II- III, relevant studies in paper IV, and from other factors 
influencing study participation.  
In Paper I, ECT patients were registered in ECT journals. Patients not registered here were 
not detected. It is possible that more patients have received ECT but were not found.  
The samples in Papers II and III were psychiatrists responding to the questionnaire on behalf 
of psychiatric units, DPC and child and adolescent units in Norway. The overall response 
rate was 54 %; however, 67 % of the psychiatric hospitals performing ECT responded.  One 
reason for the low response rate in DPCs and child and adolescent units may have been the 
rare use of ECT in these units. Another reason for non-response may have been that some 
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units did not receive the questionnaire because the units were not detected. All psychiatric 
units, DPCs and child and adolescent units were traced from the web sites of, and by 
telephone to, each health region in Norway, but it was difficult to identify all units. Attempts 
were made to avoid bias from self-selection by supplementing addresses from Medlex, 
Norwegian health information (email: info@lex.no). A third reason for non-response may 
have been the length of the questionnaire. Answering 40 items would take up to one hour if 
all information were available (which is mostly not the case). This may have been too time-
consuming for clinicians. Fewer questions might have increased the response rate. Follow-up 
of postal questionnaire by email and/or telephone would probably have increased the 
response rate further. A fourth reason for non-response may have been that psychiatrists did 
not find the questionnaire relevant, or avoided response because they were against the 
treatment.  
Study IV is a systematic review of literature and may as such include publication bias if 
essential grey literature was not found. Grey literature is defined as "information produced 
on all levels of government, academics, business and industry in electronic and print formats 
not controlled by commercial publishing i.e. where publishing is not the primary activity of 
the producing body" (ICGL Luxembourg definition, 1997 - Expanded in New York, 2004). 
Further characteristics are described as follows (317): “Grey literature publications are non-
conventional, fugitive and often ephemeral. They may include but are not necessarily limited 
to the following types of materials: reports (pre-prints, preliminary progress and advanced 
reports, technical reports, statistical reports, memoranda, state-of-the art reports, market 
research reports, etc.), theses, conference proceedings, technical specifications and 
standards, non-commercial translations, bibliographies, technical and commercial 
documentation, and official documents not published commercially (primarily government 
reports and documents)." We are not sure that all relevant studies are found in study IV.   
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We might have overlooked works in other languages and works not indexed by major tools. 
This may have resulted in more positive results, as such are published more often than 
negative (studies which are not likely to receive a statistically significant difference and thus 
might have gone unpublished). This could result in both overestimation and underestimation 
of the estimated rates of use of ECT. 
5.3.1.2. Information bias  
Information bias is the error stemming from flawed information being collected about the 
study or from the study subjects.  
Paper I: This was a retrospective study and information was obtained from medical and ECT 
records. Thus, information depended on the quality of documentation done by different 
psychiatrists. Diagnoses were not validated. Only one person worked with the information 
found, which can result in missing data. 
Paper II-III: We were not able to control the answers from the psychiatrists who responded 
to questionnaire and the information given with regard to the number of ECT, patients (age, 
gender, diagnoses), and the practical use of ECT may have been inaccurate. We did not have 
information about observation methods or scales for evaluating memory impairment, 
headache or outcome from the participating institutions, which may result in underestimation 
or overestimation of these variables. The questionnaires were usually answered by one 
psychiatrist in each hospital, and this person’s views may deviate from that of the other 
physicians. We do not know if other personnel than psychiatrists have answered. 
Furthermore, we do not know whether the attitudes of psychiatrists in the questionnaire 
study are representative of all psychiatrists in Norway. The clinicians most interested and 
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positive might have answered the questionnaire and therefore had positive attitudes toward 
ECT. 
Paper IV: The sample includes patients with different diagnoses, lack of standardized 
diagnostics and clinical characteristics. Different ECT techniques and various concomitant 
drugs are used. There is a general lack of control groups, which makes it difficult to compare 
the results from various studies. Many studies consist of small samples, much use of 
administrative data, and few are prospective. Most studies do not quantify treatment 
outcomes. The studies were done in different time periods.  
5.3.2 Study design 
5.3.2.1. Retrospective  
Paper I:  The use of ECT is compared over a time period of 11 years in a single hospital. The 
strength of this method is that it excludes variables depending on differences between 
hospitals and health regions. The limitations are that it is a retrospective study and that 
information depended on the quality of medical records and ECT journals.  
5.3.2.2. Cross-sectional 
Papers II and III: The importance of these studies is the updating of information about the 
use of ECT in Norway. This may help in developing national guidelines, standardizing ECT, 
and securing the quality of the treatment. The responses contained specific information about 
rates of use, the practice of ECT and attitudes toward ECT. Its strength are that all health 
regions in Norway are represented and 67 % of all psychiatric hospitals responded.   
A limitation of the cross-sectional or prevalence study design is its descriptive nature. 
Associations found in Papers II and III are therefore not explanatory.  This is a postal survey, 
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not an audit, which is an official inspection, typically by an independent body, of an 
organization's accounts of actual practices, and results may deviate from the real practice. 
Another limitation is the lack of response from 23% of psychiatric hospitals. Nevertheless, 
we believe that the fact that a majority of the psychiatrists (80%) had the attitude that ECT is 
underused. This is in line with the finding of lacking capacity (63% of the responding 
psychiatrists) to give ECT to patients who need treatment, as well as the unacceptably long 
delay before treatment (median= six weeks). We had no information about reasons for not 
answering the questionnaire. In spite of methodological limitations, the results represent 
valuable new information about ECT administration and treatment in Norway, and provide a 
foundation for a discussion of quality guidelines. We believe that the study gives a 
reasonably good description of how ECT is practiced in Norway. 
5.3.2.3. Systematic review  
The strengths of this study are the extensive search strategy, high number of included 
studies, methodological transparency, and summary of findings in tables, providing an 
overview of contemporary world-wide use of ECT. This has not been undertaken in such 
detail previously.   
Limitations of this review are the inclusion of non-randomized studies, questionnaire studies, 
and studies based on practitioner accounts of ECT use. This may influence the precision of 
the estimated rates depending on the accuracy of the sources.  Seemingly more accurate are 
included reports from individual hospitals or national registers. The overall diversity in data 
sources, unclear representativeness of region or land, and large heterogeneity in reported 
ECT utilization rates, did not lend the data suitable for meta-analyses. National overviews of 
ECT data published by regulatory bodies or governmental agencies on the internet are not 
always easy to access, despite such internet sites being individually searched. National 
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government overviews do not usually appear in the databases where systematic literature 
search of published journal articles and studies are undertaken.  
5.4 Conclusion and implications 
Utilization rates and practice of ECT vary considerably between continents and countries as 
well as within countries. Among patients receiving ECT there was a preponderance of older 
women with depression in western countries including Norway, versus younger men with 
schizophrenia in Asian countries. Most patients in Norway were reported to benefit from 
ECT and adverse effects, such as memory impairment and headache, were reported to be 
minor problems. Unmodified ECT is still in use in Asia, Africa, and Latin America and even 
in Europe. In spite of existing guidelines, there is no uniform worldwide practice. Large 
global variation in ECT utilization, administration, and practice advocates a need for 
worldwide sharing of knowledge about ECT, reflection, and learning from each other's 
experiences. 
There still exist some negative attitudes about ECT among the general public, patients and 
health personnel. Efforts to reduce negative attitudes toward ECT have to be coupled with 
continued research and will include improved training of residents and other physicians and 
dissemination of information to the general public. Training in ECT is important; Duffett 
and Lelliot (279) found that the better the training, the more likely that the quality of ECT 
will improve. Training should be organized as part of the psychiatric education program, 
with theory and practice, to better improve dissemination.  
ECT will probably need further documentation, possibly gathered from as many national 
psychiatric units as possible, to gain an improved image and create an improved awareness 
of the effects of the method. Thus, including a national data gathering program in the 
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guideline- specified data records might generate more valid data and research that 
psychiatric practitioners in all countries will find convincing. 
ECT should not to be a treatment of last resort in treatment algorithms. If patients are 
adequately informed about outcomes and adverse effects of ECT, and risks of not accepting 
treatment, fears and complaints might be reduced. 
5.4.1 Future research 
This thesis highlights the need for improvement of ECT utilization and practice not only in 
Norway, but also worldwide. An establishment of a National ECT health register reporting 
system in Norway, taking into account patient confidentiality, as well as the development of 
an international minimal dataset standard applied in all countries, would reduce our 
knowledge gaps. This would again contribute to more uniform worldwide ECT practice, to 
the benefit of the patient. A National survey by the Norwegian health authorities concerning 
the availability of ECT, waiting lists, training, administration of ECT, knowledge, etc. 
should be undertaken. There is also a need for Norwegian national ECT guidelines in order 
to be up to date and in line with other complicated interventions of our time. It is one of the 
most complex interventions in psychiatry, in need of a holistic medical team approach.  
An important future research topic for ECT is to develop an understanding of the 
mechanisms of action, clarification of long-term effects and side effects, explore the specific 
effects of administering medication together with ECT, and strategies for relapse prevention 
after successful ECT, since mood disorders are often chronic relapsing illnesses.  
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SPØRRESKJEMA FOR UNDERSØKELSE AV ELEKTROKONVULSIV 
BEHANDLING (ECT) I NORGE OG SVERIGE 
 
 
 
I forbindelse med etableringen av Nordisk Selskap for Konvulsiv Terapi (Nordic Association 
of Convulsive Therapy: NACT) ser man behovet for en oversikt over virksomheten av ECT 
ved psykiatriske enheter i Norden. 
Vi har utarbeidet et skjema for å kartlegge bruken av ECT i Norge. Dette skjemaet sendes til 
alle psykiatriske enheter i Norge med ønske om at det blir besvart innen 1.desember 2005. 
 
Spørsmålene etterlyser opplysninger om ECT- virksomheten fra året 2004. De som ikke 
utfører ECT ved enheten bes besvare spørsmål 1-4. 
Vennligst svar så fullstendig som mulig. 
 
På forhånd takk. 
Med hilsen 
 
 
Ass.lege/forsker Lindy Jarosch-von Schweder, leder  Prof. overlege Olav M. Linaker, 
prosjektleder 
Institutt for nevromedisin/ NTNU       Institutt for nevromedisin/ NTNU 
Postboks 3008 Lade         Postboks 3008 Lade 
7441 Trondheim        7441 Trondheim 
Telefon 73 86 45 33        Telefon 73 86 46 00 
e-post: lindy.jarosch@ntnu.no       e-post: olav.linaker@ntnu.no 
 
Overlege Björn Wahlund,        Overlege Per Bergsholm 
Forskningsleder, leder i NACT      Psykiatrisk avdeling  
Neurotec, Karolinska Institutet       Førde sjukehus 
Avdeling for psykiatri           6807 Førde   
Karolinska Universitetssjukehuset      e-post: per.bergsholm@helse-forde.no 
14186 Huddinge        
Sverige  
e-post: bwah@telia.com      
             
- 
 Sykehus/DPS: 
Adresse: 
Telefon: 
Fax: 
E-mail: 
Kontaktperson for ECT-virksomheten: 
 
 
A. Spørsmål om institusjonen 
 
1. Utføres ECT ved Deres enhet?  Ja______ Nei______ 
 
 Hvis Nei, hvorfor ___________________________ 
 
 Hva gjør Dere da dersom det er behov for ECT?__________________________ 
 
 Hvis Nei, dersom Dere hadde pasienter som fikk ECT i 2004 ved annen enhet enn 
Deres, angi  om mulig hvor mange og hvor ECT ble utført 
 ____________________________________________________________________
____ 
 
 Hvis Ja, fikk likevel noen av Deres pasienter ECT ved annen enhet?_____ Angi om 
mulig  hvor mange og hvor ECT da ble utført
 ____________________________________________________________________
_____ 
 
2. Hva er det totale befolkningsgrunnlaget (antall pasienter per avdeling/sektor)? 
 Oppgi evt. enhets andel av sektors totale dersom befolkningsgrunnlaget ikke betjenes 
alene.  ________________ 
 
3. Hvor mange pasienter var innlagt ved Deres psykiatriske avdeling i 
2004?_____________ 
 
B. Spørsmål om holdninger 
 
4. Spørsmål om holdninger til ECT: 
x Pga innføringen av psykofarmaka er ECT blitt overflødig?   Ja___ Nei___ 
x Hvert sykehus som vil tilby et omfattende behandlingstilbud, må også ha 
mulighet til å tilby ECT?   Ja____ Nei____ 
x Det finnes i dag klare indikasjoner for ECT? Ja___ Nei____ 
x ECT brukes som siste utvei? Ja____ Nei_____ 
x ECT er forbundet med ikke reversible hukommelsesproblemer? Ja____ Nei____ 
x ECT blir i dag sjeldnere anvendt enn det som er nødvendig? Ja____ Nei_____ 
x ECT kan gi hjerneskade? Ja____ Nei ____ 
 
 
 
 
C. Spørsmål tilknyttet bruken av ECT 
 
 5. Gjøres ECT på den psykiatriske enheten? _________________________________
  Hvis ikke, hvor lang distanse er det til der ECT 
utføres?_________________________ 
 
6. Er det kapasitet til å gi ECT til alle som trenger det uten ventetid? __________ 
 Hvis ikke, hvor lenge må man vente?___________  
    
7. Hvem bestemmer at ECT skal gis? ______________________________ 
 
8. Hvem gir ECT? (overlege, assistentlege, sykepleier) ________________ 
 
9. Har Dere noen formell opplæring av bruken av ECT?_______________ 
 
10. Informeres pasienten muntlig? ____ Skriftlig?____ Anvendes skriftlig 
samtykkeskjema?____ 
 
11. Brukes eget ECT-skjema eller ECT-journal? _________________ 
 
12. Brukes anestesijournal? _______________ 
 
13. Hvor mange sykepleiere deltar ved behandlingen? ________________ 
 
14. Minstekrav til undersøkelser før 
ECT?____________________________________________ 
 
15. Hvilke rutiner har Dere for samtidig bruk av psykofarmaka (blir litium, 
benzodiazepiner, antikonvulsiva eller andre medikamenter seponert før ECT)? 
       
_____________________________________________________________________ 
       
_____________________________________________________________________ 
       
_____________________________________________________________________ 
  
16. Gi en kort beskrivelse og vurdering av lokalene (hensiktsmessige?)  
 
 _________________________________________________________________ 
 
17. Hvem utfører narkosen? ________________ 
 
18. Hvilke narkosemidler brukes, og i hvilken dose 
(mg/kg)?_________________________ 
 
19. Får pasientene oksygentilførsel? _______Blir oksygenmetningen målt? _______  
 Blir pasientene eller noen av dem intubert? ______ 
 Blir pasientene ventilert under hele behandlingen? ______Blir de hyperventilert? 
____ 
 Brukes svelgtube? _______Brukes tannbeskyttelse? _______ 
 
20. Hvilket ECT- apparat brukes (MECTA, Thymatron m.fl.)? _______________ 
  
21. Anvendes EEG- monitorering? ________________ 
 
22. Hvilke elektrodeplasseringer ble brukt? (antall dersom mulig): 
 Unilateral (d`Elia): _________ Bitemporal: _________ Bifrontal: __________ 
 Andre: ___________ 
 Har Dere hos noen pasienter pga dårlig effekt skiftet fra unilateral til bilateral 
plassering? ___ 
 Hvis Ja, hvor mange pasienter? ____ 
 
23. På hvilken måte bestemmes strømmengde (mC)? 
 Ved titrering: _____ Evt hvor høyt over 
anfallsterskelen?_____________________________ 
 Ut fra alder: _____ Hvordan? 
___________________________________________________ 
 Tas kjønn med ved bestemmelsen? _____ Hvordan? 
_________________________________ 
 
24. Hvilke verdier foretrekkes for? (svar evt ”kortest mulig” eller ”lengst mulig”)  
 Pulsvidde__________ Pulsfrekvens ___________ 
 Stimuleringstid (pulstogets varighet) ___________ 
 
25. Hvordan måles krampeanfallets lengde? 
 EEG: ______ 
 Mansjettmetoden:_______ 
 Observasjon av ekstremiteter, øyelokk og/eller øyne:________________ 
 
26. Hvilke ukedager gis ECT? _____________ 
 Hvor mange pasienter er det kapasitet til per dag? ___________  
 Kan ECT om nødvendig gis andre dager? ____________ 
 
27. Hvor mange pasienter fikk ECT i 2004? ______ Antall kvinner_______ Antall 
menn_______ 
 
28. Hvor mange elektrokonvulsive behandlingsserier (uavbrutt serie) ble gitt i 
2004?_______ 
 
29. Hvor mange pasienter fikk 2 ECT- serier? ___ 3 ECT- serier? ___  
 4 ECT- serier? _____ >4 ECT- serier? ______ 
 
30. Hvor mange pasienter fikk vedlikeholds- ECT? _________________ 
 
31. Hvor mange pasienter fikk ECT poliklinisk? _________________ 
 
 
 
32. Hvilke diagnostiske grupper var pasientene i? (antall dersom mulig) 
 
a. Unipolar depresjon  __________ 
 b. Bipolar depresjon  __________ 
c. Mani    __________ 
d. Blandingstilstand  __________ 
e. Polymorf psykose  __________ 
f. Schizoaffektiv lidelse __________ 
g. Schizofreni   __________ 
h. Parkinsons sykdom  __________ 
i. Andre, hvilke diagnoser __________ 
 
33. Hvilke indikasjoner for ECT? (antall dersom mulig) 
 
a. Dårlig effekt av psykofarmaka  __________ 
b. Bivirkninger av psykofarmaka  __________ 
c. For alvorlig til å vente på effekt av psykofarmaka  
x Psykotisk     __________ 
x Sterk hemming/katatoni   __________ 
x Spise-drikkevegring    __________ 
x Suicidalfare     __________ 
x Postpartum     __________ 
x Pasienten ønsker helst ECT   __________ 
x Annet, oppgi hva    __________ 
 
 
34. Antall behandlinger per pasient?  
1-3  ______________  
4-6 ______________ 
7-9 ______________ 
10-12 ______________ 
>12 ______________ 
 
35. Angi om mulig hvor mange pasienter som kom i hver aldersgruppe:  
  
 <18   _________________ 
18-24  ________________ 
25-44  _________________ 
45-64  ________________ 
>64  _________________ 
 
36. Angi om mulig hvor mange pasienter som kom i hver CGI endringsgruppe nedenfor: 
  veldig mye bedre ____________________ 
  mye bedre  ____________________ 
  litt bedre  ____________________ 
  ingen endring  ____________________ 
  verre   ____________________ 
 
 
37. Angi om mulig hvor mange pasienter som etter behandlingen lenge klaget over:  
 veldig mye amnesi  _________ 
 mye amnesi   _________   
 litt amnesi   _________ 
  langvarig amnesi, hvor lenge _________ 
  
38. Angi om mulig hvor mange pasienter som etter behandlingen lenge klaget over: 
 veldig mye hodepine _________ 
 mye hodepine  _________ 
 litt hodepine  _________ 
 
39. Angi om mulig hvor mange pasienter som etter behandlingen lenge klaget over andre 
bivirkninger, hvilke bivirkninger _______________________________________ 
 Har Dere notert årsak f.eks. litium, langvarige krampeanfall osv.?____________ 
 
40. Opplevde Dere noen dødsfall relatert til 
behandlingen?_________________________ 
 
Kommentarer og synspunkter på spørreskjemaet: 
 
 
 
 
Takk for Deres medvirkning! 
 
Hvis Dere har spørsmål i forbindelse med spørreskjemaet er Dere velkommen til å ta 
kontakt med Lindy Jarosch-von Schweder.  
E-Mail: lindy.jarosch@ntnu.no 
Telefon: 73864533/ 95906018 
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Abstract 
 
Objectives 
This is a retrospective study of the clinical use of ECT in a county hospital in Norway 
between 1993 and 2003. The study aimed to determine the rates of use, demographics 
and diagnoses, and to compare standards for ECT practice at this specific hospital 
with similar studies conducted elsewhere.  
Methods 
The study is based on data collected from specific ECT records and the patients’ 
medical records. To compare our results with others, the frequency rates were 
calculated as number of ECT treatments per 100,000 per year, number of patients 
receiving ECT per 100,000 per year, and percent of in-patients who received ECT.  
Results 
During 11 years, 210 patients had received ECT, representing 4.2 % of in-patients. 
There was no trend in the proportion receiving ECT in the period. It varied between 
1.8% in 2000 and 5.7% in 1997. Totally, 1,657 ECT treatments were administered to 
the 210 patients, giving a rate of 109 ECT treatments per 100,000 person years. Of the 
patients, 137 (65%) were women, and 76 (36%) were 65 years or more. Unipolar or 
bipolar depressive disorders were the most common diagnostic indications (85%), 
followed by puerperal mental disorder (3.4%) and personality disorders (3%). 
Conclusions 
We found no trend in proportion of patients given ECT, as opposed to other studies. 
Most patients who received ECT were women and elderly, and depression was the 
most common disorder. ECT is an important treatment in psychiatry, especially for 
the treatment of severe depression. 
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Introduction 
Electroconvulsive therapy (ECT) has become widely available on all 
continents within psychiatric practice, and worldwide it is estimated that about one 
million patients per year receive ECT (1-8). However, there are variations in rates of 
use between countries, between regions within a country, and within individual 
centres over time (1, 8-11). Many factors contribute to these variations, such as 
patients’ and health personnel’s knowledge about ECT and their attitudes towards 
ECT, lack of training courses, economy, availability of psychiatrists or equipment, 
and some countries’ legislative requirements (1, 5, 8, 12-15). 
There are no Norwegian guidelines for the use of ECT, though psychiatrists 
are required to have knowledge about the treatment. The ECT rate of use in Norway 
was 2.4 per 10,000 population per year in 2004, but varied from 1.83 to 3.44 between 
the different health region authorities (8). In line with other western countries the 
patients receiving ECT in Norway most often are elderly women with severe 
depression (3, 10, 12, 16). However, ECT is reported to be safe and effective also for 
other psychiatric disorders such as mania, bipolar mixed states, polymorphic (cycloid) 
psychosis and schizophrenia (17-20).  
This study focuses on the clinical use of ECT in the psychiatric unit at a 
general psychiatric department in the central health region of Norway. We aimed to 
determine the rate of use over time, demographics and diagnoses of patients who 
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received ECT, and to compare our results with that of similar studies conducted 
elsewhere.  
 
 
Material and Methods 
Setting 
The study was carried out at a county Hospital in Ålesund, located on the 
western coast of Norway, which provided health services for the catchment area of 
122,000 inhabitants in 1993, increasing to 127,000 in 2003. Between 1993 and 2003 
the mean annual number of adults (≥ 18 years) admitted to the inpatient psychiatric 
unit was 491 (range 282 to 822). However, all patients receiving ECT were 20 years 
or above. The mean annual number of patients 20 years or above admitted to the 
inpatient psychiatric unit was 459 (range 282 to 776) in the study period. All ECT 
treatments in the region were done in this unit. 
 
Data collection 
All patients who were admitted to the psychiatric unit from 1993 to 2003 and 
received ECT as part of their hospitalisation, were included in the analyses. All 
patients provided informed consent for ECT. Six patients withdrew consent and 
treatment was terminated. The study is based on data collected from dedicated ECT 
records and the patients’ medical records. These two sources of information were not 
independent, as the same physician recorded both, but they included different 
information. Age, gender, diagnosis and number of treatments per course were 
recorded. Medical records of 6 patients could not be retrieved, and for these patients 
information was obtained only from the ECT journals. 
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  We found 210 patients who had received ECT during this period. All patients 
were 20 years or above. For patients who had more than one ECT series, only the first 
series was included.  
 Indications and appropriateness for ECT were evaluated by the ward 
psychiatrist. Patients were diagnosed according to ICD-9 until it was replaced with 
ICD-10 criteria in 1998. ICD-9 diagnoses were converted into corresponding ICD-10 
diagnoses.  
 
Statistical analysis 
 SPSS Version 19 and Stata Version 12 were used for statistical analyses. 
The frequencies per year were calculated as percentage of inpatients receiving ECT, 
number of ECT patients and treatment sessions per 100,000 population, and mean 
number of sessions per ECT series.  These were analysed by Poisson regression, with 
year as independent variable, adjusting for number of inpatients and population. The 
yearly variation in use of ECT was analysed in mixed model Poisson regression, with 
year as random effect. The proportion of psychiatric patients given ECT per year was 
analysed in logistic regression, with gender, age group and year as covariates. Two-
sided P-values <0.05 were considered significant, and 95% confidence intervals (CI) 
are reported when relevant. The population development in the years 1993-2003 was 
obtained from Statistics Norway (21). 
 
 
Results 
Rates of use 
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From 1993 to 2003 a total of 210 patients received ECT, representing 4.2 % of 
all the 5045 psychiatric inpatients at this psychiatric unit (≥ 20 years). Table 1 shows 
the use of ECT in the hospital from 1993 to 2003. The use of ECT per 100,000 
population per year increased totally with 7.5% (CI 2.9% to 12.3%, p=0.001). The 
total admission of patients also increased, resulting in a non-significant reduction in 
the proportion of inpatients given ECT (yearly change -2.9%, CI -6.8% to 1.3%, 
p=0.18). However, there were variations from year to year (Table 1), close to 
statistical significance (mixed model Poisson regression, p=0.052). The lowest 
percentage of ECT patients was in 2000 with 1.8% of admissions, the highest in 1997 
with 5.7% ECT of admissions. 
There was a mean of 15.2 patients per 100,000 per year treated with ECT in 
the period (range 6 to 26). Totally, 1,657 ECT treatments were administered to 210 
patients, giving a rate of 109 ECT treatments per 100,000 persons per year (range 57 
to 199). The mean number of ECT sessions per series was 7.9 ± 3.5 (range 1 to 20), 
with no time trend (p=0.98) during the study period. 
 
 Demographics and diagnoses 
Of the patients receiving ECT 137 (65%) were women and 76 (36%) patients 
were 65 years or older (Table 2). Mean age was 54 ± 18.2 (range 20-94). Mean age 
for women was 54.3 ± 18, 0 (range 20-94), mean age for men was 53.4 ± 18.7 (range 
23-88). Table 3 summarizes the use of ECT within gender and age groups in the 
periods 1993-1995, 1996-1999, and 2000-2003. Logistic regression analyses with 
gender, age group and period as categorical covariates showed a trend towards more 
frequent use in women (OR 1.32, CI 0.99 to 1.78, p=0.061), significantly more use in 
the older age groups 50-69 years (OR 2.64, CI 1.93 to 3.62, p<0.001) and 70+ years 
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(OR 4.27. CI 2.94 to 6.20, p<0.001), and no time trend (OR per year 0.992, CI 0.94 to 
1.05, p=0.77). There were no significant interactions between any of the covariates. 
Depressive disorders were the most common diagnostic indications for ECT (N=157), 
followed by bipolar disorder (N=22) and other diagnoses (N=22) (Table 2).  
 
Discussion 
Rates of use  
The 4.2 % proportion of in-patient receiving ECT is in agreement with other 
European reports (22-25). The proportion remained fairly stable between 1993 and 
2003, similar to findings in a study in Hong Kong (23), but in contrast to other studies 
that found increased or decreased rates of use (3, 16, 22).  
However, in our study fluctuations (from 1.8 to 5.7 %) from year to year were 
close to statistical significance. Such differences within a hospital have been reported 
earlier among consultant teams in Edinburgh; there was an 18-fold difference (from 
0.8 to 15.0%) in use of ECT between 11 general psychiatric teams (9).  
Variations within or between hospitals may be due to health personnel’s 
knowledge about and attitudes towards ECT. Lack of national guidelines may also 
contribute to these variations. Other factors might be differences in budgets and 
equipment, hospitals’ policies and other non-medical factors. The patient population 
and the number of anaesthesiologists or psychiatrists may also influence this (7, 26-
28).  
 The ECT rate of 15.2 per 100,000 populations per year in our study is 
comparable to the Netherlands (18 in 1999) (29) and western Australia (14 in 2001) 
(30). The rate is lower than in Belgium (68 in 2003)(31), Edinburgh (39 in 
1996/1997) (16) and Norway as a whole (24 in 2004)(8) , but higher than in Hungary 
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(3.1 in 2002) (32), Poland (1.1 in 2005) (33), Spain (6.1 in 2001) (1) and Ireland (9.6 
in 2008) (34).  
      
Gender and age 
The higher percentage of women and higher age of patients receiving ECT was in 
agreement with earlier western reports, although not in agreement with some reports 
from Asia (9, 12, 24, 35-37).  
It may be possible to explain these gender differences by the higher rates of 
depression among women also reflected in the admittance rates to hospitals and (38), 
although these rates are not unchallenged (39). 
In our study we could confirm the high rate of ECT among elderly. The high 
frequency of medical co-morbidity may be one reason for the higher age groups being 
more likely to receive ECT. Also, the lower response rate to medication in this group 
may be a contributory factor (40-42).  
 
Diagnoses 
The most frequent indication for ECT in our study was depression (unipolar and 
bipolar depression, 85%). This is similar to what is described in earlier studies (3, 12, 
22). Only a few patients with bipolar disorder with manic symptoms were treated with 
ECT, although the response rate in mania is reported to be as high as in depression 
(17). The reasons for the low ECT use in mania may be that these patients are rarely 
offered ECT, that compliance is difficult to achieve, or that the treatment with 
psychopharmacology is satisfactory. In our study only one patient with schizophrenia 
received ECT, which is in line with other studies from western countries (30, 31, 34, 
43), but contrasting Asian findings (35, 37, 44). The reasons for this may be the 
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availability of antipsychotic drugs (8). We found that seven women (3%) with 
puerperal depression were treated with ECT. This treatment, with proper medical 
care, is effective in all trimesters of pregnancy, as well as in the postpartum period 
(45). However, consideration of risk and benefits of ECT must  be taken into account 
including the risk involved for the foetus/unborn child (46). 
There is little evidence and no general acceptance for treating anxiety and personality 
disorders with ECT, but 5.4% of our patients with these diagnoses received ECT. 
   
 Conclusions 
We found that the total ECT utilization remained fairly stable in the study period. 
Patients who received ECT were most women and elderly, and depression was the 
most common diagnosis.  
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 Table 1.  The use of ECT at a county hospital in Norway from 1993 to 2003. 
 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 Mean 
Number of ECT 
patients 
(N=210) 
 
Total number of 
admitted patients 
*(N= 5045) 
 
% of patients 
given ECT 
 
13 
 
 
 
318 
 
 
 
3.86 
19 
 
 
 
341 
 
 
 
5.41 
16 
 
 
 
334 
 
 
 
4.56 
8 
 
 
 
302 
 
 
 
2.52 
17 
 
 
 
282 
 
 
 
5.69 
19 
 
 
 
347 
 
 
 
5.41 
24 
 
 
 
403 
 
 
 
5.38 
11 
 
 
 
548 
 
 
 
1.76 
23 
 
 
 
660 
 
 
 
3.08 
33 
 
 
 
735 
 
 
 
4.36 
27 
 
 
 
776 
 
 
 
3.60 
19 
 
 
 
459 
 
 
 
3.94 
Average number 
of treatments per 
ECT course 
6.3 8.4 7.8 8.9 6.9 8.9 10.5 9.7 6.0 7.6 6.9  8.0 
*Patients 20 years and above 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2.  Demographics and diagnoses of the 210 patients who 
received ECT from 1993 to 2003. 
Variables N= Total sample (%) 
Age (yrs)    
<25                         9    (4.3) 
25-34                       34  (16.2) 
35-44                       34  (16.2) 
45-54                       27  (12.9) 
55-65                       30  (14.3) 
>65                       76  (36.2) 
Mean (SD, Range)                       54  (18.2, 20 to 94) 
Gender   
Men                       73  (35) 
Women                     137 (65) 
Primary Diagnosis ICD10   
Major depressive disorder                      157  (74.9) 
Bipolar disorder, depressed                       21  (10.1) 
Puerperal mental disorder                         7    (3.4) 
Personality Disorder                         6    (3.0) 
Anxiety disorder                         5    (2.4) 
Paranoid psychosis                         3    (1.4) 
Schizophrenia                         1    (0.5) 
Bipolar disorder, mania or mixed                         1    (0.5) 
Missing diagnostic information                         9  ( 4.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table 3.  Percent of admitted patients given ECT by gender and age groups in three 
time periods  
Period 1993-1996 1997-1999 2000-2003 
Women    
20-49 years 3.6  3.4  2.7  
50-69 years 7.3  11.2  5.3  
>70 years  5.7  
 
12.5  12.4  
Men    
20-49 years 1.5  1.4  1.9 
50-69 years 5.1  12.8  5.8  
>70 years  12.2  20.0  11.0  
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Abstract
To explore contemporary (from 1990) utilization and practice of electroconvulsive
therapy (ECT) worldwide. Systematic search (limited to studies published 1990 and
after) was undertaken in the databases Medline, Embase, PsycINFO, SveMed, and
EBSCO/Cinahl. Primary data-based studies/surveys with reported ECT utilization
and practice in psychiatric institutions internationally, nationally, and regionally;
city were included. Two reviewers independently checked study titles and abstracts
according to inclusion criteria, and extracted ECTutilization and practice data from
those retrieved in full text. Seventy studies were included, seven from Australia
and New Zealand, three Africa, 12 North and Latin America, 33 Europe, and
15 Asia. Worldwide ECT differences and trends were evident, average number ECTs
administered per patient were eight; unmodiﬁed (without anesthesia) was used in
Asia (over 90%), Africa, Latin America, Russia, Turkey, Spain. Worldwide preferred
electrode placement was bilateral, except unilateral at some places (Europe and
Australia/New Zealand). Although mainstream was brief-pulse wave, sine-wave
devices were still used. Majority ECT treated were older women with depression in
Western countries, versus younger men with schizophrenia in Asian countries. ECT
under involuntary conditions (admissions), use of ambulatory-ECT, acute ﬁrst line
of treatment, as well as administered by other professions (geriatricians, nurses)
were noted by some sites. General trends were only some institutions within the
same country providing ECT, training inadequate, and guidelines not followed.
Mandatory reporting and overall country ECT register data were sparse. Many
patients are still treated with unmodiﬁed ECT today. Large global variation in ECT
utilization, administration, and practice advocates a need for worldwide sharing of
knowledge about ECT, reﬂection, and learning from each other’s experiences.
Introduction
Convulsive interventions have been used to treat mental dis-
orders since the 16th century and even today in the form of
electroconvulsive therapy (ECT). Ugo Cerletti and Luigi Bini
demonstratedECT inRome for the ﬁrst time in 1938 (Cerletti
and Bini 1938). The ECT intervention per se, that is, the ap-
plication of electrical current to the scalp in order to provoke
a generalized epileptic seizure, for the purpose of alleviating
psychotic and depressive symptoms, is still much the same
today as it was in the beginning. Modiﬁcations of Cerletti
and Bini’s original bitemporal placement of electrodes to the
scalp, administering 120 V sine-wave electrical current to the
head (Cerletti and Bini 1938), include the development of
newer brief-pulse electrical current wave devices and unilat-
eral (UL) placement of electrodes.
ECT was originally used in the treatment of schizophrenia.
ECTs effectiveness for patients with depression was estab-
lished in 1941 (Hemphill and Walter 1941). The use of ECT
declined in the 1970s and 1980s after the introduction of
c© 2012 The Authors. Published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative
Commons Attribution Non-Commercial License which permits use, distribution and reproduction in any medium, provided
the original work is properly cited and is not used for commercial purposes.
283
Use and Practice of Electroconvulsive Therapy Worldwide K. A. Leiknes et al.
pharmacotherapy for severe mental disorders (McCall 2001).
Themain indication for ECT also transformed fromﬁrst-line
to last-resort treatment for medication-resistant and very se-
vere life-threatening clinical conditions (McCall 2001; Eranti
and McLoughlin 2003). However, in 2001, guidelines devel-
oped by the American Psychiatric Association (APA) advised
that ECT should not only be used as a last resort (Amer-
ican Psychiatric Association 2001). Situations of increased
risk that need special attention are mentioned by interna-
tional guidelines, such as patients with disorders of the cen-
tral nervous system, cardiovascular and respiratory system
(American Psychiatric Association 2001; Royal College of
Psychiatrists 2005; Enns et al. 2010). As a result of cognitive
side effects (memory impairment) associationwith sine-wave
current (The UK ECT Review Group 2003), it is now advised
that brief-pulse wave be the standard treatment (American
Psychiatric Association 2001; Royal College of Psychiatrists
2005; Enns et al. 2010). The use of sine-wave constant volt-
age and constant energy devices is currently not considered
justiﬁed (APA guidelines) (American Psychiatric Association
2001).
ECT spread rapidly from Europe to other continents and
to the United States, due to the Second World War’s displace-
ment of psychiatrists (Shorter 2009). In the beginning, ECT
was administered without anesthesia (termed unmodiﬁed
ECT) and later, under anesthesia together with muscle relax-
ant succinylcholine medication (termed modiﬁed ECT), in
order to reduce side effects from the convulsions, such as bone
fractures, teeth, tendon, and muscular damage. In the last
decade, modiﬁed ECT has been recommended as the stan-
dard routine according to internationally established guide-
lines (American Psychiatric Association 2001; Royal College
of Psychiatrists 2005; Enns et al. 2010).
ECT’s mode of action has still not been clariﬁed (Fink
2001). Despite documented efﬁcacy for alleviating symp-
toms of depression (The UK ECT Review Group 2003), ECT
still remains controversial and stigma-bound. Reported side
effects, such as memory impairment (Rose et al. 2003), and
whether ECT induces long-term permanent cognitive im-
pairment remains yet obscure.
Worldwide, it has been estimated that about one million
patients receive ECT annually (Prudic et al. 2001). ECT ap-
pears to have become a widely available treatment for mental
disorders on all continents (Swartz 2009), in USA/Canada
and Latin America (Magid and Rohland 2009; Rosa and Rosa
2009), Western Europe (Benbow and Bolwig 2009; Sienaert
and van den Broek 2009) and Russia (Nelson and Giagou
2009), Africa and Asia (Chang 2009). Despite international
guidelines (American Psychiatric Association 2001; Royal
College of Psychiatrists 2005; Enns et al. 2010), large vari-
ations in clinical practice between countries and regions have
been reported (Hermann et al. 1995; Glen and Scott 2000;
Bertolin-Guillen et al. 2006; Gazdag et al. 2009a). Reports on
ECT utilization also largely vary. There have been some in-
ternational studies. A study by Van Waarde et al. (van Waarde
et al. 2009) included data from nine other countries and an-
other by Gazdag et al. (Gazdag et al. 2009a) presented an
overview of 13 surveys undertaken on the use of ECT in the
past 10 years. In the United States, the nationwide number of
persons ECT treated per 10,000 resident population per year,
was estimated to be 4.9 in 1995 (Hermann et al. 1995). On the
whole, there seems to be a paucity of updated ECT utilization
surveys, reviews, and data. There is, therefore, an imminent
need for a systematic international review concerning con-
temporary use of ECT. Against this background, the main
objective of this article is to give a systematic contemporary
overview (from 1990) of the extent to which ECT is used
worldwide.
Brieﬂy the following aspects were considered. ECT uti-
lization: ECT rates according to population, administration
frequency, and inpatient prevalence rates; ECT parameters:
the manner in which ECT is applied (modiﬁed or unmodi-
ﬁed, brief-pulse or sine-wave current, device type, electrode
placement bilateral [BL] or unilateral [UL]); and ECT prac-
tice: diagnoses, indications, gender, age, conditions (consent
or involuntary), settings (ambulatory), under which ECT is
applied.
Material and Methods
Data sources and search strategy
A systematic literature search was undertaken in the fol-
lowing databases. Medline, Embase, PsycINFO, SveMed and
EBSCO/Cinahl, limited from 1990 to November 2010 (Ap-
pendix A, Table 1). Search terms intended for Medline were
adapted as required for other databases. Terms used were
“electroconvulsive therapy,” “electroshock,” “electroconvul-
sive,” “ECT,” combined with any of the following “use,” “uti-
lization,” “practice,” “survey,” “statistical data,” “frequency,”
limited to human studies and dating from 1990 to today.
Relevant references, known to authors of this review pub-
lished on governmental internet sites or from newly pub-
lished text books (Swartz 2009) or reference lists in retrieved
included papers, were also hand found.
Inclusion and exclusion criteria
Inclusion criteria: Data-based observational studies or sur-
veys with reported ECT utilization, frequency, or prevalence
rates, by data collected from 1990 and above, for patients
in psychiatric establishments (inpatients or outpatients) in
well-deﬁned continents, countries, regions, cities, or local
hospitals. Also included were relevant studies published near
the date limits for this study (from 1990), for geographical
areas that had few pertinent publications.
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Table 1. Overview of included studies (N = 70) according to continent, country, region, city, or local hospital level.
Land (L)/Region (R)/ Publication
Country City (C)/Hospital (H) year First author (reference)
Australia and New Zealand (N = 7)
Australia L 2007 Chanpattana W (Chanpattana 2007)
New Zealand L 2006 Ministry of Health (Ministry of Health 2006)
New Zealand L 2005 Ministry of Health (Ministry of Health 2005)
Australia and New Zealand L 1991 O’Dea JF (O’Dea et al. 1991)
Victoria, Australia R 2003 Wood DA (Wood and Burgess 2003)
Western Australia R 2005 Teh SPC (Teh et al. 2005)
Sydney, New South Wales Australia C 2011 Lamont S (Lamont et al. 2011)
Africa (N = 3)
Malawi L 2008 Selis MA (Selis et al. 2008)
South Africa H 1991 Mugisha RX (Mugisha and Ovuga 1991)
Nigeria H 1985 Sijuwola OA (Sijuwola 1985)
North and Latin America (N = 12)
USA L 1995 Hermann RC (Hermann et al. 1995)
USA, tri-state New York City Metropolitan region L 2001 Prudic J (Prudic et al. 2001)
Latin America and the Caribbean L 1996 Levav I (Levav and Gonzalez 1996)
California, USA R 1999 Kramer BA (Kramer 1999)
Texas, USA R 2000 Scarano VR (Scarano et al. 2000)
Texas, USA R 1998 Reid WH (Reid et al. 1998)
USA (Medicare) R 1997 Rosenbach ML (Rosenbach et al. 1997)
North Carolina, USA R 1995 Creed P (Creed et al. 1995)
Louisiana, USA (Medicare) C 1997 Westphal JR (Westphalet al. 1997)
North Carolina, USA H 1992 McCall WV (McCall et al. 1992)
South West Pennsylvania, State Hospital, USA H 2000 Sylvester AP (Sylvester et al. 2000)
Rio de Janeiro, Brazil H 2008 Pastore DL (Pastore et al. 2008)
Europe (N = 33)
Belgium L 2006 Sienaert P (Sienaert et al. 2006)
England L 2007 Department of Health (www.dh.gov.uk)
(Department of Health 2007)
Hungary L 2004 Gazdag G (Gazdag et al. 2004a)
Poland L 2009 Gazdag G (Gazdag et al. 2009a)
Germany L 1998 Muller U (Muller et al. 1998)
Spain L 2006 Bertolin-Guillen JM (Bertolin-Guillenet al. 2006)
Russia L 2005 Nelson AI (Nelson 2005)
Netherlands L 2009 van Waarde JA (van Waarde et al. 2009)
France L 2001 Benadhira R (Benadhira and Teles 2001)
Denmark L 2002 Andersson JE (Andersson and Bolwig 2002)
Denmark L 2010 Sundhedsstyrelsen (Sundhedsstyrelsen 2011)
Norway L 2011 Schweder LJ (Schweder et al. 2011a)
Norway L 2011 Schweder LJ (Schweder et al. 2011b)
Sweden L 2010 Socialstyrelsen (www.socialstyrelse.se)
(Socialstyrelsen 2010)
Belgium R 2005 Sienaert P (Sienaert et al. 2005a)
Wales R 1999 Duffett R (Duffett et al. 1999)
England R 1998 Duffett R (Duffett and Lelliott 1998)
England R 1992 Pippard J (Pippard 1992)
Ireland R 2010 Enriquez S (Enriquez et al. 2010)
Chuvash republic, Russia R 2010 Golenkov A (Golenkov et al. 2010)
Vienna, Austria C 1997 Tauscher J (Tauscher et al. 1997)
Barcelona, Spain C 1996 Bernardo M (Bernardo et al. 1996)
London (UK) and Bengaluru, India C 2011 Eranti SV (Eranti et al. 2011)
Edinburgh, Scotland C 1999 Glen T (Glen and Scott 1999)
Edinburgh, Scotland C 2008 Okagbue N (Okagbue et al. 2008)
Munich, Germany C 2005 Baghai TC (Baghai et al. 2005)
Dikemark Hospital, Oslo, Norway H 2010 Moksnes KM (Moksnes and Ilner 2010)
(Continued)
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Table 1. Continued
Land (L)/Region (R)/ Publication
Country City (C)/Hospital (H) year First author (reference)
Ullevaal University Hospital, Oslo, Norway H 2006 Moksnes KM (Moksnes et al. 2006)
Hospital Innland, Norway H 2010 Eiring O (Eiring 2010)
Pitkaniemi Hospital, Finland H 2000 Huuhka MJ (Huuhka et al. 2000)
Hospital, Turkey H 2008 Saatcioglu O (Saatcioglu and Tomruk 2008)
Scotland H 2004 Fergusson GM (Fergusson et al. 2004)
Cukurova University Psychiatry Service, Turkey H 2003 Zeren T (Zeren et al. 2003)
Asia (N = 15)
Japan L 2004 Motohashi N (Motohashi et al. 2004)
Japan L 2005 Chanpattana W (Chanpattana et al. 2005a)
Thailand L 2004 Chanpattana W (Chanpattana and Kramer 2004)
Asia L 2003 Little JD (Little 2003)
Asia L 2010 Chanpattana W (Chanpattana et al. 2010)
Katmandu, Nepal C 2008 Ahikari SR (Ahikari et al. 2008)
Hong Kong C 2003 Chung KF (Chung 2003)
Hong Kong C 2003 Chung KF (Chung et al. 2003)
India H 2005 Chanpattana W (Chanpattana et al. 2005b)
Chulalongkorn Memorial Hospital, Thailand H 2005 Lalitanatpong D (Lalitanatpong 2005)
Local psychiatric unit, Hong Kong H 2009 Chung JPY (Chung et al. 2009)
Tokushima, University Hospital, Japan H 2000 Ishimoto Y (Ishimoto et al. 2000)
Hospital, Saudi Arabia H 1999 Alhamad AM (Alhamad 1999)
Hospital, Karachi, Pakistan H 2005 Naqvi H (Naqvi and Khan 2005)
Al Ain, United Arab Emirates H 1998 Tewﬁk KD (Tewﬁk et al. 1998)
Studies in the following languages were included: English,
Scandinavian (Norwegian, Swedish, Danish), and European
(German, French, Spanish, Portuguese, Turkish). In addition
to authors’ European language ﬂuency, the online Google
translation tool (http://translate.google.com/)wasusedwhen
needed (e.g., for Portuguese and Turkish).
Following exclusion criteria were included. Not data-
based study or survey, no or unclear report of ECT uti-
lization, frequency, prevalence rate, practice, in unclearly
deﬁned populations. All report of utilization frequency,
prevalence rates of ECT in selected samples or subgroups
(e.g., young/adolescent, elderly) or special populations (such
as pregnancy, disability, mental retardation), and qualita-
tive studies about clinician or physician subjective experience
(views or opinions) on ECT.
Screening of literature
Two reviewers (KAL, BH) independently checked the titles,
and where available, the abstracts of the studies identiﬁed
by the electronic database searches. All references appear-
ing to meet inclusion criteria, including those with insufﬁ-
cient details, were requested in full text. All reviewers (KAL,
LJVS, BH) consisting of two pairs independently extracted
data from the retrieved full-text articles according to a pre-
made data extraction scheme. All discrepancies were resolved
by consensus meeting/discussion, and the ﬁnal decision was
made by the ﬁrst author (KAL).
Data extraction and data analyses
Where possible, utilization data have been presented as ei-
ther (1) number of persons ECT treated per 10,000 resi-
dent population per year, that is, treated person rate (TPR),
(2) number of ECT administrations per 10,000 resident pop-
ulation per year, that is, ECT administration rate (EAR),
(3) the proportion in percent (%) of ECT-treated patients
among the inpatient (psychiatric ward, hospital admitted)
population, that is, inpatient prevalence (iP%), and (4) av-
erage number of ECTs administered per patient (in a series
or course), that is, average ECT number (AvE). Informa-
tion about ECT parameters, diagnoses and main indications,
gender and age is also presented. Other information such as
ethnicity, education, side effects, mortality, adverse events,
use of written consent, involuntary conditions has also been
noted.
Results
Study selection
The study selection process, databases searched and total
numbers of references identiﬁed (N = 1403), title and ab-
stract screened (N = 851), full-text screened (N = 101),
included for data extraction (N = 70) and full text excluded
(N = 31) references are given in Figure 1.
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Figure 1. Flow chart of study-selection process.
Description of studies
Overview of included studies (N = 70) and data extracted is
given in Table 1, sorted according to the continents: Australia
and New Zealand (N = 7), Africa (N = 3), North and Latin
America (N = 12), Europe (N = 33), andAsia (N = 15). Each
reference was categorized according to the data presented,
whether it represented the Land (n = 27), Region (n = 13),
City (n = 11), or Hospital (n = 19).
Overview of full text excluded references (N = 31) and rea-
sons for exclusion are given in Appendix B. Five references
were found not relevant in topic, 10 had no rate or preva-
lence data or insufﬁcient/too sparse data, six were parallelly
published in other languages than English or not possible to
ﬁnd/full-text retrieve, and the data in nine were evaluated too
old, collected before 1990.
Detailed summery of ﬁndings tables of included full-text
studies are presented in Appendix C, Tables C1–C5 accord-
ing to the ﬁve continents: (1) Australia and New Zealand,
(2) Africa, (3) North and Latin America, (4) Europe and
(5) Asia.
Seven studies were included from Australia and New
Zealand, including a recent one from Sydney (Lamont et al.
2011). Only three of six studies from Africa were included,
representing Malawi, Nigeria, and South Africa. The three
excluded (Appendix B) were two from Nigeria and one from
Egypt, due to data being too old (before 1990), insufﬁcient,
and sparse.One of the two included studies fromLatinAmer-
ica, claimed representation of 17 Latin American and four
Caribbean countries, but with unstated names except for
Haiti being excluded (Levav and Gonzalez 1996). Two of the
10 studies from North America represented Medicare pop-
ulations (Rosenbach et al. 1997; Westphal et al. 1997) leav-
ing many of all USA’s 50 States not represented. A study by
the National Institute of Mental Health (NIMH) was found
too old (Thompson et al. 1994). Altogether, 33 studies were
included from Europe and nine were from the Nordic coun-
tries. Twelve identiﬁed European studies, including one study
from Italy (Lucca et al. 2010), did not meet inclusion criteria
(Appendix B). Surveys including a number of countries
were identiﬁed from Asia (Little 2003; Chanpattana and
Kramer 2004; Chanpattana et al. 2010) and 15 studies from
this continent were included. ECT practice was veriﬁed
from 27 Asian countries: Bangladesh, China, Hong Kong,
India, Indonesia, Iran, Iraq, Israel, Japan, Jordan, South
Korea, Malaysia, Myanmar, Nepal, Oman, Pakistan, Philip-
pines, Singapore, Sri Lanka, Thailand, Turkey, United Arab
Emirates, Vietnam (Chanpattana et al. 2010), Fiji, Kiribati,
Solomon Islands (Little 2003), and Saudi Arabia (Alhamad
1999). ECT was reported not available in all countries, such
as Bhutan, Brunei, Cambodia, Georgia, Laos, and Lebanon
c© 2012 The Authors. Published by Wiley Periodicals, Inc. 287
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Figure 2. Worldwide Treated Person Rates (TPR)—number of ECTs per 10,000 resident population per year. [Correction added after ﬁrst online
publication on 20 March 2012: The TPR column for UK (Department of Health 2007) has been changed to 1.84.]
(Chanpattana et al. 2010),Micronesia andPalau (Little 2003).
The countries Cyprus, Macoa, Qatar, and Maldives had also
been excluded by a survey (Chanpattana et al. 2010).
Overall, the included studies displayed a large heterogene-
ity in thepresentationof rate andprevalencedata andpractice
of ECT worldwide. On a global basis, a crude estimate (from
numbers given in Appendix C, Tables C1–C5) of worldwide
contemporary TPR (SD) (age < 65 years) was 2.34 (1.56);
EAR (SD), 11.2 (9.0); iP (SD) 6.1 (6.9); and AvE (SD) 8 (1.4).
Globally, under half of all psychiatric institutions within the
same country provided ECT. Main ﬁndings of ECT utiliza-
tion, parameters, and practice from the ﬁve continents are
presented below.
ECT Utilization
Treated person rate
Overview of TPR from all countries providing such data is
illustrated in Figure 2.
TPR (Fig. 2) varied from 0.75 in New Zealand (Ministry
of Health 2005) to 4.4 in Victoria, Australia (Teh et al. 2005).
TPR in the USA Medicare population was 5.1 (5.7 women;
3.6 men) (Rosenbach et al. 1997). TPR by age groups (and
therefore not included in Fig. 2) ranged from 0.0001 (<18
years) to 3.8 (>65 years) in California (Kramer 1999). TPR
for the elderly (>65 years) in the Medicare population was
from 2.4 to 4.2, (Rosenbach et al. 1997; Westphal et al. 1997)
and varied from 3.8 West USA to 6.1 in the Northeast, as well
as between rural (TPR 3.2) to large urban areas (TPR 6.0)
(Rosenbach et al. 1997). TPR variations within the same State
were reported from Louisiana, TPR (>65 years): 2.8 urban
parishes versus 1.9 rural parishes (Westphal et al. 1997).
TPR in Europe varied between countries and regions and
between individual centers (Fig. 2), with the lowest TPR 0.11
in Poland (Gazdag et al. 2009a). The within-country regional
variation in Belgium (TPR 2.6–10.6) was reported as sig-
niﬁcant (Sienaert et al. 2006), which was also the case for
Norway (TPR 1.83–3.44) (Schweder et al. 2011a). In South
Africa, TPR was 1.26 (Mugisha and Ovuga 1991). In Asia,
TPR was only reported from Thailand 1.15 (Chanpattana
andKramer 2004) andHongKong ranging 0.27–0.34 (Chung
2003; Chung et al. 2003; Chanpattana et al. 2010).
Inpatient prevalence
Overview of iP from all countries providing such data is
illustrated in Figure 3.
The iP was highest in Africa 21–28% (Mugisha and Ovuga
1991; Selis et al. 2008), Nepal 22%, (Ahikari et al. 2008),
and overall in Asia estimated between <9% and 26% (Little
2003). In the United States, iP was lowest, from 0.4% to
1.3% (McCall et al. 1992; Sylvester et al. 2000), similar to
Hong Kong was 0.6–1.8% (Chung 2003; Chung et al. 2009).
In Australia, iP ranged from 1% to 8% (Wood and Burgess
2003; Teh et al. 2005), and in Europe from 0.6% (Hungary)
(Gazdag et al. 2004a) to 14% (Turkey) (Zeren et al. 2003).
Average ECT number
The AvE in New Zealand and Australia ranged from seven to
12 (O’Dea et al. 1991; Ministry of Health 2006; Chanpattana
2007), in Africa from one to 10, (Sijuwola 1985; Selis et al.
2008), in USA from ﬁve (Reid et al. 1998; Kramer 1999) to 12
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Figure 3. Inpatient prevalence rate (iP%)—percent of ECT-treated patients among inpatient population.
(Sylvester et al. 2000), USA overall seven to eight (Rosenbach
et al. 1997; Scarano et al. 2000; Prudic et al. 2001), and in
Brazil eight (Pastore et al. 2008) (AppendixC, Tables C1–C5).
AvE in Europe ranged from ﬁve (Glen and Scott 1999) to 11
(Sundhedsstyrelsen 2011a), except Sweden where it was one
to 22 (Socialstyrelsen 2010). AvE in Pakistan was one to 20
(Naqvi and Khan 2005), in Nepal two to 16 (Ahikari et al.
2008), and generally in Asia between six and eight.
ECT Parameters
Unmodiﬁed and modiﬁed
All parameter report in Australia and New Zealand indi-
cated modiﬁed ECT (O’Dea et al. 1991; Ministry of Health
2005; Chanpattana 2007; Lamont et al. 2011), similarly in the
United States (Reid et al. 1998; Scarano et al. 2000; Prudic
et al. 2001). ECT in Africa was generally administered un-
modiﬁed and in Malawi modiﬁed after 2007 (Mugisha and
Ovuga 1991; Selis et al. 2008). A study excluded from Nigeria
reported modiﬁed ECT administered in 1979, but found too
expensive (Odejide et al. 1987).
In Europe, all parameter report indicated modiﬁed ECT,
except for Russia (in contrast to Hungary [Gazdag et al.
2004a], with obligatory anesthesia) where >80% was un-
modiﬁed (Nelson 2005). In the Chuvash Republic, ECT was
modiﬁed, but 40% without use of muscle relaxants (and ad-
ministered mainly to women with schizophrenia) (Golenkov
et al. 2010). In Spain, 0.6% received unmodiﬁed ECT, and
2.3% without muscle relaxants (Bertolin-Guillen et al. 2006).
A large survey in Asia with 23 countries investigated re-
ported 129,906 unmodiﬁed ECTs administered to 22,194 pa-
tients (55.7%) at 141 (54.9%) institutions in 14 countries
(61%) (Chanpattana et al. 2010). Two-thirds of patients were
treated unmodiﬁed in Japan (1997–1999) (Motohashi et al.
2004), and 20% of all institutions administered only unmod-
iﬁed, with only sine-wave approved devices. In a later survey
from Japan (2001–2003), unmodiﬁed comprised 57% of all
administered ECTs (Chanpattana et al. 2005a). Patients se-
lected for modiﬁed (with anesthesia) in Japan were mainly
elderly or withmedical conditions (Motohashi et al. 2004). In
Thailand, almost all (94%) ECT administration was unmod-
iﬁed (Chanpattana and Kramer 2004). In India, both mod-
iﬁed and unmodiﬁed ECT was administered (Chanpattana
et al. 2005b), 52% of patients received unmodiﬁed at 50%
of all institutions, and 30% of institutions administered only
unmodiﬁed.
Overall in Asia, only 45% of facilities used modiﬁed ECT
exclusively (Chanpattana et al. 2010), in Hong Kong 87%
modiﬁed (Chung et al. 2003), and the Asian Paciﬁc Re-
gion (Little 2003) and Katmandu, Nepal, used only modiﬁed
(Ahikari et al. 2008). Eight facilities in Asia reported suc-
cinylcholine muscle relaxant used routinely without anes-
thesia (Chanpattana et al. 2010). Anesthesia was also used
without muscle relaxants in Japan, and extreme motion from
the convulsions held down with aid of assistants restrain-
ing patient’s shoulders, arms, and thighs (Ishimoto et al.
2000).
Overall, 26% Latin American countries used unmod-
iﬁed ECT (Levav and Gonzalez 1996), except for all
modiﬁed in Rio de Janeiro, Brazil and one country in
the Caribbean (Levav and Gonzalez 1996; Pastore et al.
2008).
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Placement and devices
On a worldwide scale, BL placement was the preferred elec-
trode placement. However, UL placement was the ﬁrst main
choice in Australia and New Zealand (O’Dea et al. 1991;
Ministry of Health 2005; Chanpattana 2007; Lamont et al.
2011), likewise to several European countries such as Vienna
(Tauscher et al. 1997), Munich (Baghai et al. 2005), Nether-
lands (van Waarde et al. 2009), and Norway (Schweder et al.
2011b).
In the United States, there was some sine wave (2%)
(Prudic et al. 2001) and some UL (16–21%) (Reid et al.
1998; Scarano et al. 2000; Prudic et al. 2001) report, but
BL placement (73–79%) and brief-pulse wave current (Reid
et al. 1998; Scarano et al. 2000; Prudic et al. 2001) was
mainstream. Similarly, brief-pulse wave current devices were
dominant in Europe, except sine-wave current still used in
Spain 14% (Bertolin-Guillen et al. 2006), Russia 26% (Nel-
son 2005), Belgium 34% (Sienaert et al. 2006), Poland 30%
(Gazdag et al. 2009a), Germany 39% (Muller et al. 1998), and
Hungary 52% (Gazdag et al. 2004a).
Overall electrode placement in Asia was BL (77%) (Chan-
pattana et al. 2010). Thailand (Chanpattana and Kramer
2004) and Japan (Motohashi et al. 2004) reported only the use
of BL and India always reported the use of BL in 82% (Chan-
pattana et al. 2005b). In Asia, 58% of institutions used brief-
pulse devices and 42% sine wave (Chanpattana et al. 2010).
In Japan, the device type was often Japanese-produced Sakai
C1, but also some had Thymatron R© DGx devices (Somat-
ics, Inc., www.thymatron.com) (Chanpattana et al. 2005a). In
India, a diversity of devices was in use, including locallymade
(Chanpattana et al. 2005b). In Katmandu, Nepal, device type
was only brief pulse (Ahikari et al. 2008).
ECT Practice
Provision of ECT and training
In Australia, ECT was provided by 66% institutions and ECT
training by 73% (Chanpattana 2007).
In the tri-state New York City metropolitan region, 55% of
institutions provided ECT (Prudic et al. 2001), 33% in Texas
(Reid et al. 1998), and 44% of all psychiatric hospitals in
North Carolina (Creed et al. 1995). A decrease from 1990 to
1994 in provision of ECT was reported in California and ECT
provided by public institutions to be very low, <6% (Kramer
1999).
In Europe, ECT provision in the Netherlands was 23%
(van Waarde et al. 2009), Belgium nationwide 22% (Sien-
aert et al. 2006), Flanders and Brussels capital region 26%
(Sienaert et al. 2005a), Poland 34% (Gazdag et al. 2009a),
Spain and Russia 46% (Nelson 2005; Bertolin-Guillen et al.
2006), France 51%(Benadhira andTeles 2001),Hungary 57%
(Gazdag et al. 2004a), Germany 59% (Muller et al. 1998),
Norway 72% (Schweder et al. 2011a), and in Denmark 100%
(Andersson and Bolwig 2002). In Norway, patients had to
wait up to eight weeks for treatment due to a low capacity in
administrating ECT (Schweder et al. 2011b).
ECT was mainly performed by junior doctors in Denmark
(Andersson and Bolwig 2002), England (Duffett and Lelliott
1998), and Norway (Schweder et al. 2011b). In Norway, 6%
of ECTs were administered by nurses (Schweder et al. 2011b)
and in the Netherlands sometimes by geriatricians or physi-
cians (van Waarde et al. 2009). About one-third of clinics
in England had developed clear policies to help guide ju-
nior doctors in administering ECT effectively (Duffett and
Lelliott 1998). ECT teaching programs were found at 59% of
institutions in India (Chanpattana et al. 2005b), and 78% in
Japan, but rated in 10% as fair to poor (Chanpattana et al.
2005a). Acceptable ECT training in Thailand was only found
for ﬁve hospitals (Chanpattana and Kramer 2004). In Saudi
Arabia, a two-lecture course on ECT was given every year
for junior doctors, as well as practical demonstration and
training (Alhamad 1999).
Diagnoses and diagnostic indication
Main diagnoses, diagnostic indication for ECT in Australia,
NewZealand,USA, SouthAmerica, andAfrica, are illustrated
in Figure 4.
Affective disorder (unipolar/bipolar depression) was the
main diagnoses in Australia and New Zealand (O’Dea et al.
1991; Wood and Burgess 2003; Teh et al. 2005; Chanpattana
2007; Lamont et al. 2011), but other main indications for ad-
ministering ECT were also noted (Lamont et al. 2011), such
as being too distressed to await drug response, patient pref-
erence, previous response, life saving, and medication resis-
tance. Affective disorders (unipolar/bipolar depression) were
also the main diagnoses in USA (72–92%), and schizophre-
nia and/or schizoaffective disorders were much less (8–29%)
(McCall et al. 1992; Hermann et al. 1995; Rosenbach et al.
1997; Reid et al. 1998; Scarano et al. 2000; Sylvester et al.
2000; Prudic et al. 2001). However in Africa, the main diag-
noseswere schizophrenia andpsychotic conditions (60–83%)
(Sijuwola 1985; Mugisha and Ovuga 1991; Selis et al. 2008),
and in Brazil 49% of cases reported same conditions (Pastore
et al. 2008).
Main diagnoses, diagnostic indication for ECT in Europe,
are illustrated in Figure 5.
Although affective disorders (unipolar and/or bipolar de-
pressionwith orwithout psychosis) were themost prominent
in Europe (Fig. 5), schizophrenia and/or schizoaffective dis-
order were major in Hungary 64%, Chuvash Republic 88%,
andTurkey 37% (Gazdag et al. 2004a; Saatcioglu andTomruk
2008; Golenkov et al. 2010).
Schizophrenia and/or schizoaffective disorder were much
less common in Belgium 5% (Sienaert et al. 2006), Nor-
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Figure 4. Diagnoses and ECT in Australia, New Zealand, USA, South America, Africa.
way 5% (Schweder et al. 2011a), Ireland 4% (Enriquez et al.
2010), and Scotland 5% (Fergusson et al. 2004). ECT for
mania varied from 0.2% (Munich) (Baghai et al. 2005)
to 12% (Spain) (Bertolin-Guillen et al. 2006). The main
indication for ECT was medication resistance, but also life
saving, catatonia, previous good response, and patient pref-
erence (Muller et al. 1998; Duffett et al. 1999; Zeren et al.
2003; Schweder et al. 2011a). ECT administered under preg-
nancy was noted at 10 Polish sites (Gazdag et al. 2009a) and
in Spain (Bertolin-Guillen et al. 2006).
Main diagnoses, diagnostic indication for ECT in Asia, are
illustrated in Figure 6.
Main diagnostic indication in Asia overall (Little 2003;
Chanpattana and Kramer 2004; Chanpattana et al. 2005b,
2010) was schizophrenia (Ishimoto et al. 2000; Motohashi
et al. 2004; Chanpattana et al. 2005a). However, in Saudi
Arabia (Alhamad 1999), Pakistan (Naqvi and Khan 2005),
and Hong Kong (Chung et al. 2009), depressive illness was
the main indication (over 60%). Reasons for giving ECT
to patients with schizophrenia (74%) in Thailand was small
budget for mental health care and no antipsychotics included
in the essential drug list from the Ministry of Health (Chan-
pattana and Kramer 2004). In India, ECT was prescribed to
other diagnoses, including drug abuse (Chanpattana et al.
2005b). Indication for ECT in Asia was also severe violence,
suicide and refractory treatment (Lalitanatpong 2005), need
of rapid improvement (Ishimoto et al. 2000), drug resis-
tance, or life-threatening situation (Naqvi and Khan 2005),
and in Saudi Arabia 35% as ﬁrst-choice emergency treatment
(Alhamad 1999).
Gender, age, and ethnicity
An overview of studies presenting gender and age data is
given in Table 2.
ECT-treated patients in Australia and New Zealand were
mainly women (63–71%) (O’Dea et al. 1991; Wood and
Burgess 2003; Teh et al. 2005; Ministry of Health 2006; Chan-
pattana 2007; Lamont et al. 2011), and one-third of patients
were above 65 years (O’Dea et al. 1991; Wood and Burgess
2003; Teh et al. 2005; Ministry of Health 2006; Chanpattana
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Figure 5. Diagnoses and ECT in Europe.
2007; Lamont et al. 2011). Similarly in the United States,
66–79% of patients were women (Rosenbach et al. 1997;
Westphal et al. 1997; Reid et al. 1998; Kramer 1999; Scarano
et al. 2000; Sylvester et al. 2000), and 48–59% were elderly
(over 60 years) (Reid et al. 1998; Sylvester et al. 2000; Pru-
dic et al. 2001). In New Zealand, >80% were of European
ethnicity (Ministry of Health 2006) and in USA Caucasian
white ethnicity was dominant (87% to >90%) (Rosenbach
et al. 1997;Westphal et al. 1997; Reid et al. 1998; Kramer 1999;
Scarano et al. 2000).A typical ECTpatient in theUnitedStates
was said to be an elderly white female paying for treatment
with insurance or private funds (Kramer 1999).
In Europe, not all studies reported gender and age, such as
Russia (Nelson 2005) and Denmark (Andersson and Bolwig
2002). The percent of ECT-treated European women ranged
from 44% to 81%. Mean age for ECT in Europe was overall
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Figure 6. Diagnoses and ECT in Asia.
high (49–66 years) (Tauscher et al. 1997; Duffett et al. 1999;
Huuhka et al. 2000; Baghai et al. 2005; Moksnes et al. 2006;
Moksnes and Ilner 2010; Socialstyrelsen 2010; Eranti et al.
2011), except 33.1–35.1 years in Turkey (Zeren et al. 2003;
Saatcioglu and Tomruk 2008) and 34.4 years in the Chu-
vash Republic (Golenkov et al. 2010). Patients above 64 years
seldom received ECT in Turkey (1–3%) (Zeren et al. 2003;
Saatcioglu and Tomruk 2008), in the Chuvash Republic none
(Golenkov et al. 2010). UK’s National Health Service data
revealed 0.2% ECT-given young patients (16–18, but none
<16 years) in 2007 (Department of Health 2007). The high-
est treatment rates in theUnitedKingdomwere found among
those with Caucasian white ethnicity (Department of Health
2007).
In Africa, men were treated with ECT more often than
women (29% women), and mean age was young (30.7
[Mugisha and Ovuga 1991], range 17–37 years [Selis et al.
2008]). Similarly, percent of ECT-treated female patients in
Asia was generally low, for example, 28% Katmandu (Ahikari
et al. 2008) 33% Emirates (Tewﬁk et al. 1998), 39% In-
dia (Chanpattana et al. 2005b), 28–63% Thailand (Chan-
pattana and Kramer 2004; Lalitanatpong 2005), and overall
estimated to be 38% (Chanpattana et al. 2010). In some
places, the female proportion was higher, for example, 51%
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Japan (Ishimoto et al. 2000), 56% Pakistan (Naqvi and Khan
2005), 60% Saudi Arabia (Alhamad 1999), and 68–88%
Hong Kong (Chung et al. 2003, 2009). In Saudi Arabia, the
typical ECT patient was described to be a Saudi married
woman, with medium level of education, living in the City,
not employed outside the home, and with affective disor-
der (Alhamad 1999). Proportion of young (<18 years) ECT-
treated patients in Asia was overall 6% (Chanpattana et al.
2010), 5%HongKong (Chung2003), 1% India (Chanpattana
et al. 2005b), and 11% (<19 years) Katmandu (Ahikari et al.
2008). In Thailand, ECT-treated patients with schizophre-
nia were younger than those with depression (Lalitanatpong
2005).
Other data—conditions, adverse events, side
effects, training, guidelines, legal
regulations conditions
In Australia and New Zealand, consent by Mental Health
Review Tribunal varied from 21% to 60% (Teh et al. 2005;
Lamont et al. 2011). In the United States, use of informed
consent was noted as 37% always and 26% never (Levav and
Gonzalez 1996), involuntary conditions and use of guardian
consent ranged from 1–2% in Texas (Reid et al. 1998; Scarano
et al. 2000), 3% California (Kramer 1999) to 29% North
Carolina (McCall et al. 1992). From 1993, mandatory report
of ECT use to health authorities was initiated in Texas and
ECT use was prohibited for patients <16 years of age (Reid
et al. 1998).
Report of involuntary ECT conditions varied in Europe
from 1% in Spain (Bertolin-Guillen et al. 2006), 3.2% Den-
mark (2009) (Sundhedsstyrelsen 2011a), to 20% Germany
(Muller et al. 1998), 24% Scotland (Fergusson et al. 2004),
and 26% in Finland (Huuhka et al. 2000). In Scotland, 18%
of patients received ECT under the safeguards of the Scottish
Mental Health Act of 1984 (Fergusson et al. 2004), and in
England 60%, of those formally detained, did not consent to
ECT treatment (Department of Health 2007).
The use of written informed consent documents was oblig-
atory in Poland (Gazdag et al. 2009a), and reported as 15%
in Germany (Muller et al. 1998), 44% in Belgium (Sienaert
et al. 2006), and 50% in Norway (Schweder et al. 2011b).
Written informed consent was mainly obtained from family
members in Japan (Motohashi et al. 2004; Chanpattana et al.
2005a), Thailand (Chanpattana and Kramer 2004), and Pak-
istan (Naqvi and Khan 2005), and countersigning by a near
relative practiced in Saudi Arabia (Alhamad 1999). In Hong
Kong, 13%were judged incapable of giving informed consent
(Chung 2003).
Adverse events and side effects
Adverse events (within two weeks after ECT) in Texas, in
1998 (Reid et al. 1998), were eight deaths (two were noted
as possibly anesthesia-related complications) and in 2000,
25 deaths (Scarano et al. 2000), with mortality rate (within
two weeks after ECT) estimated at 14 deaths per 100,000
treatments (Scarano et al. 2000). Side effects were noted in
37% in Japan, including one case of compression fractures of
vertebrae (Ishimoto et al. 2000). Side effects from unmodi-
ﬁed ECT in India were fractures, dislocations, teeth injury,
and one death in the one-year study period (Chanpattana
et al. 2005b). Mortality rate was estimated 0.08% in Thai-
land (Chanpattana and Kramer 2004), although there were
no ECT-related deaths in the survey period.
Maintenance, continuation, and
ambulatory ECT
Maintenance ECT was practiced in Texas (Reid et al. 1998),
and continuation ECT (C-ECT) in Australia (Chanpattana
2007). Ambulatory ECT (A-ECT) was lacking in the Chu-
vash Republic (Golenkov et al. 2010), rarely used in Belgium
(Sienaert et al. 2006), andnotperformed inPolishoutpatients
clinics (Gazdag et al. 2009a). A-ECT was reported available
in 2% of Russian institutions (Nelson 2005) and 63% of Nor-
wegian (Schweder et al. 2011b). Proportion of A-ECT-treated
patients was 15% in Norway (Schweder et al. 2011b), 16%
Wales (Duffett et al. 1999), 18%Ireland (Enriquez et al. 2010),
and 19% UK (Department of Health 2007). A-ECT was also
practiced in Thailand (Lalitanatpong 2005) but A-ECT and
C-ECT rarely were used in Hong Kong (Chung 2003). In
India, C-ECT report varied from given to 1–10% to 60% of
patients (Chanpattana et al. 2005b).
Legislation and guidelines
InVictoria, Australia legislation requiresmandatorymonthly
reports (Teh et al. 2005). In Poland (Gazdag et al. 2009a) and
the Chuvash Republic (Golenkov et al. 2010), the presence of
an anesthetist under ECT was mandatory.
Locally developed guidelines were described in Norway
(Moksnes et al. 2006; Schweder et al. 2011b) and Vienna
(Tauscher et al. 1997), and in Belgium less than 44% of de-
partments did not follow guidelines (Sienaert et al. 2005a).
Guidelines were used only by 28% of Japanese institutions
(Motohashi et al. 2004). In Hong Kong, a hospital policy
of patient assessment every one to two treatments during
an ECT course was practiced only sometimes (Chung et al.
2003).
Other—funding and attitudes
Over half (57%) funding of ECT in the United States was
ﬁnanced by public third party payment source (including
Medicare) (Reid et al. 1998). Attitudes of psychiatrists toward
ECTwere generally favorable inEurope, for example, in Spain
(Bertolin-Guillen et al. 2006), Germany (Muller et al. 1998),
Russia (Nelson 2005), and Norway (Schweder et al. 2011a).
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Table 2. Overview of ECT treatment worldwide by gender and age.
Percent of
Age in yearsECT-treated
Country First author (reference) women %N >65 (%) Mean Range
Australia and New Zealand
Sydney, Australia Lamont (Lamont et al. 2011) 71 28
New Zealand Ministry of Health (Ministry of Health 2006) 69 40 (2004/2005)
Western Australia Teh (Teh et al. 2005) 65
Australia Chanpattana (Chanpattana 2007) 63 38
Victoria, Australia Wood (Wood and Burgess 2003) 63 33
Africa
Malawi Selis (Selis et al. 2008) 49 17–35
South Africa Mugisha (Mugisha and Ovuga 1991) 29 30.7
North America
Louisiana Westphal (Westphal et al. 1997) 79 100
Pennsylvania Sylvester (Sylvester et al. 2000) 71 59 (>60)
Texas Reid (Reid et al. 1998) 70 48
Texas Scarano (Scarano et al. 2000) 69
California Kramer (Kramer 1999) 69
USA Rosenbach (Rosenbach et al. 1997) 66
USA Prudic (Prudic et al. 2001) 55 (>60)
North Carolina McCall (McCall et al. 1992) 44.3 19–75
South America
Brazil Pastore (Pastore et al. 2008) 71 41.3
Europe
Austria Tauscher (Tauscher et al. 1997) 81 49 23–69
Finland Huuhka (Huuhka et al. 2000) 76 58.9 18–83
Norway Moksnes (Moksnes and Ilner 2010) 74 64 29–87
UK Department of Health (Department of Health 2007) 71 46
Wales Duffett (Duffett et al. 1999) 71 56.9 (women)
55.5 (men)
Scotland Glen (Glen and Scott 1999) 71
London, UK Eranti (Eranti et al. 2011) 70 62.8
Scotland Fergusson (Fergusson et al. 2004) 70 26
Norway Moksnes (Moksnes et al. 2006) 69 67 (women) 23–91
65 (men)
Ireland Enriquez (Enriquez et al. 2010) 66 50.6 18–87
Munich Baghai (Baghai et al. 2005) 66 51.2
Poland Gazdag (Gazdag et al. 2009a) 65
Norway Schweder (Schweder et al. 2011a) 65 55
UK Duffett (Duffett and Lelliott 1998) 64
Sweden Socialstyrelsen (Socialstyrelsen 2010) 59 54.5 15–92
Hungary Gazdag (Gazdag et al. 2004a) 59
Russia Golenkov (Golenkov et al. 2010) 56 34.4 15–64
Turkey Zeren (Zeren et al. 2003) 52 3(>64) 33.1
Turkey Saatcioglu (Saatcioglu and Tomruk 2008) 44 1(>64) 35.1
Asia
Hong Kong Chung (Chung et al. 2009) 88 60 62 21–87
Hong Kong Chung (Chung 2003) 68 15
Thailand Lalitanatpong (Lalitanatpong 2005) 63
Saudi Arabia Alhamad (Alhamad 1999) 60 27.9 15–60
Pakistan Naqvi (Naqvi and Khan 2005) 56 7 (>60)
Japan Chanpattana (Chanpattana et al. 2005a) 54 39 (>64)
Japan Ishimoto (Ishimoto et al. 2000) 51 27.5 13–59
Bengaluru, India Eranti (Eranti et al. 2011) 51 30.3
India Chanpattana (Chanpattana et al. 2005b) 39 15
Asia Chanpattana (Chanpattana et al. 2010) 38 4 (>64)
United Arab Emirates Tewvik (Tewﬁk et al. 1998) 33 30.1
Thailand Chanpattana (Chanpattana and Kramer 2004) 28
Nepal Ahikari (Ahikari et al. 2008) 28
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Reasons for not prescribing ECT in Europe were attributed
to lack of equipment, economy, and difﬁculties in recruiting
anesthetist (Muller et al. 1998; Nelson 2005; Bertolin-Guillen
et al. 2006; Schweder et al. 2011b).
Main ﬁndings of this review are summarized as
follows:
(1) There is a large variation in ECT utilization and practice
worldwide today. Global crude estimates of TPR (age < 65
years) is 2.34, EAR 11.2, iP 6.1, and AvE eight. Only some
(usually under half) of all institutions within the same coun-
try provide ECT. Mandatory report of ECT use and moni-
toring by governmental agents is overall scant. Reporting of
side effects, adverse events, and mortality is sparse. The re-
sults reﬂect that the guidelines by APA and Royal College of
Psychiatrists are not internationally acknowledged, except in
Western countries, and therefore the lack of implementation
may be rational in these regions of the world.
(2) Overall, there is a considerable variation inECTadminis-
tration and parameters worldwide. Unmodiﬁed ECT is sub-
stantially used today, not only in Asia (over 90%), Africa,
Latin America, but also occurs in Europe (Russia, Turkey,
and Spain). The most common electrode placement is BL,
but a few places in Europe and Australia/New Zealand ad-
here toUL as ﬁrst choice. Brief-pulse wave current devices are
used worldwide, but old sine-wave stimulus and apparatus
still in use.
(3) In Western countries (Europe, USA, Australia, and New
Zealand), ECT is at large administered to elderly female pa-
tients with depressive disorders. In those areas of the world
(Asia, Africa, Latin America, Russia), where ECT is still often
administered unmodiﬁed, it is predominantly prescribed to
younger patients (often more male) with schizophrenia. ECT
is administered worldwide under involuntary and guardian
consent conditions (ranging from a few percent up to nearly
two-thirds). (Involuntary conditions, implying also ECT ad-
ministered under involuntary admission, are though in the
extracted data but not always directly equivalent or indicative
of involuntary [against wish] treatment.)
(4) New trends are revealed. ECT is used as ﬁrst-line acute
treatment and not only last resort for medication resis-
tant conditions in many countries. Other professions than
psychiatrists (geriatricians and nurses) are administering
ECT. ECT use among outpatients (ambulatory setting) is
increasing.
Discussion
ECTutilization andpractice are presented fromall continents
of the world in this review, representing a widespread use of
ECT in the today’s world. Two continents, Africa and Latin
America, have sparse ECT country data, which might indi-
cate a trend away from ECT (Levav and Gonzalez 1996), but
this does not at all seem to be the case in the rest of the world.
Although the report of ECT seems abundant in Europe, Asia,
and America, the data do not cover all countries known
to have ECT practice. For example, no “up to date” 1990
and after ECT studies are identiﬁed from either Iceland or
Canada.
Large variations between continents, countries, and re-
gions in ECT utilization, rates, and clinical practice are dis-
played, despite international guidelines (American Psychi-
atric Association 2001; Royal College of Psychiatrists 2005;
Enns et al. 2010). Due to no uniform standard of reporting
ECT utilization, rates are computed in the data extraction
to TPR per 10,000, to make it comparable. This revealed
a large worldwide TPR variation, from 0.11 (Gazdag et al.
2009a) to 5.1 (Rosenbach et al. 1997). Likewise worldwide
iPs varied greatly. Although the large worldwide differences
in ECT utilization have been pointed out previously (Her-
mann et al. 1995; Glen and Scott 2000; Bertolin-Guillen et al.
2006; Gazdag et al. 2009a), and the differences between coun-
tries on the basis of practice reports are not so easy to compare
(Little 2003), overall variations in contemporary practice be-
tween the continents (Asia and Africa vs. USA, Australia and
New Zealand, Europe) revealed by this review are immense.
Explanations of these variations are complex, encompassing
not only the diversity in organization of psychiatric services,
butnodoubt also grounded inprofessional beliefs concerning
the efﬁcacy and safety of ECT (The UK ECT Review Group
2003).On aworldwide scale, the number of patients receiving
unmodiﬁed ECT is large, nearly 20,000 of patients in India
(Chanpattana et al. 2005b), over 6000 in Thailand (Chan-
pattana and Kramer 2004), and overall in Asia estimated at
11.2 patients treated with unmodiﬁed ECT per 100,000
(Chanpattana 2010).
Diverse reasons for this high use of unmodiﬁed ECT
have been put forth, such as lack of equipment, personnel
and anesthesiologists, contraindication for anesthesia, con-
venience, emergency, and economic purposes (Chanpattana
et al. 2005b). Whether these arguments are acceptable in
this modern era and in light of knowledge about beneﬁts
and harms of ECT is another question. In spite of attempts
to ban it (Mudur 2002), the debate defending unmodiﬁed
ECT practice (Andrade et al. 2010), and voices claiming this
practice to be unjustiﬁed and unethical (Grunhaus 2010) is
ongoing today. Unmodiﬁed ECT is still practiced in some
parts of Russia, Turkey, and Spain (Zeren et al. 2003; Nelson
2005; Bertolin-Guillen et al. 2006), and international guide-
lines (American Psychiatric Association 2001; Royal College
of Psychiatrists 2005; Enns et al. 2010) appear to have failed
(Strachan 2001) in inﬂuencing important aspects of today’s
ECT practice.
The practice in many countries of Asia (Chanpattana and
Kramer 2004; Chanpattana et al. 2005a, b, 2010), LatinAmer-
ica (Levav and Gonzalez 1996), and Africa (Odejide et al.
1987; Mugisha and Ovuga 1991; Selis et al. 2008; James
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et al. 2010) bear a resemblance to the beginning of ECTs
medical history in Europe (Cerletti and Bini 1938). The
Asian practice of today resembles practice that was used
in Finland in 1944 and 1964 (Huuhka et al. 2000), where
the majority of ECT-treated patients were diagnosed with
schizophrenia (75–78%) and treated unmodiﬁed. Likewise,
in 1944 in Finland, ECT was (Huuhka et al. 2000) more of-
ten given to men than women (36% women). In 1997 in
Finland, a major shift occurred toward majority of patients
(78%) having affective disorders (unipolar/bipolar depres-
sion) and treated modiﬁed (Huuhka et al. 2000). This shift in
Western world practice and the increasing use of ECT among
women is also found both in USA and Australia, in the 1980s
to 1990s (Galletly et al. 1991; Rosenbach et al. 1997). Similar
changes seem to be occurring in some areas of Asia (Alhamad
1999; Naqvi and Khan 2005; Ahikari et al. 2008; Chanpat-
tana et al. 2010). One reason for the lingering ECTuse among
patients with schizophrenia might be availability of antipsy-
chotic medication, such as in Thailand, where the essential
drug list from the Ministry of Health does not include an-
tipsychotics (Chanpattana and Kramer 2004). Also, shortage
of anesthesiologist and negative images is another explana-
tion that is given for having hindered Japanese psychiatrists
fromreformingECTpractice for a long time (Motohashi et al.
2004).
Another explanationof practice differences, diagnostic and
gender disparities between Asia and Europe, Australia and
New Zealand, and USA might be the historical use of ECT,
being much longer in Europe where it originated in 1938
(Cerletti and Bini 1938) and its early spreading to the United
States (Cerletti and Bini 1938; Hemphill and Walter 1941;
Shorter 2009). In Thailand, ECT was ﬁrst administered un-
modiﬁed in 1950, modiﬁed in 1974, and brief-pulse wave
ﬁrst applied in 1992 (Chanpattana 2010). Whereas, in Japan,
ECTwas ﬁrst administered unmodiﬁed in 1939 andmodiﬁed
1958 (Chanpattana et al. 2005a), but even so the practice of
unmodiﬁed ECT in Japan in the 1990s is still profuse (Moto-
hashi et al. 2004; Chanpattana et al. 2005a).
In Europe, USA, and Australia/New Zealand, practice was
almost entirely modiﬁed ECT and even in Hungary (Gazdag
et al. 2004a) anesthesia was obligatory. In several countries,
Chuvash Republic, Russia, Spain, and Japan, the practice of
modiﬁedECTwas sometimeswithoutmuscle relaxants (Ishi-
moto et al. 2000; Bertolin-Guillen et al. 2006; Golenkov et al.
2010), and even assistants were used to restrain extreme mo-
tion from the convulsions in Japan (Ishimoto et al. 2000).
The unusual practice of muscle relaxants without anesthesia
is also undertaken in a few Asian institutions (Chanpattana
et al. 2010), and availability and recruitment of anesthesi-
ologists pointed out as a problem both in Asia and Europe
(Duffett and Lelliott 1998; Motohashi et al. 2004; Schweder
et al. 2011b). On the other hand, Wales has no shortage of
anesthesiologists (Duffett et al. 1999).
Preferred placement of electrodes worldwide (approxi-
mately 80%) is BL, as it was from the very beginning
(Cerletti and Bini 1938), except for Australia, New Zealand
(O’Dea et al. 1991), Norway (Schweder et al. 2011b), Vienna
(Tauscher et al. 1997), Munich (Baghai et al. 2005), and the
Netherlands (van Waarde et al. 2009) where UL is the ﬁrst
choice, but they also use both types. Brief-pulse wave cur-
rent devices appearwidespreadworldwidely.Many countries
(Scandinavia, Australia, and New Zealand) adhere to brief-
pulse wave and UL electrode placement as ﬁrst choice (Fink
2001; Rose et al. 2003; Shorter 2009), no doubt due to the
reported trade-off effect between effectiveness and memory
impairment (The UK ECT Review Group 2003), but switch
to BLwhen the clinical response is judged as too poor. In spite
of sine-wave current being declared unjustiﬁed by guidelines
today (American Psychiatric Association 2001), it still occurs
in Europe (14–52%) (Muller et al. 1998; Gazdag et al. 2004a,
2009a; Nelson 2005; Bertolin-Guillen et al. 2006; Sienaert
et al. 2006), Asia (30–58%) (Chanpattana et al. 2005a, b,
2010), and USA (2%) (Prudic et al. 2001).
Previous literature indicates a predominance of patients
receiving ECT in Western countries to be elderly female with
affective disorder (unipolar/bipolar depression) (Reid et al.
1998; Glen and Scott 1999; Fergusson et al. 2003; Baghai et al.
2005; Moksnes et al. 2006), as is also conﬁrmed by this re-
view, and also in Hong Kong (Chung et al. 2009). Except for
age being younger, female and depression predominance was
also the case for Saudi Arabia (Alhamad 1999) and Pakistan
(Naqvi andKhan2005). In someEuropean sites (Brussels and
Wallonia inBelgium),ECT is regardedas an“antidepressant,”
since it is used exclusively for the treatment of depressive dis-
order (Sienaert et al. 2006). In contrast, ECT in Asia it is
regarded as an “antipsychotic” agent (Little 2003; Chanpat-
tana et al. 2005a, b, 2010; Chanpattana and Kramer 2004;
Ahikari et al. 2008). Discrepancies in indication could be
due to differences in diagnostic practice, a lower recognition,
and under treatment of depressive disorder, and also lower
mental health care budgets (Chanpattana and Kramer 2004).
In contrast to Asia, the typical ECT patient in the United
States is said to be an elderly white female paying for treat-
ment with insurance or private funds (Kramer 1999). Higher
ECT treatment rates are found among Caucasian white eth-
nicity in Pennsylvania (Sylvester et al. 2000), England (De-
partment of Health 2007), and Western Australia (Teh et al.
2005),whichmight implydiscriminatory factors in treatment
selection.
Worldwide, there is a general tendency toward a low,
within-country, ECT provision by psychiatric institutions,
varying from below 6% in USA (Kramer 1999), to 23–51%
in Europe (Benadhira and Teles 2001; Sienaert et al. 2005a,
2006; Bertolin-Guillen et al. 2006; van Waarde et al. 2009;
Schweder et al. 2011a), 66% inAustralia (Chanpattana 2007),
and 59–78% in Asia (Chanpattana et al. 2005a, b). In Nor-
c© 2012 The Authors. Published by Wiley Periodicals, Inc. 297
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way, institutions even have waiting lists for ECT treatment
(Schweder et al. 2011b). Altogether, this might indicate a
trend toward ECT being provided by specialized units, but
could also be a result of worldwide paucity in ECT train-
ing (Duffett and Lelliott 1998; Chanpattana et al. 2005a, b;
Chanpattana and Kramer 2004), and even changing treat-
ment trends.
ECT has for a long time been over held as a last-resort
treatment for medication-resistant and very severe life-
threatening clinical conditions (McCall 2001; Eranti and
McLoughlin2003), as reported fromUSA(Prudic et al. 2001).
However, a transformation in ECT indication into ﬁrst-line
acute treatment (life saving, catatonia, previous good re-
sponse, and patient preference) is apparent not only in Eu-
rope (Muller et al. 1998; Duffett et al. 1999; Zeren et al.
2003; Schweder et al. 2011a), but also in Saudi Arabia (Al-
hamad 1999) and Australia (Lamont et al. 2011). Although
world widely ECT is mainly administered by psychiatrists
and trainee psychiatrists, another change is that of other pro-
fessions than psychiatrists (geriatricians and nurses) admin-
istering ECT in Europe (van Waarde et al. 2009; Schweder
et al. 2011b). The trend toward increasing ambulatory ECT
and ECT use among outpatients in Europe (15–19%) (Duf-
fett et al. 1999; Department of Health 2007; Enriquez et al.
2010; Schweder et al. 2011b) is conceivably, parallel to other
ambulatory treatment tendencies, out of the best interest to
the recovering patient and his caregivers.
Overall, the report of side effects, adverse events, and mor-
tality rates is sparse. Although mortality rate is reported
from Thailand (0.08%) (Chanpattana and Kramer 2004)
and Texas (14 deaths per 100,000 treatments within two
weeks after ECT) (Scarano et al. 2000), it is not clear if the
ECT-related deaths are due to lethal side effects (e.g., car-
diac arrhythmia) or comorbid somatic illnesses or anesthetic
complications.
ECT is administered worldwide under involuntary and
guardian consent conditions, ranging from a few percent
in USA and Europe 1–3% (Reid et al. 1998; Kramer 1999;
Scarano et al. 2000; Bertolin-Guillen et al. 2006; Sund-
hedsstyrelsen 2011a) to 20–29% (McCall et al. 1992; Muller
et al. 1998; Huuhka et al. 2000; Fergusson et al. 2004). In-
voluntary conditions in the extracted data though cannot be
taken as directly equivalent to or directly indicative of invol-
untary (against wish) treatment. In Asia, written informed
consent is mainly obtained directly or counter signed by fam-
ily members (Alhamad 1999; Chanpattana and Kramer 2004;
Chanpattana et al. 2005a; Naqvi and Khan 2005). Consent
given by legal bodies varies from 18% in Scotland (under the
Scottish Mental Health Act) (Fergusson et al. 2004) to 60%
in Sydney, Australia (by the Mental Health Review Tribunal)
(Lamont et al. 2011). Mandatory ECT data reporting is al-
most nonexistent and found only in a few places (Texas, USA,
andAustralia) (Reid et al. 1998; Scarano et al. 2000;Woodand
Burgess 2003). Likewise legislature regulating practice, such
as obligatory anesthesia (Gazdag et al. 2004a), obligatory
written informed patient consent (Schweder et al. 2011b),
ECT licensed facilities (Wood and Burgess 2003), prohib-
ited administered to persons under 16 years of age (Reid et al.
1998), involuntary by order of court or legal body (Fergusson
et al. 2004; Lamont et al. 2011), is also nonexistent.
Implications of ﬁndings
Worldwide improvement of ECT utilization and practice is
needed, alongside development of an international minimal
dataset standard applied in all countries. Continuous and
mandatory monitoring and use of ECT health registrar re-
porting systems, taking into account patient conﬁdentiality,
would also ultimately reduce our knowledge gaps. Thiswould
again contribute to more uniform worldwide ECT practice,
to the best for the patient.
Strengths and limitations
Strengths of this study are the extensive search strategy, high
number of included studies, methodological transparency,
and summaryof ﬁndings table, providing anoverviewof con-
temporary worldwide use of ECT, which has not been under-
taken in such detail previously. Limitations of this review are
the inclusion of nonrandomized survey/questionnaire stud-
ies, based on practitioner accounts of ECT use, inﬂuencing
the precision of the estimated rates, either to be overesti-
mated or underestimated depending on the accuracy of the
source. Seemingly, more accurate are direct reports from in-
dividual hospitals studies or national registers. The overall
diversity in practice data reporting unclear representative-
ness of region or land as a whole and large heterogeneity
in reported ECT utilization rates did not lend the data to
meta-analyses. National overviews of ECT data published
by regulatory bodies or governmental agencies on the in-
ternet are not so easily accessed, despite such internet sites
being hand searched. National government overviews do
not usually appear in the databases where systematic lit-
erature search of published journal articles and studies is
undertaken.
Conclusion
Today utilization rates, practice, and ECT parameters vary
greatly throughout continents and countries. Unmodiﬁed
ECT is still in use (Asia, Africa, Latin America, and even in
Europe). In spite of existing guidelines, there is no uniform
worldwide practice. Large global variation in ECTutilization,
administration, and practice advocates a need for worldwide
sharing of knowledge about ECT, reﬂection, and learning
from each other’s experiences.
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Appendix A. Search strategy.
Ovid MEDLINE(R)
1950 to
November 2010
Week 2
EMBASE 1980 to
2010 Week 45
PsycINFO 1806 to
November 2010
Week 3 SveMed+ EBSCO; Cinahl
1 Electroconvulsive
Therapy/
Electroconvulsive
Therapy/
Electroconvulsive
exp Shock/
Explodeso¨kning pa˚
Electroconvulsive-
Therapy
S7 or S14
2 (electroconvulsive$
or electr$
convulsive$).tw.
(electroconvulsive$
or electr$
convulsive$).tw.
(electroconvulsive$
or electr$
convulsive$).tw.
(electroconvulsive$ or
electr$ convulsive$)
S8 or S9 or S10 or S11 or S12 or S13
3 (electroshock$ or
electr$
shock$).tw.
(electroshock$ or
electr$
shock$).tw.
(electroshock$ or
electr$
shock$).tw.
(electroshock$ or
electr$ shock$)
TI ((practice of electroconvulsive*) or
(practice of electr* convulsive*) or
(practice of electroshock*) or
(practice of electr* shock*) or
(practice of ect)) or AB ((practice of
electroconvulsive*) or (practice of
electr* convulsive*) or (practice of
electroshock*) or (practice of
electr* shock*) or (practice of ect))
4 ect.tw. ect.tw. ect.tw. ect TI ((ect n1 “use of”) or (ect n1 used)
or (ect n1 frequen* of) or (ect n1
analys* of)) or AB ((ect n1 “use
of”) or (ect n1 used) or (ect n1
frequen* of) or (ect n1 analys* of))
5 or/1–4 or/1–4 or/1–4 elterapi or
elektrokonvulsiv$ or
elektrosjokk$ or
elektrochok$ or
elchok$ or
eletrochock$ or
elchock$ or
elektrostim$
TI ((electroshock* n1 “use of”) or
(electroshock* n1 used) or
(electroshock* n1 frequen* of) or
(electroshock* n1 analys* of)) or
AB ((electroshock* n1 “use of”) or
(electroshock* n1 used) or
(electroshock* n1 frequen* of) or
(electroshock* n1 analys* of))
6 (utiliz$ or
survey$).tw.
(utiliz$ or
survey$).tw.
(utiliz$ or
survey$).tw.
S1 OR S2 OR S3 OR
S4 OR S5
TI ((electr* shock* n1 “use of”) or
(electr* shock* n1 used) or (electr*
shock* n1 frequen* of) or (electr*
shock* n1 analys* of)) or AB
((electr* shock* n1 “use of”) or
(electr* shock* n1 used) or (electr*
shock* n1 frequen* of) or (electr*
shock* n1 analys* of))
7 5 and 6 5 and 6 5 and 6 utiliz$ or survey$ or
bruk$ or anvend$
or anva¨nd$ or
benytt$
TI ((electro convulsive* n1 “use of”)
or (electro convulsive* n1 used) or
(electro convulsive* n1 frequen*
of) or (electro convulsive* n1
analys* of)) or AB ((electro
convulsive* n1 “use of”) or (electro
convulsive* n1 used) or (electro
convulsive* n1 frequen* of) or
(electro convulsive* n1 analys* of))
8 Electroconvulsive
Therapy/sn, ut
[Statistics &
Numerical Data,
Utilization]
((electroconvulsive$
or electr$
convulsive$ or
electroshock$ or
electr$ shock$ or
ect) adj1 (“use
of” or used)).tw.
((electroconvulsive$
or electr$
convulsive$ or
electroshock$ or
electr$ shock$ or
ect) adj1 (“use
of” or used)).tw.
praksis$ or prakti$ or
frekven$
TI ((electroconvulsive* n1 “use of”)
or (electroconvulsive* n1 used) or
(electroconvulsive* n1 frequen* of)
or (electroconvulsive* n1 analys*
of)) or AB ((electroconvulsive* n1
“use of”) or (electroconvulsive* n1
used) or (electroconvulsive* n1
frequen* of) or (electroconvulsive*
n1 analys* of))
(Continued)
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Appendix A. Continued.
Ovid MEDLINE(R)
1950 to
November 2010
Week 2
EMBASE 1980 to
2010 Week 45
PsycINFO 1806 to
November 2010
Week 3 SveMed+ EBSCO; Cinahl
9 ((electroconvulsive$
or electr$
convulsive$ or
electroshock$ or
electr$ shock$ or
ect) adj1 (“use
of” or used)).tw.
(practice of
electroconvulsive$
or practice of
electr$
convulsive$ or
practice of
electroshock$ or
practice of electr$
shock$ or practice
of ect).tw.
(practice of
electroconvulsive$
or practice of
electr$
convulsive$ or
practice of
electroshock$ or
practice of electr$
shock$ or practice
of ect).tw.
S7 OR S8 S5 and S6
10 (practice of
electroconvulsive$
or practice of
electr$
convulsive$ or
practice of
electroshock$ or
practice of electr$
shock$ or practice
of ect).tw.
(((frequen$ adj of) or
(analys$ adj of))
adj1 (electrocon-
vulsive$ or electr$
convulsive$ or
electroshock$ or
electr$ shock$ or
ect)).tw.
(((frequen$ adj of) or
(analys$ adj of))
adj1 (electrocon-
vulsive$ or electr$
convulsive$ or
electroshock$ or
electr$ shock$ or
ect)).tw.
s6 and s9 S1 or S2 or S3 or S4
11 (((frequen$ adj of) or
(analys$ adj of))
adj1 (electrocon-
vulsive$ or electr$
convulsive$ or
electroshock$ or
electr$ shock$ or
ect)).tw.
or/8–10 or/8–10 TI (utiliz* or survey*) or AB (utiliz* or
survey*)
12 8 or 9 or 10 or 11 7 or 11 7 or 11 AB ect or TI ect
13 7 or 12 human/ limit 12 to
yr =“1990
-Current”
AB ((electroshock* or electr*
shock*)) or TI ((electroshock* or
electr* shock*))
14 humans.sh. 12 and 13 AB ((electroconvulsive* or electr*
convulsive*)) or TI
((electroconvulsive* or electr*
convulsive*))
15 13 and 14 limit 14 to
yr =“1990
-Current”
(MH “Electroconvulsive Therapy”)
16 limit 15 to
yr =“1990
-Current”
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Appendix B. Excluded studies (N = 31).
First author (reference)
Country or continent and
reason for exclusion:
(1) not relevant topic
(2) no rate or prevalence
data, very sparse data,
review without primary
data
(3) parallel other language
publication, not possible to
ﬁnd or full-text retrieve
(4) too old, <1990 Comments
O’Dea JF (O’Dea et al. 1991) Australia and New Zealand (1) Questionnaire survey of ECT practice and attitudes to medical
superintendents at hospitals. Frequency of unilateral versus bilateral
electrode placement main aim. Sparse ECT utilization data
Galletly CA (Galletly et al. 1991) South Australia (4) Too old, use of ECT data at hospital in Adelaide from 1981 to 1985
(ﬁve years). [Decline in use over period due to reduction of ECT for
patients with schizophrenia]
Gassy JE (Gassy and Rey 1990) NSW, Australia (4) Too old, a general hospital psychiatry unit use of ECT from April 1982
to December 1987
Ikeji OC (Ikeji et al. 1999) Nigeria (2) A prospective open-label study of 70 unmodiﬁed ECT treated patients
without rate or prevalence data
Odejide AO (Odejide et al. 1987) Nigeria (4) Sparse data from <1990, records from 1982 and1984 examined.
Unmodiﬁed bilateral ECT. Modiﬁed ECT was tried in 1979, but found
too expensive. Thirty percent of patients ECT treated in 1984 and
average no. of ECTs six, range 1–19
Okasha TA (Okasha 2007) Egypt (2) General article about ECT use, economic aspects, problems of training,
ethical issues, and discrepancies between developed and developing
countries in its application. No ECT utilization data
Alhamad AM (Alhamad
andal–Haidar 1999)
Saudi Arabia (3) Parallel publication, same data presented as in other included reference
by same author (Alhamad 1999)
Hermann RC (Hermann et al.
1999)
USA (1) Retrospective study of ECT use among beneﬁciaries of a New England
insurance company in 1994 and 1995
Olfson M (Olfson et al. 1998) USA, New York (1) ECT use for general hospital in patients with only recurrent major
depression diagnoses and estimate of effect on prompt ECT on the
length of stay and cost of inpatient care
Fink M (Fink and Kellner 2007) USA (1) General about ECT practice, no primary data
Eranti SV (Eranti and McLoughlin
2003)
UK, USA (2) Editorial article state of the art, no primary data
Thompson JW (Thompson et al.
1994)
USA (4) Too old, National Institute of Mental Health (NIMH) data, ECT-treated
patients in 1975, 1980, and 1986, focusing on data from 1980 and
1986
Levav I (Levav and Gonzalez
1998)
Latin America (3) Parallel publication in English, replication of primary data presented in
earlier study/ publication in 1996 (Levav and Gonzalez 1996)
Glen T (Glen and Scott 2000) Edinburgh, Scotland, UK (1) Calculated annual and aggregate rates of ECT use by consultant teams,
not relevant
Fergusson G (Fergusson et al.
2003)
Scotland (3) Parallel publication, same data presented in included 2004 publication
(Fergusson et al. 2004), by same ﬁrst author
Berg JE (Berg 2009) Diverse countries in three
continents (2)
Report from visiting 14 diverse hospitals in three continents about ECT
practice. ECT data unclear, insufﬁcient and no overall ECT utilization
country-speciﬁc data
Gazdag G (Gazdag et al. 2009b) Hungary (2) To analyze the referral practice of patients for ECT, no rate or
prevalence data
Lucca AM (Lucca et al. 2010) Milan, Italy (2) Letter to editor about 33 patients receiving ECT, insufﬁcient ECT
utilization data
(Continued)
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Appendix B. Continued.
First author (reference)
Country or continent and
reason for exclusion:
(1) not relevant topic
(2) no rate or prevalence
data, very sparse data,
review without primary
data
(3) parallel other language
publication, not possible to
ﬁnd or full-text retrieve
(4) too old, <1990 Comments
Stromgren LS (Stromgren 1991) Nordic countries: Denmark,
Norway Sweden, Iceland (4)
Too old, use of ECT survey in the Nordic countries, from1977–1987
Frederiksen SO (Frederiksen and
d’Elia 1979)
Sweden (4) Too old, ECT survey data in 1975
Kornhuber J (Kornhuber and
Weller 1995)
Germany (3) Not possible to full-text retrieve
Sienaert P (Sienaert et al. 2005b) Flanders and Brussels Capital
Region (3)
Parallel publication in Dutch language to already included study
(Sienaert et al. 2005a)
Gazdag G (Gazdag et al. 2004b) Hungary (3) Parallel publication in Hungarian language to already included study
(Gazdag et al. 2004a)
Palinska D (Palinska et al. 2008) Poland (3) Polish language and ECT utilization in Poland of later date by Gazdag G
(Gazdag et al. 2009a) included
Latey RH (Latey and Fahy 1985) Ireland (4) Too old, ECT survey data from 1982
Baudis P (Baudis 1992) Czech Republic (4) Too old, ECT survey data from 1981 to 1989
Agarwal AK (Agarwal et al. 1992) India (2) About issues relating to administration of ECT, no ECT utilization data
Andrade C (Andrade et al. 1993) India (2) About practical administration of ECT, no ECT utilization data
Chanpattana WM (Chanpattana
2010)
Thailand (2) Review article, not a primary study with data
Takebayashi M (Takebayashi
2010)
Japan (2) Review article about history of the practice and guidelines of ECT in
Japan
Kramer BA (Kramer, Hsin-Tung
1990)
Asia (China, Hong Kong,
India, Indonesia, Japan,
Korea, Malaysia, Pakistan,
Singapore, Sri Lanka,
Thailand) (4)
Too old survey of ECT use in 28 institutions from 11 Asian countries,
unclear time period before 1990. (Unmodiﬁed ECT always used at 12
institutions)
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